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ABSTRACT

Bacteriophages are the most abundant biological entities on earth, yet relatively
few have been characterized. In this project, a novel bacteriophage was isolated from the
environment, characterized, and compared with others in the databases. Mycobacterium
smegmatis, a harmless soil bacterium, served as the host and facilitated the enrichment
and recovery of mycobacteriophages. A single phage type was purified to homogeneity
and named TiroTheta9 (TT9). Electron microscopy revealed that the phage particles have
icosahedral heads 58 ± 2 nm in diameter and tails 174 ± 5 nm in length. The TT9 genomic
DNA was purified and sequenced using 454 pyrosequencing technology. The 51,367 bp
genome contains 87 genes that were identified using the gene prediction programs
Glimmer and GeneMark. However, only 31 genes could be assigned functions based on
BLAST analysis. Genome wide comparisons using the Phamerator program and BLAST
revealed that TT9 is most closely related to members of the A4 subcluster of
mycobacteriophages. Although the A4 subcluster phages have been isolated from
geographically distinct locations, their genomic sequences are highly conserved.
Comparative analysis of the subcluster reveals evidence of evolution through both
vertical sequence divergence and horizontal gene transfer, as evidenced by the existence
of three unique groups of integrases. These results have contributed to the rapidly
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expanding database of mycobacteriophage genomes; mining this rich source of genetic
information should provide new insights into phage diversity and evolution.

Keywords: Bacteriophage, Mycobacteriophage, Mycobacterium smegmatis, Phage
diversity, Phage evolution, Bioinformatics
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CHAPTER 1

INTRODUCTION
Mere nanometers in length, they are among nature’s tiniest biological entities, and
yet the scientific mysteries they have already helped us unlock are unimaginably
immense. Inhabiting almost every conceivable environment, altogether more than 1031
individual particles populate the planet, a number so large that despite the miniscule size
of a single entity they could form a line stretching 200 million light years [1], and yet
only an infinitesimal sliver of that line has been even superficially studied. The study of
bacteriophage (phage), viruses that attack bacteria, is full of such ironies. As researchers
delve deeper into the mysteries of phage, it becomes ever clearer that although they have
already taught us much, we have barely begun to truly understand their astounding
complexity.
Ever since their discovery in the early 1900s, bacteriophage have been at the
center of numerous applied and basic research initiatives. Throughout the mid-1900s,
they starred in landmark experiments that identified DNA as the genetic material in living
organisms, uncovered the existence of messenger RNA, and revealed the triplet nature of
the genetic code, among numerous other contributions to bacterial genetics, molecular
biology, and virology [2]. In fact, phages were so essential to the development of
molecular biology that a dedicated Phage Course was taught each year from 1945 to 1970
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at Cold Spring Harbor Laboratory to train researchers on the cutting edge of the nascent
field [3].
Despite their utility in the laboratory, our knowledge of phage has been largely
limited to a few well-studied model species, Lambda, T4, and M13 being among the best
known. With the advent of next-generation sequencing methods, however, there has been
renewed interest in expanding our knowledge of phages through the isolation and
sequencing of a variety of novel phage genomes. Given the ecological importance of
phages as well as their current and potential applications in basic research, medicine, and
industry, such efforts promise to catalyze a wealth of new discoveries across a diverse
range of fields.
This work describes a new contribution to the effort to expand our knowledge of
bacteriophage in the form of the isolation and sequencing of the novel
mycobacteriophage TiroTheta9. In order to place this research in the proper context, the
first part of this work attempts to capture the current scope of knowledge regarding
bacteriophage, as well as highlight their importance in nature, in the laboratory, and in
day-to-day life, by describing their biology, ecology, history, and applications.
Mycobacteriophages are introduced in the second half of this work, which details the
discovery, characterization, and sequencing of TiroTheta9. Finally, TiroTheta9 is
compared with a group of related mycobacteriophages across several dimensions,
including geography, genomic sequence, and other genomic parameters, in order to draw
conclusions related to bacteriophage genetics and evolution.
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PART I
INTRODUCTION TO BACTERIOPHAGE –
BIOLOGY, HISTORY, AND APPLICATIONS

Be it in nature or in the lab, bacteriophage possess undeniable power. Although
structurally very simple, bacteriophage are ubiquitous and play key roles in the biosphere.
Ever since their discovery in the early 20th century, their power has also been harnessed
in the lab, resulting in a variety of useful applications across several diverse fields. These
applications, as well as the biology, ecological significance, and research history of
bacteriophage, are detailed in the following chapters.
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CHAPTER 2

BIOLOGICAL CHARACTERISTICS OF BACTERIOPHAGE

A. BACTERIOPHAGE STRUCTURE
Bacteriophage are viruses that infect bacteria. Like all viruses, they consist of a
very simple structure: each phage particle consists of two main components, structural
protein and genetic material; a few phage types also incorporate lipids. Although
morphology varies greatly (see Chapter 2C and Figure 3), all phage have a protein head
or capsid that functions to protect and transport the genetic material that it surrounds.
Packaged inside the capsid, the genetic material can be single-stranded DNA, doublestranded DNA, single-stranded RNA, or double-stranded RNA. In addition to these
universal components, many phage also have protein-based components such as a tail
sheath, a baseplate, and tail fibers that serve to facilitate host infection (Figure 1).

Figure 1: Structure of a Bacteriophage Particle. The figure depicts a typical myoviridae phage particle
with an icosahedral head, DNA, full-length contractile tail, and tail fibers. All phage have protein-based
heads, or capsids, and either DNA or RNA as their genetic material, but capsid and tail morphologies vary.
Tails and related components may be absent. Source: https://biology10thgrade.wikispaces.com/
Cell+structure+and+function%3B+review.
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Phage bind to receptors on the host cell surface. Because different receptors are
expressed by different species of bacteria, each type of bacteriophage is limited to a
specific range of host bacterial species depending on which receptor it utilizes for
infection. Adsorption is the first step in the infection process; after adsorption to the
bacterial cell surface, many phage inject their genetic material into the host. Unlike many
eukaryotic viruses, the protein components of bacteriophage do not enter the cell along
with the genetic material, but rather remain attached to the host cell surface.

B. BACTERIOPHAGE LIFECYCLES
After infecting its host, many bacteriophages undergo one of two distinct
lifecycles. The first is the lytic cycle. After the genome of a lytic phage enters its host, it
circularizes and immediately begins replicating. Normal functioning of the bacterium is
brought to a halt as the phage hijacks the cellular machinery, utilizing the cell’s resources
to synthesize new capsids and tails, if applicable, as well as to produce copies of the
phage’s genetic material. Newly synthesized genetic material is packaged into the capsids,
any additional components such as tail sheaths and tail fibers are appended onto the
capsid, and as little as 20 minutes after initial infection, fully-formed progeny phage burst
from the host in a process called lysis. The progeny phage are then free to disperse, each
with the potential to infect a healthy cell and carry on the replication process.

5

Figure 2: Bacteriophage Lifecycles. After infecting its host, a bacteriophage can undergo one of two
lifecycles depending on environmental cues. The lytic cycle (1) involves immediate replication of phage
particles and ultimately results in the death of the host bacterium, which is lysed at the end of the process to
release progeny phage. The lysogenic cycle (2) involves incorporation of the phage genome with the host
chromosome, where it remains dormant and is replicated along with the bacterial chromosome. An
integrated phage can be induced by factors such as DNA damage to excise itself and enter the lytic cycle.
Not all phage are capable of forming lysogens; those than can are known as temperate phage. Source:
http://www.bio.miami.edu/dana/pix/bacteriophage_life_cycle.jpg.

When environmental conditions are not optimal for sustaining lytic growth – for
example, when host density is low or nutrients are scarce – some phage are capable of
undergoing an alternate lifecycle known as the lysogenic lifecycle. Unlike a phage
undergoing the lytic cycle, a phage undergoing the lysogenic cycle does not immediately
begin replication after injecting its genetic material into the host. Instead, the genetic
material is integrated into the host’s genome as double stranded DNA, becoming a
prophage and transforming its host into a lysogenic cell, or lysogen. The prophage uses a
DNA binding repressor protein to prevent expression of its own replication and lytic
genes, instead replicating along with the host genome whenever the host divides.
However, environmental factors such as DNA damage can induce the prophage to excise
6

itself from the host chromosome and begin the lytic cycle. While some phages are
exclusively lytic, phages that are capable of undergoing the lysogenic cycle are known as
temperate phage.
Although most known phages adhere to these two lifecycles, a select group of
phage known as filamentous phage exhibits yet another mechanism of replication. Like
lytic phage, filamentous phage genomes generally circularize and begin replication
immediately after entering a host cell. However, rather than killing and lysing their hosts
as they replicate, filamentous phage release their progeny through channels in the cell
membrane without killing the host bacterium, although bacterial growth is slowed in
many cases [4]. Parallel to the typical lytic and lysogenic cycles described above, some
filamentous phage exhibit strictly episomal replication, while others are “temperate,”
alternating between periods of integration into the host chromosome and periods of
episomal replication.

C. BACTERIOPHAGE CLASSIFICATION
Given that viruses are generally considered nonliving, the rigorous binomial
nomenclature system in place for classifying living organisms cannot be applied. Instead,
scientists typically classify bacteriophage based on lifecycle, type of genetic material,
morphology, and/or host range. As discussed previously, bacteriophage can be classified
as either lytic or temperate based on the lifecycle they follow. Alternatively, they can be
grouped into four distinct categories based on the type of genetic material they contain:
single stranded (ss) RNA, double stranded (ds) RNA, ssDNA, and dsDNA. Taking
differences in morphology into account, these four types can be further divided into 14
subtypes as depicted in Figure 3. The figure also showcases the wide diversity of
7

bacteriophage morphologies, ranging from the archetypal tailed phages with icosahedral
capsids to tailless phages consisting of only a capsid to the long, fiber-like filamentous
phages. Selected characteristics of each subtype are summarized in Table 1.
Of the bacteriophages that have been isolated so far, the vast majority belong to
the double stranded DNA subtype siphoviridae [5], which have long, noncontractile tails
attached to icosahedral or elongated capsids. However, it should be noted that this may
reflect a bias inherent in the laboratory techniques used to isolate environmental phages
rather than a naturally greater abundance of this type of phage. In addition to these
classification systems, bacteriophage can also be grouped based on their host range; for
example, phages that infect bacteria of the genus Mycobacterium are collectively known
as mycobacteriophage.
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Figure 3: Bacteriophage Subtypes. Bacteriophage can be classified into fourteen different subtypes based
on genetic material and morphotype. Source: http://www.snow.edu/kevins/Biol_2200_files/
Prescott17_Viruses.pdf.
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Table 1: Selected Characteristics of Phage Subtypes. Source: Ackermann, HW. Bacteriophage
classification, p 69-90. In Kutter E, Sulakvelidze A (ed), Bacteriophage: Biology and Applications, 1st ed.
CRC Press, Boca-Raton, FL.
Nucleic
Acid

Type

Capsid

Tail

Adsorption
Site

Release

Host-Virus
Relationship

Example

dsDNA

Myoviridae

Icosahedral
or prolate

Contractile

Cell wall,
capsule,
pili, flagella

Lysis

Lytic or
Temperate

T4

Siphoviridae

Icosahedral
or prolate

Long, noncontractile

Cell wall,
capsule,
pili, flagella

Lysis

Lytic or
Temperate

Λ

Podoviridae

Icosahedral
or prolate

Short,
noncontractile

Cell wall,
capsule,
pili, flagella

Lysis

Lytic or
Temperate

T7

Lipothrixviridae

Filamentous,
external lipidcontaining
envelope

None

Pili

Lysis

Temperate

TTV1

Corticoviridae

Internal
phospholipoprotein
vesicle

None

Cell wall

Lysis

Lytic

PM2

Tectiviridae

Internal
lipoprotein
vesicle,
apicle spikes

Pseudotail
formed by
lipoprotein
vesicle

Pili, cell
wall

Lysis

Lytic

PRD1

Rudiviridae

Filamentous stiff rods

None

Cell wall

Unknown

Carrier state

SIRV-1

Fuselloviridae

Lemonshaped,
external lipidcontaining
envelope

None

Unknown

Extrusion

Temperate or
carrier state

SSV1

Plasmaviridae

Lipidcontaining
envelope only

None

Plasma
membrane

Budding

Temperate

L2

Guttaviridae
(SNDV-like)

Dropletshaped

None

Unknown

Unknown

Carrier state

SNDV

Microviridae

None

Cell wall

Lysis

Lytic

φ, X174

None

Plasma
membrane

Extrusion

Carrier state

Fd

Inoviridae
(Inovirus)

Icosahedral
Filamentous long
filaments
Filamentous short rods

None

Pili

Extrusion

Carrier state
or temperate

MV-L51

dsRNA

Cystoviridae

Icosahedral

None

Lysis

Lytic

φ6

ssRNA

Leviviridae

Icosahedral

None

Lysis

Lytic

MS2

ssDNA

Inoviridae
(Plectrovirus)

Pili, cell
wall
Pili

10

D. BACTERIOPHAGE ECOLOGY
To appreciate the enormous roles bacteriophage play in nature, their abundance in
the environment must first be quantified. Given that phage require bacterial hosts to
replicate, they tend to be found wherever their hosts are abundant. As bacteria have been
identified in almost all environments on Earth, it follows that bacteriophage are equally
ubiquitous. But just how numerous are bacteriophage? Measures of virus particles in
estuarine water estimate 107 particles/ml, corresponding to about a 10:1 virus-tobacterium ratio [6]. Similar numbers apply to marine waters, with an estimated total of
1030 phage populating the ocean. High phage titers have also been reported in marine
sediment (109 particles/g), terrestrial soil (107 particles/g), the feces of ruminant animals
(107 particles/g), food products such as whey (109 particles/ml), and even the air (105
particles/m3) [7].
What are the consequences of such ubiquity and high abundance of phage
particles? In short, it means that phage play a large and essential role in their
environments. The environmental role of phage can be considered from four hierarchal
levels of influence: organismal, population, community, and ecosystem [8]. Phage
organismal ecology involves factors that affect a phage’s ability to survive in the
environment, infect a host, and produce viable progeny. A number of environmental
factors influence free phage in their search for a host bacterium. For example, terrestrial
soils are often only partially hydrated, hampering diffusion of phage particles. Phage can
become trapped in biofilms, sticky networks of bacteria and sometimes other
microorganisms that frequently grow on surfaces, and often experience reversible nonspecific adsorption to particles in the environment or adsorb to nonviable bacterial
11

fragments. In addition, high pH and UV radiation can degrade free phage particles [9]
[10]. Adaptations in surface chemistry, virion size, and pH resistance can improve a
phage’s ability to survive and find a suitable host for replication [11].
Phage population ecology includes phage growth patterns and competition among
multiple phages for hosts. A primary factor at this level is the balance between the lytic
and lysogenic lifecycles. In general, the lytic lifecycle is associated with rapid phage
population increase and is best suited to environments where nutrients are plentiful and
bacteria are actively dividing so that there are enough healthy hosts available to support
the burgeoning phage population. The lysogenic lifecycle, on the other hand, is useful for
sustaining phage populations at carrying capacity in environments where the bacterial
population is stable or declining because most phage in these conditions exist as dormant
prophage rather than actively replicating. Due to the binding kinetics of the DNA
repressor proteins that prophages use to remain integrated in the host chromosome, a
basal level of spontaneous induction effects the replication and release of small quantities
of phage particles, but their small numbers coupled with the immunity afforded to
lysogens carrying homoimmune prophage ensure that the limited host population is not
rapidly depleted. The filamentous phage lifecycle can similarly maintain phage and host
populations when viable hosts are limited.
Phage also have a significant impact on the ecology of their bacterial hosts; these
phage-host interactions are encompassed by phage community ecology. On the level of
individual bacteria, phage infection can induce abnormal patterns of gene expression that
often alter the bacterial phenotype. These shifted gene expression patterns can be related
to the host stress response invoked by infection or to certain phage-encoded factors. It is
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also possible for temperate phages to encode genes that are expressed when the phage
integrates into the host chromosome. In fact, many bacterial virulence genes, including
the toxin produced by Vibrio cholera that is responsible for the diarrheal disease cholera,
are encoded by temperate phage that convert their nonpathogenic hosts into pathogens
upon infection.
Phage-host interactions are also extremely important from an evolutionary
standpoint. The constant selective pressure that phage apply to their hosts drives bacterial
diversification as the bacteria evolve new defense systems to evade their viral attackers
[12]. Accordingly, as non-resistant bacteria are decimated during lytic phage growth,
bacterial populations are shifted towards phage-resistant varieties, which may differ in
additional ways from their non-resistant predecessors.
Phage also facilitate horizontal gene transfer between themselves and their hosts;
in fact, up to 20% of the genome of some bacteria is comprised of phage DNA [13]. As
detailed previously, some phage are capable of integrating into the chromosome of their
bacterial hosts, where they can confer new biological properties, such as virulence, on
their hosts. This process is called lysogenic conversion. In addition, over time, integrated
prophage may lose the ability to excise themselves through mutation, deletion, or genetic
rearrangement; their genes thus become permanent fixtures in the genomes of their hosts.
Such phages are referred to as defective or cryptic. Examples of this phenomenon are
abundant in the well-characterized E. coli K-12 strain, which contains nine cryptic
prophages that constitute 3.6% of its genome [14]. Both active and cryptic prophages
contribute to bacterial evolution and have been shown to increase the fitness of their
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bacterial hosts in some cases, boosting resistance to certain antibiotics and environmental
stresses, increasing growth, and facilitating biofilm formation among other benefits [14].
In a phenomenon known as transduction, transducing phage can also ferry
bacterial DNA between hosts. During lytic replication, an empty phage capsid can
occasionally be packaged with bacterial DNA, which is then transferred to a new host
upon infection by the faulty phage in a process known as generalized transduction.
Specialized transduction occurs when a prophage excises itself imprecisely from the host
genome, taking adjacent bacterial genes along with it. These genes are packaged into the
capsids of the progeny phage, which can transfer them to new hosts upon lysogenization.
Depending on the host range of the phage in question, genes can be transferred between
different strains or even different species of bacteria.
It is important to note that the sheer abundance of phage in the environment
makes their role in bacterial evolution even greater. Because their numbers are so
immense, even relatively rare phage-mediated events occur with striking overall
frequency. For example, transduction is observed in only one out of every 108 infections
under optimal laboratory conditions [7]. However, when the 1030 estimated marine phage
and the 1023 estimated infections they initiate every second [15] are taken into account,
transduction events occur about 20 million billion times per second in the ocean alone
[16]. This represents an enormous amount of potential horizontal gene flow among
marine bacterial species and is likely to play a significant role in their evolutionary
histories.
Despite their tiny size, phage can exert an enormous influence on the level of
entire ecosystems, an area examined by phage ecosystem ecology. As mentioned
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previously, phages exert selective pressure on bacterial populations that can favor the
dominance of phage resistant strains in the presence of phage. Often, however, this
resistance comes at a metabolic cost to the bacteria. This in turn can reduce metabolic
activities such as nitrogen fixation that are beneficial to plant growth, thereby affecting
entire ecosystems. For example, observations recorded in a 1935 study by Demolon and
Dunez demonstrated large-scale obstruction of plant growth in an agricultural setting
after phage infection. Researchers have hypothesized that selection for a bacterial
phenotype that was phage-resistant but less efficient at fixing nitrogen was the root cause
[17]. Alternatively, phage can destroy bacteria that benefit animal or plant members of an
ecosystem.
Phage can also play a largely positive role in the ecosystems to which they belong.
They can prevent bacterial population explosions that might drive other microorganisms
to extinction or cause disease in higher organisms. Additionally, as they are responsible
for the death of 80% of prokaryotes in deep sea sediments [18] at a rate of about 15% of
the total bacterioplankton population per day [7], phage are major players in the shifting
of nutrients from living organisms back into the environment. Consequently, they play
major roles in global biogeochemical cycles, including the carbon, nitrogen, and
phosphorus cycles vital to the maintenance of essentially every ecosystem on the planet.
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CHAPTER 3

HISTORY OF BACTERIOPHAGE RESEARCH

A. THE DISCOVERY OF BACTERIOPHAGE
As early as 1896, British bacteriologist Ernest Hankin noted an unknown
antibacterial agent at work in the waters of the Ganges River while studying cholera in
India. Several years later in 1915, another British bacteriologist Frederick Twort was
studying staphylococcal contamination of smallpox vaccines when he noticed small, clear
spots emerging on his plates of Staphylococcus bacteria. Although he knew these spots
were indicative of areas where the bacteria had been killed by some sort of antibacterial
substance, Twort did not state conclusively that the substance was a virus; rather, he
speculated that it may be an enzyme secreted by the bacteria themselves among other
possibilities. Although Twort published his observations in the British journal The Lancet
[19], the significance of his discovery was not immediately recognized.
Around the same time, French-Canadian microbiologist Felix d’Herelle noticed
similar clear spots on his own plates while investigating a severe outbreak of bacterial
dysentery among a group of French troops stationed outside of Paris. Having observed
the same phenomenon five years earlier while researching infectious insect diseases in
Mexico, d’Herelle decided to investigate further and published his findings in a French
journal in 1917 [20]. He proposed that the mysterious substance was a type of virus and
coined the name “bacteriophage” – meaning “eater of bacteria” [21]. However, it was not
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until German scientist Helmut Ruska utilized the newly-invented electron microscope to
take the first pictures of bacteriophage in 1940 [22] that the rest of the scientific world
was convinced that d’Herelle’s bacteriophage were indeed viruses.

B. BACTERIOPHAGE RESEARCH FROM THE 1920S TO THE 1940S
Bacteriophage research from the 1920s to the 1940s was primarily concerned with
the medical applications of bacteriophage. The concept of bacteriophage therapy, in
which bacteriophage are employed to treat bacterial infections, especially in humans, was
proposed and developed during this period. Phage therapy’s earliest proponent was Felix
d’Herelle, who used the viruses he had helped discover to develop treatments for avian
typhosis in chickens and shigella infections in rabbits [23]. After achieving success, he
initiated similar experimental treatments in humans in 1919, successfully treating
bacterial dysentery in several patients at a hospital in Paris [21].
Over the next few years, researchers used lytic bacteriophage to treat an
increasingly wide variety of bacterial infections. In 1921, French researchers Richard
Bruynoghe and Joseph Maisin published the first article related to phage therapy of
human disease, reporting the successful treatment of Staphylococcus infections on the
skin [24]. After completing his work on dysentery in France, d’Herelle traveled to India
to work on phage therapy strategies for cholera; under his direction, one of India’s
research institutes began researching phage therapy and achieved great success in treating
cholera during the 1920s and 30s [25]. In 1932, American doctor Robert Schless
published results reporting the successful use of phage to treat bacterial meningitis caused
by Staphylococcus aureus [26]. During the late 1930s and early 1940s, phage therapy
research was especially productive in the former Soviet Union. Soviet researchers
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reported great successes in using phage to treat bacterial infections in fields as diverse as
dermatology, ophthalmology, urology, stomatology, pediatrics, and otolaryngology [27]
as well as to prevent and cure infections in surgical incisions and open wounds [28].
During this time, there were also reports of Soviet and German soldiers utilizing phage
therapeutics to treat wounds and prevent bacterial infections [25].
The earliest commercial phage products also appeared during this time period
[21]. The French company L’Oreal marketed at least five different phage products for
human use, all developed by d’Herelle in his commercial laboratory in Paris. In the 1940s,
the American company Eli Lilly developed and marketed seven therapeutic phage
preparations effective against such maladies as Staphylococcus, Streptococcus, and
Escherichia coli among other pathogens. These products were primarily used in the
treatment of abscesses, suppurative wounds, vaginitis, upper respiratory tract infections,
and mastoid infections. In addition, significant research efforts into phage therapeutics
were carried out at the George Eliava Institute of Bacteriophage, Microbiology, and
Virology in Tbilisi, Georgia, which was founded in 1923 by d’Herelle and Georgian
bacteriologist Giorgi Eliava. At its height, the Institute was capable of producing twelve
different phage products targeted against Staphylococcus, Pseudomonas, Proteus, and
several enteric pathogens, often in large amounts for use throughout Eastern Europe and
the Soviet Union, and also provided many of the phage used in experiments by Soviet
researchers.

C. BACTERIOPHAGE RESEARCH SINCE 1950
From the 1950s onward, bacteriophage research in Eastern European countries,
including most prominently the Soviet Union and Poland, continued to be centered
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around phage therapy. In 1968, a team of Georgian researchers led by E.G. Babalova,
K.T. Katsitadze, and L.A. Sakvarelidze conducted a particularly influential large-scale
study in Tbilisi, Georgia, to provide further evidence for the efficacy of phage therapy
[29]. The study involved 30,769 children between the ages of six months and seven years
divided into two groups. The first group consisted of 17,044 children who were given a
dose of Shigella bacteriophage orally once per week. The second group, consisting of
13,745 children, served as a control and was not given phage. After 109 days of treatment,
the researchers discovered that the incidence of diarrheal disease in the control group was
3.8 times higher than that of the group treated with phage based on clinical diagnosis and
2.6 times higher based on cases confirmed through laboratory culture. Despite the fact
that the phage administered to the experimental group had been specific to Shigella
bacteria, the incidence of diarrheal disease of unknown cause was also 2.3 times higher in
the control group. The results of this experiment provided strong evidence for the
effectiveness of phage therapeutics in preventing diarrheal disease in children.
In the 1970s, Polish and Soviet researchers successfully used phage therapy to
treat peritonitis, osteomyelitis, abscesses, post-operative infections, antibiotic-associated
dysbacteriosis, and suppurative surgical infections caused by antibiotic resistant
Staphylococcus aureus, Streptococcus, and Proteus species. Many similar studies and
experiments continued throughout the 1980s and 90s, providing researchers with
additional evidence for the efficacy of phage therapy in treating bacterial infections [21].
Although the majority of phage therapy research during this time period was
conducted by scientists in Eastern Europe, several notable projects were completed in
other countries, as well. In the late 1960s, the World Health Organization conducted
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research directed towards using phage therapy against cholera in Pakistan, although they
ultimately concluded that phage therapy as used in the study was inferior to standard
antibiotic treatments [30], citing problems such as differential susceptibility to the
therpeutic phages among vibrio serotypes and rapid passage of orally administered phage
through the GI tract. In the 1980s, a group of British researchers headed by H. Williams
Smith and M.B. Huggins successfully used phage therapy to treat E. coli infections in
animals [31] [32]. In addition, several countries, including France, Poland,
Czechoslovakia, England, and a few North American countries, launched mostly
successful clinical trials of phage-based therapies throughout the 1960s, 70s, and 80s [25].
In contrast to the focus on phage therapy by Eastern European researchers,
starting in the 1950s, most phage research in the West was focused on basic molecular
biology. One of the main factors that deterred Western researchers from pursuing phage
therapy with the same fervor as their Eastern European counterparts was the advent of
antibiotics in the 1940s. Easy to manufacture and highly effective against a wide range of
infectious diseases, antibiotics quickly took center stage in the clinic as Western
enthusiasm for phage therapy was all but extinguished. However, despite minimal
contributions to the field of phage therapy during this time, Western researchers instead
utilized model phages such as T4 and Lambda to make revolutionary discoveries in
molecular biology and genetics. One such groundbreaking experiment was that of Alfred
Hershey and Martha Chase, who in 1952 used the E. coli phage T2 to prove that DNA
and not protein served as the genetic material in living organisms [33] (Figure 4). Model
phage catalyzed many other important discoveries, including messenger RNA, DNA
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recombination, the triplet nature of the genetic code, DNA ligase, gene regulation, and
epigenetic gene regulation (see Reference [2] for list of relevant citations).

Figure 4: The Hershey-Chase Experiment. In 1952, A. Hershey and M. Chase used radioactively-labeled
bacteriophage to show that it was the phage’s DNA, and not its protein coat, that entered the host cell and
provided instructions for the synthesis of new phage. This, combined with similar conclusions from O.
Avery, C. MacLeod, and M. McCarty’s transformation studies with Streptococcus pneumoniae bacteria,
served as conclusive evidence that DNA, and not protein, serves as the genetic material in living organisms.
Source: https://www.msu.edu/course/lbs/333/ fall/hersheychaseexpt.html.

In recent years, bacteriophage research has expanded into many different fields
and yielded a variety of innovative applications. Some of the most significant of these
applications will be discussed in the next chapter.
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CHAPTER 4

CURRENT APPLICATIONS OF BACTERIOPHAGE

A. BASIC RESEARCH APPLICATIONS
As touched upon previously, bacteriophage have been utilized in basic research
since the mid-1900s. Today, they continue to be important tools in molecular biology
laboratories. Temperate phage such as P1 can be engineered and used as vectors to insert
genes of interest into bacterial genomes [34]. Phage can also be programmed to express
foreign proteins on the surface of their protein coats. For example, in 1994 a team of
American scientists led by Maruyama succeeded in expressing E. coli and plant proteins
on the protein coat of Lambda phage [35].
A derivative of this concept is phage display technology, in which scientists
express a protein of interest on the protein coat of a phage in order to explore its
interactions with DNA, peptides, and other proteins. Generally, a DNA, peptide, or
protein target is attached to the surface of a microtiter plate well. A library of phages,
each displaying a different protein, is added to the well; those expressing interaction
partners of the target will bind, while the other phage will be washed away. The attached
phage are then eluted and amplified in bacterial hosts, resulting in an enhanced library
containing much fewer non-binding phages. The process can be repeated several times
with the new library to further refine the population, and then the genomes of the
interacting phages can be sequenced to identify the protein interaction partners of the
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target. Recently, phage display has been of great interest in screening libraries of
antibodies for those with the desired affinity for a particular antigen [36] and has also
been utilized in drug discovery [37].
Certain phage gene products are also being utilized in basic research. One such
product is integrase, the enzyme responsible for mediating site-specific recombination
between the genome of an integrating temperate phage and that of the host bacterium.
Life Technologies (Invitrogen Corporation, Carlsbad, CA) manufactures a commercial in
vitro cloning method called GATEWAYTM that utilizes integrase from phage Lambda to
clone a variety of bacterial, mammalian, and plant inserts more efficiently than is
possible with traditional restriction enzyme methods [38]. In addition, certain phage
integrases have been shown to facilitate site-specific recombination in mammalian cells,
opening up promising new avenues for integrase-mediated cell line manipulation,
transgenic organism creation, and gene therapy. In fact, several gene therapy successes
have already been achieved with the φC31 integrase in the lab. For example, Olivares et
al. have reported stable, long-term, and therapeutically significant expression of human
α1-antitrypsin and human factor IX in the livers of mice [39], while other studies have
reported the use of φC31-mediated gene therapy to restore function of laminin B3 in
human skin cells and human Type VII collagen in human skin cells and fibroblasts [38].
Another novel application for phage integrases is in developing rewritable digital
data storage modules to store digital information, such as cell division or differentiation
events, within a chromosome in live cells. Such modules are potentially applicable to the
study and engineering of a variety of biological systems related to aging, cancer,
development, and other diseases and processes [40].
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Phage studies also continue to contribute to our understanding of gene regulation.
The processes that regulate gene expression in the temperate E. coli phage Lambda,
including the “switch” that allows the phage to shift between the lytic and lysogenic
lifecycles, are well-characterized [41]. However, phage encompass a vast range of
genetic diversity that still holds many secrets, particularly in terms of how different phage
regulate their gene expression. For example, in 1993, Oberto et al. identified a novel type
of antitermination in the E. coli phage HK022, a relative of Lambda [42]. In Lambda and
many of its relatives, early phage genes are located downstream of a set of transcription
termination sites, or terminators, that cause RNA polymerase to halt transcription. To
achieve full gene expression, these phages express a protein called N, which, in
conjunction with several E. coli-encoded genes, modifies RNA polymerase so that it can
read through these terminators and continue to transcribe downstream genes. Thus, N is
called a transcription antiterminator. As a Lambda relative, HK022 contains a similar
genetic organization, with early phage genes located downstream of terminators.
However, unlike for Lambda, no protein outside of RNA polymerase is required to
achieve antitermination [43]. Instead, the phage genome contains two cis-acting sites
called putL and putR whose transcripts form putative stem-and-loop structures that
directly modify RNA polymerase to promote “factor-independent” antitermination [44].
Characterization of these new RNA structures has been limited by a lack of
knowledge of similar structures in other phages, but the increasingly availability of new
phage sequences has facilitated the identification of similar sites in other phage through
comparative sequence analysis. Notably, in 2011 King et al. reported the discovery of
put-like elements in two other E. coli phages as well as in the Erwinia tasmaniensis
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phage Et88 [44]. Interestingly, such elements were also identified in the genomes of
three bacterial species, and similar but likely mechanistically distinct cis-acting RNA
elements have been described in Bacillales bacteria [45]. As these Bacillales elements
have been implicated in antitermination of operons that control biofilm and capsular
polysaccharide formation, a thorough understanding of such novel RNA molecules could
be useful in unraveling these processes, which are often related to pathogenesis, and
perhaps open new therapeutic avenues.

B. INDUSTRIAL APPLICATIONS
Bacteriophage have traditionally been considered a nuisance in industries that
utilize bacteria to make products, including the food, chemical, pharmaceutical, feed, and
pesticide industries [46]. One industry in which these problems have been extensively
documented is the dairy industry. The production of milk-based products such as yogurt
and cheese requires inoculation of starter cultures of lactic acid bacteria, which are added
to pasteurized milk to begin the production process. If even a single active phage capable
of infecting the starter culture strains is present in the milk or any of the other ingredients,
it can multiply rapidly, killing sensitive starter culture bacteria and reducing the quality of
the final product. In severe cases, the inoculated milk has to be thrown out entirely. Since
the first report of phage contamination in dairy starter cultures in 1935, several advances
have been made towards alleviating the problem, including adapted factory design,
improved sanitation, production process alterations, strain rotation, and use of phageresistant strains. At the same time, research into these solutions has catalyzed the
biological characterization of dairy phages. Efforts to understand phage diversity and
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phage-host interactions continue as new phage variants emerge and the search for novel
control strategies continues [47].
Despite their notoriety in the dairy industry, phage have many promising
beneficial applications in other fields. Just as phage contamination can be detrimental in
the dairy industry, bacterial contamination is a major problem in many other industries,
including biofuel production and food safety. In these industries, phage are a potential
ally rather than a foe. In the food industry, contamination by pathogenic bacteria can
sicken consumers, trigger costly product recalls, and damage a company’s reputation
permanently. Chemical or antibiotic treatments, while they may be effective at killing
bacterial contaminants, are undesirable as they may be harmful to humans who later
purchase and consume the product. Thus, phage represent an ideal solution for combating
pathogenic bacteria on food products. Recognizing their potential, the biotechnology
company Intralytix (Baltimore, MD) has developed whole-phage preparations effective
against Listeria monocytogenes, E. coli, and certain Salmonella serotypes. ListShieldTM,
EcoShieldTM, and SalmoShieldTM each contain a mixture of several lytic phage strains
and have been demonstrated to significantly reduce levels of their target pathogens on
food [48].
Another phage-based approach to reducing bacterial contamination has shown
promise in the biofuel industry. Like the use of integrase in basic research, this approach
utilizes a phage gene product rather than whole phage – phage lysis enzymes called
endolysins, or simply lysins, are isolated and used to destroy bacterial contaminants
through the degradation of peptidoglycan, the major structural component of bacterial
cell walls. Ironically, some of the most detrimental of these contaminants are the same
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lactic acid bacteria that are essential to the dairy industry. To eliminate them in biofuel
production settings, where they can reduce ethanol production by up to 27%, Roach et al.
have purified several phage lysins and demonstrated their utility in reducing
contamination by gram positive bacteria in a biofuel production context [49].
In addition to the many applications of natural phage and phage gene products,
genetic engineering can further expand the utility of bacteriophage in industry to almost
limitless possibilities. In one particularly innovative initiative, a team of material
scientists at MIT has created functional nanobatteries from engineered filamentous M13
phage. The engineered phage, dubbed E4, express a compound called tetra glutamate on
their outer protein coats; this compound allows them to organize into nanowires when
exposed to aqueous Co3O4, a paramagnetic compound that is the main component of the
anodes found in lithium-ion batteries [50]. The virus nanowires then self-assemble on
polymer films to form anodes. The same E4 phage were used as the starting point for the
cathode-forming phage; in the cathode, the tetra glutamate reacts with FePO4 to form
nanowires. To improve the conductivity of the cathode, essential to ensure the speed of
the completed battery, the researchers modified a minor protein coat protein so that it
would bind to conductive carbon nanotubes. These phage-nanotube complexes selfassemble to create a highly conductive material for the cathode [51]. When combined, the
phage-based anode and cathode produce an economical and environmentally friendly
alternative to traditional lithium-ion batteries. The nature of these self-assembling viral
arrays is such that they could be formed into extremely light-weight batteries of virtually
any shape, from traditional button-cell disks to pliable, unobtrusive films that could be
utilized in products such as high-tech clothing and electric blankets [52].
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Another phage engineering project that demonstrates the wide applicability of
engineered phage is one led by Timothy Lu, who created phage capable of dispersing
bacterial biofilms [53]. Biofilms are communities of bacteria that frequently grow on
surfaces in a variety of environments, including dental plaque, water pipes, medical
devices, and industrial equipment. Bacteria in biofilms are surrounded by an extracellular
matrix of polysaccharides, proteins, nucleic acids, and lipids that provides an
impenetrable barrier to antibiotics and other chemical treatments, meaning that biofilms
are difficult to remove and thus can constitute a continuous source of contamination or
infection. There has been some success in using natural lytic phage to destroy biofilms,
but phage, too, are often hindered by the sticky extracellular matrix. To alleviate this
problem, Lu engineered phage to produce a matrix-degrading enzyme during replication.
Upon release at the conclusion of the lytic cycle, the enzyme degrades the extracellular
matrix, allowing phage to penetrate into the innermost layers of the biofilm (Figure 5). Lu
reported approximately 99.997% reduction in bacterial biofilm counts using the
enzymatic phage, representing a 2 orders of magnitude improvement over nonenzymatic
phage. This project, along with the phage-based batteries discussed earlier, demonstrates
the vast array of possibilities that can be unlocked by customizing phage form and
function through genetic engineering.
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Figure 5: Engineered Phage Produce an Antibiofilm Enzyme. To combat biofilms, which are
characterized by a thick extracellular matrix that constitutes a significant barrier to antibiotic treatment, T.
Lu has engineered lytic bacteriophage to produce a matrix-degrading enzyme as they replicate. Upon lysis,
the enzyme is released into the environment along with the progeny phage particles, where it degrades the
extracellular matrix and renders inner-layer bacteria accessible to the phage. Source: http://www2.
technologyreview.com/TR35/Profile.aspx?TRID=967.

C. MEDICAL APPLICATIONS
As touched upon in the last chapter, researchers have been interested in the
medical applications of bacteriophage ever since their discovery. Because of the recent
explosion of antibiotic resistant pathogens, research into these applications is of
increasing importance. As mentioned previous sections, phage-based treatments can be
applied to contaminated foods to kill pathogenic bacteria and prevent infection, and
phage integrases have shown promising applications in gene therapy. However, phage
can also be used to prevent and treat disease more directly. One application for which
researchers are developing phage is the diagnosis of bacterial pathogens. Because of their
specificity of infection, phage can distinguish between different species, and often
different strains, of bacteria, which can aid in the rapid culture-based diagnosis of
pathogens such as tuberculosis. Such research has been abundant recently in China. In
2000, for instance, Lu Bin et al. developed recombinant phage capable of recognizing
rifampicin-resistant tuberculosis [54]. Similarly, in 2004, Hu Zhong-Yi et al. described a
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method for rapid diagnosis of tuberculosis using phage [55], and in 2007 Lin Zhao-Yuan
et al. researched phage-based methods for early diagnosis of tuberculosis-related pleurisy
[56].
Phage have also been shown to be an effective means of vaccine delivery. Using
phage display technology, immunogenic peptides can be expressed on the protein coat of
filamentous phage. Once injected into a macroscopic host, these phage are capable of
inciting both cellular and humoral immune responses, making them superior to vaccines
containing just the peptide itself [57]. Additionally, in 2003, Westwater et al. genetically
engineered a phage strain capable of delivering an antibacterial agent to pathogenic
bacteria [58].
Facing the growing threat of antibiotic-resistant pathogens, many researchers have
once again begun to consider phage therapy as a viable strategy to treat bacterial
infections. Besides a number of anecdotal reports, phage therapies have recently been
tested more rigorously in clinical trials. In 2006-2007, for example, phage were
successfully used to treat chronic Pseudomonas aeruginosa ear infections in one of the
first modern phase-two clinical trials involving phage therapy; within six weeks of
treatment with a single 2.4-ng dose of a six-phage mixture, 92% of patients showed
marked improvement, while the infections in 25% had resolved completely [59]. In 2009,
a phase-one safety trial of phage active against Staphylococcus aureus, Pseudomonas
aeruginosa, and E. coli reported no adverse effects in 39 patients with chronic venous leg
ulcers after 12 weeks of treatment with targeted bacteriophage [60]. Also in 2009, a
research team in Bangladesh began a clinical trial sponsored by multinational food and
beverage giant Nestlé to assess the efficacy of bacteriophage-based therapeutics in
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treating childhood diarrhea caused by E. coli [61]; the trial was completed in January
2013, but results have yet to be published [62].
The great potential that bacteriophage hold with regards to the treatment of
bacterial infections is particularly important as ever more deadly antibiotic-resistant
pathogens emerge. Phage therapy, including its advantages, its disadvantages, hurdles
hindering its development, and some strategies for overcoming those hurdles, is treated in
more detail in the next chapter.
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CHAPTER 5

PHAGE THERAPY

Of all the applications of bacteriophage, phage therapy is perhaps the one whose
potential benefits have been most underdeveloped. As described in previous chapters,
phage therapy is a method of using lytic phage to treat bacterial infections, especially in
humans, and was first utilized by Felix d’Herelle in 1919. Phage therapy was further
developed primarily in Eastern Europe and the former Soviet Union. In the West,
however, the widespread emergence of antibiotics in the 1940s caused most research into
phage therapy to cease. At the time, phage therapy was plagued by low efficiency and
toxicity (due to contamination of phage preparations with bacterial cell wall components)
that stemmed primarily from an insufficient understanding of phage biology; to Western
researchers, it seemed no match for the wide applicability, ease of production, and
staggering efficacy of antibiotics. In addition, the stigma attached to anything associated
with the Soviet Union provided further reason for some Western scientists to abandon the
pursuit of phage as therapeutics.
Despite the relative dearth of phage therapy research in the West, it has been
continuously developing in Eastern Europe and the former Soviet Union since the 1940s.
Although the majority of research results reported have been positive, the fact that it has
mostly been published in non-English language journals and often has not adhered to the
rigorous scientific standards required in most Western countries has caused the potential
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value of phage therapy to be largely overlooked in other parts of the world. However,
recently a formidable new threat has emerged: the rapid rise of antibiotic resistant
bacterial infections. In the scramble for a solution, an increasing number of scientists,
including those in the West, are looking to phage therapy.

A. THE RISING THREAT OF ANTIBIOTIC RESISTANCE
Antibiotic resistance itself is not a new phenomenon. Even before the first
antibiotic was discovered by Swiss scientist Alexander Fleming in 1928, there existed
many bacteria naturally immune to their effects. But since humans began utilizing
antibiotics to treat bacterial infections on a global scale, antibiotic-resistant bacteria have
been emerging at an accelerated rate, and many bacterial pathogens that were once easily
conquered by common antibiotics have already developed resistance.
The recent rapid increase in antibiotic resistant bacteria can be attributed
primarily to human abuse and overuse of antibiotics. To understand how this sort of
human activity can lead to antibiotic resistance, it is helpful to consider the development
of resistance on a molecular scale. In general, a bacterium can become resistant to
antibiotics through two different pathways. The first is random mutation (Figure 6a). As
bacteria grow and divide, occasional mutations can occur randomly in their genomes.
Sometimes, one or more mutations alters the bacteria in a way that makes them
invulnerable to a particular antibiotic. For example, the mutant bacteria may produce an
enzyme that modifies or degrades the antibiotic, rendering it inactive. The second is
horizontal gene transfer (Figure 6b). Bacteria containing resistance genes can sometimes
transfer these genes horizontally to non-resistant bacteria, making them resistant as well.
When antibiotics are applied, non-resistant bacteria are killed, leaving behind a few
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resistant bacteria that can multiply rapidly without competition. The abuse and overuse of
antibiotics by humans only increases this selective pressure.

Figure 6: Molecular Pathways Involved in the Development of Antibiotic Resistance. Panel a.) shows
how drug resistance is generated through random mutation. Panel b.) illustrates how drug resistance
spreads to non-resistant bacteria through horizontal gene transfer. In both cases, the use of antibiotics
facilitates the propagation of drug resistant bacteria by removing non-resistant competitors. Source:
National Institute of Allergy and Infectious Diseases, http://www.niaid.nih.gov/topics/antimicrobial
Resistance/Understanding/Pages/causes.aspx.

The Infectious Disease Society of America estimates that as much as half of
antibiotic use is unnecessary or inappropriate [63]. As human abuse of antibiotics
continues, antibiotic resistant infections have become an increasingly serious problem
worldwide. Take Streptococcus pneumoniae, the infectious agent responsible for
pneumonia, meningitis, sepsis, and acute sinusitis among other diseases, for example. In
1980, only 5% of S. pneumoniae bacteria were resistant to the commonly used antibiotic
Penicillin. Today, that number has risen to a staggering 40% [64].
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Another startling phenomenon has been the emergence of methicillin-resistant
Staphylococcus aureus (MRSA). Its rise has been marked by a similar trend – 2.4% of
Staph infections in U.S. hospitals were methicillin resistant in 1987, a figure that had
risen to 29% by 1991 and 59.5% in 2003, representing a growth rate of more than 12%
per year on average [65]. In 2005, there were 100,000 cases of MRSA infection recorded
in the United States. Of those, 20,000 died of their illness, exceeding the number of
patients who died of AIDS that same year [66]. Multiple-resistant tuberculosis is another
deadly disease that has been on the rise; each year, it infects 440,000 people and kills
150,000 globally [67].
In addition the loss of human life, there are also serious economic costs associated
with antibiotic resistant infections. Patients afflicted with such infections spend an extra
1-2 weeks in the hospital and require $20,000-$30,000 extra in treatment costs, equating
to $35 billion in lost wages and a $20 billion burden on the health care system in the
United States alone [68]. It is easy to see from these statistics that in order to ease these
heavy economic burdens and prevent further loss of life, we need a solution to antibiotic
resistant infections as quickly as possible.
In accordance with the severity of the problem, a number of potential solutions
are currently under development. Many researchers are focusing their efforts on the
development of new antibiotics. However, not only is this expensive and time-consuming,
but it is also unlikely to provide a lasting solution: in a few years, bacteria resistant to
newly developed antibiotics will begin to emerge as well. In fact, some experts even
maintain that existing antibiotics already represent the best we will ever have [69]. To
combat antibiotic resistance, then, we need to look elsewhere for a solution.
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Fortunately, many novel approaches are currently being considered by researchers
and doctors across the globe. Potential alternatives to antibiotics include colloidal silver,
antibacterial peptides, antibacterial vaccines, bacterial interference, and a number of
natural antibacterial molecules found in foods such as cranberries, honey, garlic, and
coconut oil. However, one of the most promising of these “new” approaches is not new at
all. Phage therapy already has almost 100 years of documented success in treating
bacterial infections to back it up, and several clear advantages help it stand out further as
a promising alternative to our rapidly dwindling antibiotic lineup.

B. PHAGE THERAPY CASE STUDIES
Although phage therapy is not a new idea, it is still a relatively novel concept to
most people, especially Westerners. However, in a number of isolated cases, primarily in
Eastern Europe and the former Soviet Union but also occasionally in the West, many
patients have already reaped its benefits. One such patient is Roy Brillion, a Texas retiree
who struggled with an antibiotic-resistant bacterial infection in a palm-sized open wound
on his thigh for months until his doctor, Randy Wolcott, took a chance on phage therapy.
Wolcott, having exhausted his hospital’s arsenal of antibiotics to no effect, had heard of a
clinic in the Republic of Georgia that offered over-the-counter phage preparations. Out of
conventional options and with his patient’s infection only worsening, he decided to give
phage therapy a shot and headed to Georgia. Incredibly, just a few drops of the phage
solution Wolcott brought back were sufficient to completely heal the wound within three
weeks [60].
Brillon’s case is by no means the only success story. The George Eliava Institute
in Tbilisi, Georgia, from which Wolcott obtained his phage preparations, has successfully
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treated countless patients using phage therapy since its founding in 1923. Records of
phage therapy successes are also present in more recent literature. Of these, a series of
studies undertaken by Polish microbiologist and immunologist Stefan Slopek at the
Hirszfeld Institute in Poland have been particularly influential. From 1981 to 1986,
Slopek used phage therapy to treat 550 patients with various bacterial illnesses, including
Staphylococcus aureus, Pseudomonas, E. coli, Salmonella, and Klebsiella pneumoniae
infections [70]. Of the 550 patients, who ranged in age from one week to 86 years, a full
92.4% regained health following their treatment; 6.9% showed transient improvement,
and phage therapy had no effect in only 0.7% of cases.
A similar, more recent study was conducted by Beata Weber-Dabrowska et al. at
the Polish Academy of Sciences Institute of Immunology and Experimental Therapy
from 1987 to 1999 [71]. Of the 1307 patients who received phage therapy as part of the
study, 85.9% completely recovered, while another 10.9% showed transient improvement
and just 3.8% did not improve at all. Notably, most of the cases involved in these two
studies were chronic infections where antibiotics had already failed; in fact, in the Slopek
study, 94.2% of cases were antibiotic-resistant, meaning that phage therapy provided
these patients with perhaps their only means of recovery. A number of other successful
phage therapy studies conducted over the second half of the 20th century are summarized
in Table 2.
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Table 2: Major Phage Therapy Successes in Poland and the Former Soviet Union. Source:
Sulakvelidze A, Alavidze Z, Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother.
45(3):649-59.
Pub.
Year

Authors

Targeted
Infection(s)

Targeted
Pathogen(s)

Study Details

1968

Babalova
et al.

Bacterial
dysentery

Shigella

Successful prophylaxis using phage

1974

Sakandelidze
and
Meipariani

Peritonitis,
osteomyelitis,
lung abscesses,
post-surgical
wound infections

Staphylococcus,
Streptococcus,
Proteus

Antibiotic-resistant infections in 236
patients treated with phage; infection
eliminated in 92%

1978

Litvinova
et al.

Intestinal
dysbacteriosis

E. coli, Proteus

Combination of phage and bifidobacteria
successful in treating antibiotic-resistant
dysbacteriosis in 500 low birth weight
infants

1978

ZhukovVerezhnikov
et al.

Suppurative
post-surgical
infections

Staphylococcus,
Streptococcus, E.
coli, Proteus

Adapted phages selected against bacterial
strains isolated from individual patients
reported to be to superior to commercial
phage preparations in the treatment of 60
patients

1980

Ioseliani et
al.

Lung and pleural
infections

Staphylococcus,
Streptococcus, E.
coli, Proteus

Combination of phage and antibiotics
successful in treating 45 patients

1981

Tolkacheva
et al.

Bacterial
dysentery

E. coli, Proteus

Combination of phage and bifidobacteria
superior to antibiotics in treatment of 59
immunosuppressed leukemia patients

1982

Meladze
et al.

Lung and pleural
infections

Staphylococcus

Full recovery observed in 82% of 223
patients treated with phage versus 64% of
117 treated with antibiotics

1987

Cislo et al.

Suppurative skin
infections

Pseudomonas,
Staphylococcus,
Klebsiella, E. coli,
Proteus

Chronically infected skin ulcers in 31
patients treated with phage; 74% success
rate

1987

KucharewiczKrukowska
and Slopek

Various
infections

Pseudomonas,
Staphylococcus,
Klebsiella, E. coli,
Proteus

Immunogenicity of therapeutic phages not
observed to impact therapy in 57 patients

1987

WeberDabrowska
et al.

Suppurative
infections

Staphylococcus,
various gramnegative bacteria

Successful treatment of 56 patients; orally
administered phage observed to reach blood
and urine

1989

Kochetkova
et al.

Post-surgical
wound infections

Staphylococcus,
Pseudomonas

Successful treatment in 82% of 65 cancer
patients treated with phage versus 61% of
66 treated with antibiotics

1991

Bogovazova
et al.

Skin and nasal
mucosa
infections

1991

Sakandelidze

Rhinitis,
pharyngitis,
dermatitis,
conjunctivitis

Klebsiella ozaenae,
K. rhinoscleromatis,
K. pneumoniae
Staphylococcus,
Streptococcus, E.
coli, Proteus,
Enterococcus, P.
aeruginosa
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Successful treatment of 109 patients using
adapted phage
Clinical improvement observed in 86% of
360 patients treated with phage, 48% of 404
treated with antibiotics, and 83% of 576
treated with both phage and antibiotics

1993

Miliutina and
Vorotyntseva

Bacterial
dysentery,
salmonellosis

Shigella, Salmonella

Combination of phage and antibiotics
successful in cases where antibiotics
ineffective

1994

Kwarcinski
et al.

Recurrent
subphrenic
abscesses

E. coli

Antibiotic-resistant strain successfully
treated with phage

1995

Perepanova
et al.

Inflammatory
urologic diseases

Staphylococcus, E.
coli, Proteus

1999

Stroj et al.

Cerebrospinal
meningitis

K. pneumoniae

Clinical improvement observed in 92% and
bacterial clearance observed in 84% of 46
patients treated with adapted phage
Successful treatment by orally administered
phage after failure of antibiotics in a
newborn

C. ADVANTAGES OF PHAGE THERAPY
As these reports illustrate, phage therapy has the potential to become a highlyeffective replacement for our failing antibiotics. In particular, phage therapy possesses
several major advantages over antibiotics and many other potential alternatives; five such
advantages are detailed below.
1. Ability to Self-Replicate: Unlike antibiotics, bacteriophage when used in the treatment
of disease are a self-replicating therapeutic; that is, as they exert their anti-bacterial
effects, they also replicate to create more therapeutic agents – more phage. In the last step
of the lytic cycle, the bacterial host cell is lysed, releasing these new therapeutics into the
environment to infect and kill more bacteria. This way, the number of therapeutic agents
available is uniquely tied to the number of host bacteria – the phage multiply more
rapidly when hosts are plentiful and disappear once their hosts have been depleted,
ensuring they are present in large numbers when necessary to fight pathogens and recede
once their job is done. Another advantage lies in the fact that unlike antibiotics, which are
dispersed throughout the body after administration, phage are concentrated at the site
where their hosts are located, potentially affording them very high efficiency in fighting
infection.
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The relatively large number of progeny phage released per cycle, known as burst
size, in conjunction with the short amount of time required make the self-replicative
ability of phage an even greater advantage. In general, a single DNA phage can generate
several hundred progeny in a span of 30 to 60 minutes, while an RNA phage can produce
5,000 to 10,000 [72]. To fully appreciate the powerful multiplicative effect this produces,
consider the well-characterized E. coli phage T4 as a typical example. A double-stranded
DNA phage, T4 has a burst size of around 200 and requires about 30 minutes per
replication cycle [73]; under ideal conditions and with an unlimited host population, a
single T4 phage particle is capable of producing 1023 progeny in just five hours. Thus, a
relatively low initial dose of therapeutic phage could theoretically be sufficient to tackle a
bacterial infection of any magnitude, and massive stocks of phage can be produced easily
and cost-effectively for distribution to patients.
2. Cost Effectiveness: A second advantage of phage therapy is cost effectiveness. The low
cost of phage therapy is due to two main factors. The first is the self-replicative ability of
phage. Because phage are self-replicating, only a suitable host species and an appropriate
culture medium are required to manufacture almost unlimited amounts in vitro for use in
therapeutic preparations. The self-replicative ability of phage also means that the dosage
size and frequency of reapplication can potentially be very low, minimizing treatment
costs for patients.
The second factor that contributes to the cost-effectiveness of phage therapy is
that novel phage types can be isolated from the environment with relative ease. In
contrast, most new antibiotics must be synthesized in the lab, generally a very costly
process in terms of both time and capital. In fact, a new phage strain can be isolated and
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purified in a matter of weeks with a few hundred dollars, but a new chemical antibiotic
takes on average eight to ten years and $800 million to $1.7 billion to bring to the market
[74].
Because of these two factors, phage preparations are generally much less
expensive than antibiotics. For example, phage preparations such as the ones Randy
Wolcott obtained in his search for an alternative to antibiotics can be purchased from the
George Eliava Institute for just $2 per vial [75]. In stark contrast, a typical regimen of
common antibiotics such as Ciprofloxacin, Ofloxacin, and Azithromycin can cost
upwards of $100, with newer and more powerful antibiotics costing even more [65].
3. Specificity: As covered in Chapter 1, each type of phage is capable of infecting only a
limited range of bacterial hosts based on the receptors to which it adsorbs. This
specificity represents a unique advantage to phage-based therapeutics, as it means that a
properly chosen phage strain will destroy pathogenic bacteria while leaving the beneficial
bacteria normally present in the body intact. In contrast, most antibiotics exert a much
more generalized effect, killing both pathogenic and beneficial bacteria. This leads to a
variety of side effects, including diarrhea, vomiting, stomachaches, headaches,
opportunistic infections by other microbes or parasites, and liver damage. These are
unpleasant at the very least and can even be fatal in patients already weakened by disease.
Because of the strong specificity of phage, phage therapy eliminates almost all of these
adverse side effects.
4. Ability to Evolve: The dynamic evolutionary nature of phage is another of phage
therapy’s main advantages. Just as bacteria can develop resistance to antibiotics, they are
also capable of becoming resistant to phage. However, unlike static antibiotics, phage can
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counteract the resistance mounted against them and evolve right alongside their hosts to
regain their infectivity. Thus, a constant evolutionary arms race naturally rages between
bacteria and the phage that infect them. This phenomenon has been documented
experimentally; in 2002, English scientists Angus Buckling and Paul Rainey performed a
series of experiments involving multiple generations of bacteria and phage [76]. Starting
from a single isogenic culture of Pseudomonas fluorescens SBW25, they inoculated
bacterial cells with the naturally associated bacteriophage SBW25Φ2. Every two days,
the researchers isolated bacterial colonies and phage particles from the culture before
transferring a portion of the culture to a new culture vessel, completing a total of 50
transfers (representing approximately 400 bacterial generations). After every two
transfers (~15 bacterial generations), they evaluated the resistance of the bacteria to the
phage from the same culture as well as to phage from previous and subsequent cultures.
While the phage from previous cultures encountered a high rate of bacterial resistance
due to the evolution of bacterial mechanisms against them, those from subsequent
cultures were able to infect bacterial hosts at a higher rate than those from the same
culture, showing that they had evolved through the generations to renew their infective
abilities.
Contributing to phage evolutionary dynamics is the acquisition of new traits
possible through horizontal gene transfer between different phages and even between
phages and their bacterial hosts. Horizontal gene transfer between different phages,
illustrated in Figure 7a, can occur when two or more lytic phages co-infect a single host
bacterium. As they replicate, their genomes can recombine with each other, producing
unique progeny with genes from multiple parent phages. As an extreme example of this
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recombination, there have even been reports of phage genomes containing the entire
genome of another phage [77]. This suggests that some phage genomes may be able to
shuttle between the genomes of other phage and create viral chimeras that could lead to
the rapid evolution of new phage types.
Temperate phage can also undergo recombination with their bacterial hosts as
depicted in Figure 7b. When an integrated prophage excises itself from the host
chromosome, on occasion it can erroneously excise a portion of the host genome as well.
As the excised phage subsequently undergoes lytic replication, its progeny will all
contain a copy of the mistakenly-excised bacterial genes. These two avenues for
horizontal gene transfer coupled with the quick replication cycles of bacteriophage serve
to greatly facilitate phage evolution as they fight to maintain infectivity against their
hosts.
5. Natural Abundance: Besides their evolutionary prowess, the natural abundance of
phage types in the environment provides another avenue for combating phage resistance:
even if a population of bacteria develops resistance to one phage type, there naturally
exist many more distinct phages to which these resistant bacteria may still be vulnerable.
In fact, for each of the approximately 10 million bacterial species on the planet it is
estimated that there exist 10 distinct bacteriophage genomes that can infect it [78].
Moreover, if the case of the soil bacterium Mycobacterium smegmatis is any indication,
these numbers may be severe underestimates – more than 4000 distinct phage types
specific to M. smegmatis have already been isolated, over 600 of which have been fully
sequenced (The Mycobacteriophage Database [phagesdb.org]). Furthermore, phage can
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be easily manipulated in the lab to produce “artificial” phage with certain desired
properties; examples of such engineered phage were discussed in Chapter 3.

Figure 7: Mechanisms of Horizontal Gene Transfer. Panel a.) depicts horizontal gene transfer between
two different parent phages. In clonal infection (low multiplicity of infection), a single parent phage infects
a host bacterium, and the resulting progeny phage are clones of the parent. In co-infection (high
multiplicity of infection), two or more different phages simultaneously co-infect the same host bacterium.
As they replicate, their DNA recombines, producing a diverse set of progeny with genes from some or all
of the parent phages. Source: Dennehy JJ. 2009. Bacteriophages as model organisms for virus emergence
research. Trends Microbiol. 17(10):450-7. Panel b.) shows a mechanism of horizontal gene transfer
between a temperate phage and its bacterial host. The integrated prophage excises itself imprecisely from
the bacterial chromosome, and the extra bacterial DNA is incorporated into the phage progeny when the
parent phage replicates. Source: http://www.personal.psu.edu/czc5161/blogs/testing/transduction.html.

D. CHALLENGES FACING PHAGE THERAPY
Given the clear advantages of phage therapy over antibiotics and even other
antibiotic alternatives, why are researchers everywhere not scrambling to isolate new
phages effective against increasingly common antibiotic resistant infections such as
MRSA? Why are Western doctors not already routinely prescribing phage capsules
instead of antibiotic pills? Unfortunately, there have been, and are still, many obstacles
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blocking the road to making widespread phage therapy a reality. Some are inherent in the
biology of phage themselves, an area that remains poorly understood, while others are
man-made. Several challenges from both realms are outlined in this section.
Biological Challenges
1. Kinetics: As the title of an article published in 2000 suggests, phage are subject to
“peculiar kinetics” [79] in vivo that have complicated efforts to apply them
therapeutically. In particular, their status as self-replicating therapeutics means that
dosage is inherently impossible to control with any sort of rigor – no matter how many
phage are initially administered, the numbers to which they multiply after reaching their
hosts cannot be controlled or even accurately predicted. This means that it is difficult to
determine how to dose phage therapeutics, as well as how often to re-administer them, in
order to treat a particular infection. Even assuming the dosage could be determined
accurately, reaching the target bacteria is no easy matter, especially for internal infections
such as in the lungs. Although phage cannot harm human cells directly, they are still a
foreign entity and are recognized as such by the immune system, which is very efficient
at clearing them from the body entirely before they ever reach their intended bacterial
targets [80].
Another kinetics issue lies in the fact that the behavior of phage observed in vitro
is often very different from their behavior in vivo. This is often because conditions in the
body affect the way phage interact with their hosts. For example, the efficiency of phage
infection is tied to host density, and there is often a threshold density below which phage
replication is not observed at all – studies have reported threshold values of 102 cells/mL
for cyanophage and 104 cells/mL for T4 phage [7]. Host bacteria may therefore be
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present in high enough concentrations to cause disease, but not high enough to achieve
robust phage replication. In addition, phage are generally only able to infect actively
dividing hosts – if bacterial populations within the body enter a latent state, as is the case
for the agent of tuberculosis Mycobacterium tuberculosis, phage may be unable to
remove them or even physically reach them in the first place.
2. Toxicity: As described previously, phage themselves do not harm human cells.
However, they may incite harmful effects while interacting with their host bacteria. In the
last step of the lytic cycle, for example, lysis of the host can release endotoxins located on
the bacterial cell surface into the body (Figure 8a). These endotoxins can subsequently
induce detrimental reactions such as septic shock.
Some temperate phage also carry toxin genes within their genomes; when these
phage integrate into the host chromosome, they transfer these genes to their host, which
can then begin to produce the toxin and become pathogenic. Pathogenic strains of Vibrio
cholera, E. coli, Clostridium botulinum, Corynebacterium diphtheria, and Streptococcus
pyogenes all obtain their respective toxin genes from bacteriophage as summarized in
Table 3.
Table 3: Bacterial Virulence Factors Carried on Phage. Source: http://www.sci.sdsu.edu/~smaloy/
MicrobialGenetics/topics/phage/phage-virulence.html.
Bacterium

Phage

Disease

Vibrio cholerae

CTX phage

Cholera

Escherichia coli

Lambda phage

Hemorrhagic diarrhea

Clostridium botulinum

Clostridial phages

Botulism

Corynebacterium diphtheriae

Corynephage beta

Diphtheria

Streptococcus pyogenes

T12

Scarlet fever

3. Specificity: The host specificity of bacteriophage is a double-edged sword: on one hand,
it can be considered an advantage in that it precludes the destruction of beneficial bacteria
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in the body, thus preventing many of the adverse side-effects associated with antibiotics.
On the other hand, specificity can also be considered a disadvantage to phage-based
therapies. As detailed previously, most antibiotics are effective against a relatively wide
range of bacterial species, while each type of bacteriophage is limited to a very narrow
host range, sometimes even restricted to specific strains within a species. This means that
it is essential that the pathogen be identified to a high degree of accuracy before an
effective therapeutic can be prescribed. This can sometimes be a relatively timeconsuming process, and for some patients in critical condition identification results may
come too late. Furthermore, if the pathogen is misidentified, a patient’s condition may
worsen as they waste time taking a phage therapeutic that is ineffective against the true
cause of their infection.
This challenge in particular played a large role in the widespread abandonment of
phage therapy research with the advent of antibiotics in the mid-1900s. Because the
specificity of phage was not well understood at the time, many researchers interpreted
disappointing experimental results as a failure of the entire concept of phage therapy
when in reality many of these failed trials were likely due to the administration of the
incorrect phage types. In contrast, antibiotics often showed dramatic effects against broad
classes of bacterial pathogens, and thus were adopted as the preferred method of treating
bacterial infections in the West.

47

Figure 8: Toxicity and Specificity Issues Pose Problems in Phage Therapy. Panel a.) illustrates the
toxicity problems sometimes associated with phage therapies that involve lytic phage. When the phage lyse
their hosts, bacterial endotoxins can be released, leading to adverse inflammatory responses in the body.
Panel b.) depicts the downside of phage specificity: each type of phage can only infect a select range of
bacterial species, meaning an accurate diagnosis is a mandatory prerequisite to ensure a phage therapy
regimen has any effect. Source: Lu TK, Koeris MS. 2011. The next generation of bacteriophage therapy.
Curr. Opin. Microbiol. 14(5):524-31.

Additional Challenges
1. Regulatory Restrictions: In many areas of the world, regulatory restrictions pose a
large obstacle to the establishment of phage therapy as a viable treatment strategy for
bacterial infections. This problem is especially evident in the United States due to the
relative unfamiliarity of the U.S. Food and Drug Administration (FDA) with
bacteriophage. According to general FDA regulations for therapeutics, the safety of every
distinct type of bacteriophage would have to be established separately before it could be
approved for use in humans. For cocktails containing multiple phage types, a common
strategy to alleviate difficulties with specificity and the development of resistance, the
safety of each combination of phages would also have to be confirmed in addition to the
safety of each individual phage in the mixture [81]. This represents an expensive and
time-consuming process that could deter U.S. drug companies from investing in the
development of phage therapies.
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2. Intellectual Property Issues: Issues of intellectual property are another barrier
hindering widespread development of phage therapies. Almost a century old, the concept
of phage therapy itself cannot be patented. Although patents can be issued for specific
phage types, the immense diversity and ubiquity of phages means that a competitor could
easily isolate another distinct but still efficacious phage and develop a competing
pharmaceutical for a particular disease [80]. As an illustration, a company may spend
several years and considerable capital developing a phage-based pharmaceutical for E.
coli infections. To protect their investment, the company could obtain a patent for the
particular phage type their product employs, but another company looking to develop a
similar product would only have to go through the relatively simple process of isolating a
different E. coli phage to develop its own competing product. Because making a profit is
what ultimately motivates pharmaceutical companies to mass-produce and distribute
products, such an easily-copied product as a phage therapeutic is much less likely to be
the subject of enthusiastic development than, for example, a newly-synthesized and
patentable chemical antibiotic.
3. Lack of Awareness: A general unfamiliarity with phages is perhaps one of the greatest
non-biological obstacles that stand in the way of phage therapy’s further development.
Because the development of phage therapy has historically taken place in Eastern Europe
and the former Soviet Union, most early phage therapy research was published in
Russian- and Polish-language journals, where it largely escaped the notice of Western
scientists. Another consequence was that many of these studies, lacking important
experimental components such as control groups and sufficiently large study populations,
did not adhere to the relatively rigorous standards of Western science. As a result, most
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scientists in the West were unable to keep up with new developments in the field, much
less realize its potential, and this general ignorance of the concept of phage therapy
remains in effect today.
Currently, one of the only clinics actively pursuing phage therapy is the George
Eliava Institute. Located in the Republic of Georgia, the Institute and its phage-based
therapeutics remain far from the minds of scientists, doctors, and patients in the West.
Complicating matters further is the fact the general public possesses little to no
understanding of bacteriophages. Even if a patient was offered a phage-based treatment
for his or her illness, he or she might remain extremely skeptical, and perhaps even be
afraid to try the therapy. The patient may wonder: how can a virus cure another disease?
Don’t viruses cause diseases themselves? Without a basic understanding of phage
biology, these questions and fears might be enough to deter the patient from selecting a
phage therapy regimen. If this general ignorance of phage therapy among patients,
doctors, and scientists continues, it will be difficult, if not impossible, for phage therapy
to develop on a large scale. Fortunately, the various obstacles described in this chapter,
including lack of awareness, can be overcome. The next chapter explores several
potential strategies for conquering each of these challenges.

E. POTENTIAL STRATEGIES FOR ADVANCING PHAGE THERAPY
Solutions to Biological Challenges
Several strategies exist for combating the challenges associated with phage
kinetics. The first is the continued study of phage characteristics and behavior, especially
in vivo. Through such study, researchers will gain a better understanding of the
conditions required to eliminate pathogens in vivo. This will help them to better predict
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phage behavior, thus allowing them to decide which phages in what doses are most
appropriate for therapeutic use. A team of British scientists led by Robert J.H. Payne at
Oxford University have already made significant headway in this type of research. In
2000, they published a series of equations that describe key events in phage in vivo
kinetics [79]; such mathematical descriptions of phage behavior will be useful in making
phage therapy maximally effective. Furthermore, although different equations would
likely be required for distinct phage groups, kinetic behaviors observed in one phage
could potentially be extrapolated to phages of similar genetic makeup to further simplify
the complications associated with currently unpredictable kinetic patterns.
Another strategy for overcoming the kinetic challenges posed by phage
therapeutics is the utilization of artificial selection and genetic engineering to generate
maximally effective therapeutic phage strains (Figure 9a-b). Take the problem of
clearance by the immune system for example. In order to obtain phages capable of
resisting clearance for a longer period of time, researchers can follow the example of Carl
Merril et al., who developed a unique artificial selection method called serial passaging
[82]. After injecting phage into the bloodstream of mice, the researchers re-isolated those
phages that were able to survive in the bloodstream the longest, repeating the experiment
until they had succeeded in directing the evolution of long-circulating phages that also
had greater antibacterial capabilities than the parent strains. Researchers can also utilize
genetic engineering to create phage with desired kinetic characteristics. For example,
phage can be engineered to express certain proteins on their capsids that can prevent
antibodies from recognizing and subsequently clearing the phage [83].
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Circumventing the challenges associated with the self-replicating nature of phage
therapeutics altogether, some researchers have proposed using lysis enzymes isolated
from phage to treat bacterial infections [84] [85] [86], a strategy parallel to the use of
lysins in the biofuel industry described in Chapter 3B. Working toward developing such
strategies to combat Mycobacterium tuberculosis infections, several groups have
analyzed various properties of lysinB proteins isolated from mycobacteriophages [87].
Although this strategy eliminates many of the kinetic issues associated with whole-phage
preparations, it also reduces some of the advantages of phage therapy that arise from the
self-replicative and evolutionary abilities of the phage and does not address the issue of
potential toxicity from release of bacterial endotoxins upon lysis of the host cell.
Other researchers have considered using engineered phage incapable of lysing
their hosts to prevent possible toxic effects from the release of bacterial endotoxins [88].
However, similar to the use of phage lysins, therapeutics derived from these phage would
lack the benefits associated with the self-replicative and evolutionary properties of
normal lytic phage. To address the issue of toxicity induced by phage-mediated transfer
of toxin genes to bacteria, continuing large-scale research efforts into the genetic
characteristics of bacteriophage should provide immense benefits. The analysis of a large
number of phage genomes will allow researchers not only to catalog toxicity genes, but
also to identify which phages contain these genes. Such information will aid researchers
in selecting phages without the potential of transferring toxicity to their bacterial hosts for
therapeutic use.
For this strategy to be maximally effective, it necessarily involves the isolation
and characterization of novel phage types. Fortunately, new phage sequences are by no
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means elusive. In fact, it is estimated that the current volume of sequence-characterized
phages represent less than 0.0002% of the total worldwide diversity of phage genomes
[78]. Given the vast number of phage genomes that remain to be discovered, it is crucial
that researchers engage in large-scale isolation and genomic analysis of novel phage
types in order to identify a more complete set of toxicity genes and work towards a better
understanding of phage genomics and phage biology in general.
The isolation and characterization of novel phage types also promises benefits for
solving the problems related to phage host specificity – with more phages to choose from,
a more diverse range of bacterial infections can be treated through phage therapy.
However, phage researchers in Eastern Europe have already arrived at another solution,
the efficacy of which has been demonstrated many times throughout phage therapy’s long
history. Their strategy is to use a cocktail of bacteriophages containing multiple types of
phages in a single solution (Figure 9c). For example, a pharmaceutical may contain 30
different phages targeting five different species of bacteria [81]. This way, even if the
specific pathogen infecting a particular patient is undetermined, there is still a high
likelihood of the medication having an effect.
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Figure 9: Potential Solutions to Phage Therapy Challenges. To address the problem of clearance by the
immune system, a.) artificial section for phages able to circulate in the body longer can be applied to obtain
phages capable of evading the immune system, and b.) phages can be engineered to circulate longer in the
body, for example by expressing proteins on their capsids that prevent antibodies from recognizing and
clearing them. To address the problem of phage specificity, c.) cocktails containing several different types
of bacteriophage targeting a variety of common bacterial pathogens can be used to increase the likelihood
of a therapy being effective. Source: Lu TK, Koeris MS. 2011. The next generation of bacteriophage
therapy. Curr. Opin. Microbiol. 14(5):524-31.

In Eastern Europe, where medical regulations are comparatively relaxed, the
production and distribution of these sorts of phage cocktails presents few problems.
However, in Western countries such as the U.S. with much stricter rules governing the
pharmaceutical industry, the safety of every phage type used in such cocktails would
have to be established both individually and in combination, an issue detailed in the
previous section. Therefore, in order to implement many of the strategies for overcoming
the biological challenges facing phage therapy, including the use of phage cocktails,
Western countries need first to address some of these regulatory roadblocks.
Solutions to Additional Challenges
Finding solutions to bureaucratic challenges will represent a critical step in the
advancement of phage therapy, particularly in Western countries. Towards such solutions,
the U.S. FDA, along with regulatory agencies in other countries, needs to modify policies
for managing phage-based therapeutics based on their unique characteristics, many of
which were described in the previous section. However, for this to occur, regulatory
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agencies must first establish a better understanding of these characteristics. Strategies to
achieve this could include special training courses or the establishment of a small
department with express regulatory control over phage therapeutics. In fact, the U.S.
FDA has already begun to encounter phage therapeutics. Recently, the FDA approved
three whole-phage preparations developed by the biotechnology company Intralytix
(Baltimore, MD) to kill common food-borne pathogens on human food [48]. Through
these sorts of encounters, the FDA will continue to develop experience in working with
phage, and the approval of phage therapies for direct use in human patients will move
closer and closer to becoming a reality.
Key to overcoming issues of intellectual property is the fact that, although a
patent cannot be obtained for the concept of phage therapy itself, many aspects related to
phage therapy are in fact patentable if companies would invest in research to develop
superior phage. Carl Merril’s serial passage technique to isolate phages able to circulate
in the body for a longer time, for example, has been patented; a company owning such a
patent could expect to rise above competition due to the biological superiority of their
phage product. Genetically engineered phage strains, such as phage expressing special
proteins on their coats to evade the immune system, are also patentable. In short, the issue
of intellectual property and patentability is no more severe for phage therapy than for any
other product. It comes down to the willingness of companies to think outside the box in
order to create their own unique phage product that edges out the competition by its own
superiority.
To address the challenges presented by general lack of awareness, the best
strategy is to heighten the awareness of phage and their therapeutic potential among both
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scientists and the general public. This way, more scientists will be willing to devote their
efforts to researching phage therapy, and, once such therapies are realized, more patients
will be willing to use them to treat their illnesses. Specific strategies for achieving this
goal could include placing an introduction to bacteriophage in middle and high school
science courses to ensure that almost all members of the general public have at least a
basic understanding of phage. To target future scientists, more detailed information about
phage and phage therapy could be integrated into college biology courses. In addition,
including the premise of phage therapy in medical school coursework would ensure that
doctors have an understanding of phage therapy, as well. If the majority of scientists,
doctors, politicians, policy-makers, pharmaceutical company managers, and the general
public are made knowledgeable about phage therapy through these mechanisms, the other
challenges facing phage therapy will be easier to overcome.
Some researchers have already realized the importance of alleviating this general
lack of awareness and begun to work towards a solution. In 2008, University of
Pittsburgh professor Graham Hatfull along with several colleagues at the Pittsburgh
Bacteriophage Institute that he co-founded in 1993 teamed up with the Howard Hughes
Medical Institute Science Education Alliance (HHMI SEA) to create a national
bacteriophage research program [89]. To date, more than 4,800 students from 73
institutions have participated in the HHMI SEA Phage Hunters Advancing Genomics and
Evolutionary Science (SEA-PHAGES) course (formally known as the National
Genomics Research Initiative) [90]. A similar mycobacterial genetics program has even
been set up at the Kwazulu-Natal Research Institute for Tuberculosis and HIV in South
Africa. A list of participating U.S. institutions ordered by the year they joined the

56

program as well as a summary of the educational impact the program has had can be
found in Reference [90].
The general sequence of the two-semester course is outlined in Figure 10. In the
first semester, each enrolled student isolates a novel bacteriophage from a self-collected
environmental soil sample. Working on an individual basis, they characterize their
phages using molecular and imaging techniques including electron microscopy, DNA
extraction, and DNA restriction digests. During the students’ winter break, one phage
from the class with a high-quality and high-quantity DNA preparation is sent to a
sequencing center to undergo whole-genome sequencing. In the second semester,
students form small groups and work together to explore, analyze, and complete the
annotation of the raw sequence, which involves using a suite of bioinformatics tools to
determine the location of genes within the genomic sequence and identify functions for
some of those genes based on database matches to known sequences. Finally, the
completed genome is published on GenBank, the open-access sequence database
maintained by the U.S. National Center for Biotechnology Information (NCBI).
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Figure 10: SEA-PHAGES Course Sequence. During the first semester of the course, students work
independently to isolate and characterize novel mycobacteriophages from environmental soil samples. One
phage from the class is selected to be sequenced over the winter break, and students work together during
the second semester to complete the annotation of the genome, which is ultimately published on GenBank,
where it is available to researchers worldwide.

How does a program like this help raise awareness of bacteriophage and phage
therapy? Through working with phage in a research setting over the course of a year,
undergraduate students are able to forge a deeper understanding of phage biology. At
some participating schools, these students are all biology majors. Thus, the future
biologists, researchers, doctors, and professors among them all receive a thorough
introduction to the world of phage and may even develop a lasting interest that will fuel
future research pursuits. Other schools intentionally limit participation in the course to
non-science majors. This arrangement also has major benefits for increasing general
awareness of phage: these schools are introducing phage to future businesspeople,
lawyers, politicians, and journalists. After these students enter the workforce in their
respective fields, they can use their understanding of and interest in phage to start phagebased pharmaceutical companies, advocate for policies to promote phage therapy, and
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write compelling articles to share phage-related concepts with the general public. Outside
of the future contributions students who participate in the course may make, they also
naturally introduce bacteriophage to their friends and family as they share their work. In
this way, even more people are able to learn about phage and phage therapy.
It is worth noting that this program provides additional benefits beyond raising
general awareness of phage – another important goal of the program is to increase the
amount of phage-related data available to bacteriophage researchers. Each year, hundreds
of novel phage types are isolated and characterized by students in the program. These
phages and the completely annotated genomes the students publish are all added to the
pool of information available for researchers across the globe to access and analyze. To
make this data more readily available to researchers, the Pittsburgh Bacteriophage
Institute maintains the Mycobacteriophage Database at phagesdb.org, where information
regarding all currently known mycobacteriophages is stored in a highly accessible
fashion. Archived samples of each phage isolated in the program are also stored and
available to researchers upon request.
These efforts to isolate and characterize novel mycobacteriophages have also
inspired similar projects for other groups of phage, including Arthrobacter, Bacillus, and
Streptomyces phages. In an effort to streamline information regarding these phages in a
similar manner to the mycobacteriophage, the Pittsburgh Bacteriophage Institute has
recently established databases for these phage groups as well (The Arthrobacter Phage
Database [http://arthrobacter.phagesdb.org/], The Bacillus Phage Database [http://bacillus.
phagesdb.org/], The Streptomyces Phage Database [http://streptomyces.phagesdb.org/]).
Although currently very small in comparison to the mycobacteriophage database, these
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databases can be expected to follow the example of their predecessor and continue to
expand rapidly. Such a huge amount of new data stemming from a variety of geographic
locations and encompassing a growing number of phage types greatly facilitates
researchers as they work to solve the many biological challenges currently facing phage
therapy.

F. CONCLUSIONS AND OUTLOOK
Phage therapy is a form of treatment for bacterial infections that was first
developed in 1919, shortly after the initial discovery of bacteriophage. As described
previously, it utilizes lytic bacteriophage as agents to kill pathogenic bacteria. Although it
was largely overshadowed by the advent of antibiotics in the 1940s, phage therapy has
several distinct advantages over antibiotics and has especially great potential for
combating antibiotic-resistant infections. As detailed throughout this chapter, over the
course of its more than 90-year history, researchers from all over the world have
successfully used phage therapy to combat a wide range of bacterial infections, but
because of a variety of biological and bureaucratic challenges, its true potential has yet to
be realized. However, as noted in the last section, these challenges are by no means
insurmountable, and many investigators are already engaged in research to solve some of
these challenges.
Overall, it can be said that the road to wide-spread implementation of phage
therapy is still long. However, if more researchers, supported by policy-makers,
politicians, doctors, journalists, and the general public, join the effort to make it a reality,
phage therapy could very well become one of our most powerful weapons in the fight
against the growing threat of antibiotic resistance.
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PART II

ISOLATION AND CHARACTERIZATION OF TIROTHETA9,
A NOVEL MYCOBACTERIOPHAGE

Bacteriophage play key ecological roles and have a wide range of potential
applications. However, the development of many of these applications, including phage
therapy, has been limited by a lack of understanding of phage biology. Thus, the full
potential of such applications will only be realized if we work to increase our knowledge
of phage and their biology.
New applications for phage will also only come through improving our
understanding of phage genetics and diversity. With so much of the phage metagenome
yet to be discovered, phage represent an enormous pool of unknown genetic information
that could harbor new gene products with compelling applications of similar significance
to those of phage integrase and lysis enzymes. Through the characterization of novel
phage genes, it may even become possible to develop “designer” phage composed of
genes selected from a central database. Insights into bacterial evolution are also possible
– with an increased knowledge of phage genetics, phage-derived genes, including both
active and cryptic prophages, could be identified within a number of different bacterial
species, yielding insights into the evolutionary history of these species. Such insights
could be important in understanding the divergence and continuing evolution of clinically
relevant bacteria such as Mycobacterium tuberculosis, recently discovered to be
comprised of seven related but distinct strains, one of which appears to be particularly
well-equipped to take advantage of the high levels of interconnectedness and population
density that characterize modern society [91]. These novel phage genes and their
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functions will only be uncovered through the isolation and sequencing of new phage
types.
The research presented in the following chapters describes just such an endeavor.
The work was completed in part through the HHMI SEA-PHAGES program, a national
bacteriophage research initiative described in Part I Chapter 4E. The phages isolated
through this program all belong to a group of phages called mycobacteriophage, which
infect bacteria of the genus Mycobacterium. The significance of mycobacteriophage, as
well as an overview of their characteristics, diversity, evolution, and research history, is
detailed in the following chapter, which consists of a review of relevant literature in the
mycobacteriophage field. The remaining chapters present original research regarding
TiroTheta9, a novel mycobacteriophage isolated from the soil, and its relationship to
other mycobacteriophages.
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CHAPTER 6

REVIEW OF MYCOBACTERIOPHAGE DIVERSITY AND EVOLUTION

The first mycobacteriophages were isolated more than 60 years ago using the
harmless soil bacterium M. smegmatis as a host. The isolation of mycobacteriophages
specific to the agent of tuberculosis, M. tuberculosis, followed a few years later [92].
While early mycobacteriophage research focused predominately on their utility in typing
clinical isolates of mycobacteria [93], more recent efforts have centered on developing
mycobacteriophage as i) tools for elucidating and manipulating the genetics of their
mycobacterial hosts [93] [94], ii) as models for phage evolution and diversity [93] [95]
[96], and iii) as an educational platform for introducing young scientists to authentic
scientific research [97] [98].
Although all three of these roles for mycobacteriophage have been researched
rather extensively, the scope of this chapter focuses mainly on the insights into
mycobacteriophage evolution and diversity gained through recent comparative analyses.
Such studies have been fueled by the recent explosion of newly discovered
mycobacteriophages and sequenced mycobacteriophage genomes, largely due to
contributions from student participants in the Howard Hughes Medical Institute SEAPHAGES program, who isolate and characterize their own novel bacteriophages in a
year-long course (see Chapter 5E). Just ten years ago, only four mycobacteriophage
genomes had been sequenced [96]. By 2008, that number had risen to more than 50 [98]
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and had reached upwards of 70 by 2010 [93]. As of May 2014, there were 4666 archived
mycobacteriophages (and counting) and 671 finished sequences registered in the online
Mycobacteriophage Database (phagesdb.org), with 348 of those sequences published in
the National Center for Biotechnology Information’s open-access sequence database
GenBank. This profusion of sequence data has greatly facilitated the elucidation of phage
genetics and evolution.
This chapter covers four main topics under the overarching theme of
mycobacteriophage evolution and diversity. First, “General Characteristics and Diversity
of Mycobacteriophages” provides a brief overview of the general morphologic and
genomic properties of the mycobacteriophages that have been characterized and reported
in the literature thus far. Although some general conclusions can be made, this section
also highlights the remarkable diversity of these phages. The second section, “Taxonomy
of Mycobacteriophages and Their Genes,” explains the clustering system that has been
designed to classify mycobacteriophages based on nucleotide similarities, as well as the
system of “phamilies” that has been developed to categorize mycobacteriophage genes.
This establishes the basis for the next section, “Further Insights from Mycobacteriophage
Comparative Analyses,” which recaps some of the major conclusions of comparative
analysis studies involving mycobacteriophages. This category specifically incorporates
discussion of the mosaic nature of the mycobacteriophage genomes, their geographic
distribution and its relation to genome sequences and cluster classification, and immunity
studies that investigate the superinfective abilities of related phages. Finally, “Generation
of Mycobacteriophage Diversity” covers some major theories that exist to explain the
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mechanism by which the wide degree of diversity evident among mycobacteriophages
and bacteriophages in general has been generated throughout their evolutionary history.

A. GENERAL CHARACTERISTICS AND DIVERSITY OF
MYCOBACTERIOPHAGES
Except for the first three mycobacteriophages to be sequenced, all of the
mycobacteriophages with genomes currently available through GenBank were isolated
using Mycobacterium smegmatis, which is a common, non-pathogenic soil bacterium
[93]. All but one of these phages are known to infect the commonly-used laboratory
strain M. smegmatis strain mc2155 [99]. Although the sequenced phages share a common
host, they are still remarkably diverse both morphologically and at the nucleotide
sequence level.
As more and more mycobacteriophages have been isolated, several studies
comparing these phages have been conducted in efforts to generalize basic
mycobacteriophage characteristics and catalog their diversity. As one of the first such
studies, a 2008 paper published by Hatfull et al. [98] comparing 32 phages revealed that
all of the mycobacteriophages analyzed are tailed, double-stranded DNA phages with
genomes ranging from 42 kilo base pairs (kbp) to 150 kbp in length and averaging about
70 kbp. The GC content1 of the genomes, which can sometimes be a useful predictor of
host range as phage are often assumed to have a similar GC content to their preferred host,
averaged 63.7%. This is similar to that of M. smegmatis (63%), although the range of GC
contents observed (59% to 69%) may reflect differences in the natural host ranges of the
various phages. Despite these differences, all of the 32 phages analyzed and many of the
1

The GC content of a genome is the percentage of nucleotide bases in the genome that are either guanine
(G) or cytosine (C). This value varies greatly among organisms.
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other hundreds of mycobacteriophages that have since been reported in the literature were
isolated using a single host, the relatively fast-growing and avirulent Mycobacterium
smegmatis mc2155. In addition, at least one phage has been isolated on M. avium, and
approximately 10% are estimated to be capable of infecting M. tuberculosis as well.
All of the mycobacteriophages analyzed in the paper fell into two of the three
morphotype categories currently identified for dsDNA phages, although in very unequal
proportions. Thirty, possessing long, flexible, non-contractile

2

tails, were of the

siphoviridae type, while two belonged to the myoviridae, characterized by shorter,
contractile tails. Interestingly, no mycobacteriophages of the stubby-tailed podoviridae
type were observed (see Part I Chapter 1C and Figure 3 for a review of phage
morphotypes). Finally, the authors noted that the majority of the phages analyzed have
isometric heads, but a few display a prolate, or elongated, head morphology. These
morphologies are illustrated in Figure 11, which shows representative phages of each
type (siphoviridae and myoviridae) as well as examples of each of the two observed head
shapes, isometric and prolate. This article provided one of the first comprehensive
analyses of the growing number of mycobacteriophages and serves as a definitive starting
point for both the studies which came after as well as future investigations.

2

In phages with contractile tails, the tail fiber is covered by a contractile sheath that contracts when the
phage adsorbs to the outside of its host to reveal the inner tail fiber. The contraction facilitates passage of
the phage’s genetic material into the host. Phages with non-contractile tails do not have a contractile sheath
and utilize various other infection mechanisms.
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Figure 11: Mycobacteriophage Morphotypes. Most characterized mycobacteriophages belong to the
siphoviridae, exemplified by Gumball and Corndog, while the others are myoviridae like Cali. Of the
siphoviridae, most have isometric heads like Gumball, while a few display a prolate head morphology
similar to Corndog. Source: Hatfull GF, Cresawn S, Hendrix R. 2008. Comparative genomics of the
mycobacteriophages: insights into bacteriophage evolution. Res. Microbiol. 159(5):332-339.

A second paper published by Hatfull et al. in 2010 expanded these observations to
a much larger group of sixty phages, providing additional morphological details that
further elucidated the general characteristics and diversity of mycobacteriophage [100].
Despite the addition of nearly 30 new mycobacteriophages to the analysis, the average
genome length (72.6 kbp) as well as average GC content of the genomes (63.4%)
remained remarkably close to the values reported in 2008. Although the averages
remained constant, the limits of the ranges observed for each of these parameters were
expanded slightly – genome size ranged from 41.9 kbp to 164.6 kbp and GC content
ranged from 56.3% to 69.1%. An additional characteristic of the mycobacteriophage
genomes analyzed was also reported: thirty-five of the genomes contained defined
physical ends3 with small, single-stranded extensions on the 3’ end ranging from 4 to 14

3

Defined physical ends are characteristic of phages whose genomes are cleaved at specific recognition
sequences as they are packaged into the progeny phage heads (cos packaging). This method ensures that
each progeny phage is packaged the same way and possesses a single copy of the genome. The singlestranded 3’ overhang, known as the cos site, allows the phage genome to circularize upon injection into a
host bacterial cell.
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bp, while the remaining twenty-five genomes were observed to be circularly permutated4.
The authors also noted that the average mycobacteriophage genome contains 114 proteincoding genes, each of which was an average of 616 bp long (about two-thirds the average
length of a mycobacterium gene).
In terms of morphology, a higher proportion of the phages in this expanded study
were identified as myoviridae (7/60, approximately 11%) compared to the 2008 study
(2/32, approximately 6%), although the vast majority still belonged to the siphoviridae,
and no podoviridae examples were reported. The tails varied greatly in length, ranging
from 135 nm to 350 nm, a more than two-fold spread. All of the myoviridae phages had
isometric heads approximately 85.9 nm in diameter, while fifty of the phages belonging
to siphoviridae (94.3%) had smaller isometric heads ranging from 55 nm to 60 nm in
diameter. The remaining three siphoviridae phages (5.7%) contained prolate heads of
varying length-to-width ratios. The authors noted that in general, head dimensions tended
to correlate with genome size, although dimensions measured from electron micrographs,
as these were, can sometimes misrepresent actual values in active phages. However, if
this relationship is true, it would suggest that the DNA packaging densities are similar
across the mycobacteriophages. This paper provided an even more comprehensive
analysis of the general characteristics and diversity of the mycobacteriophages and
additionally served to reinforce the general patterns reported in the 2008 paper described
above.

4

In contrast to defined physical ends, circularly permuted genomes result when progeny phage heads are
packaged with genetic material until the head is completely full (headfull packaging). Each progeny phage
is packaged differently and contains more than a complete genome, generally displaying terminal
redundancy.
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Following

the

isolation

and

sequencing

of

increasing

numbers

of

mycobacteriophage, other studies reporting similar results have been published [101] [96]
[95], including a recent Journal of Virology paper that formally announced the genomic
sequence of 138 novel mycobacteriophages [102]. From these studies, it is evident that
the typical mycobacteriophage has a genome about 70 kbp in length with a GC content of
about 63%, contains approximately 114 protein-coding genes, belongs to the siphoviridae
(i.e. has a long, flexible, non-contractile tail), and has an isometric head between 55 nm
and 60 nm in diameter. The prevalence of long-tailed siphoviridae and absence of stubbytailed podoviridae consistently observed among the mycobacteriophages may indicate the
utility of the tail structure in maneuvering around the unusually thick cell wall that
characterizes the Mycobacteria during infection [98].
Of course, these measurements are only averages, and it is clear that despite their
utilizing a common host species, remarkable diversity has been established among these
phages, evident from the wide range in genome size and differences in head and tail
morphologies described above. And this may represent just the tip of the iceberg when it
comes to the full range of mycobacteriophage diversity – the fact that most currently
known mycobacteriophages have been isolated using a common host has likely precluded
the discovery of much of this diversity. The techniques used have also been exclusive to
the isolation of dsDNA phages, leaving potential ssDNA, ssRNA, and dsRNA
mycobacteriophages yet to be discovered. As more mycobacteriophages are isolated and
characterized, this vast diversity as well as the mechanisms that shaped it are becoming
increasingly apparent, and through the use of a wider variety of Mycobacterium hosts and
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different sets of isolation techniques, we may find that the true extent of
mycobacteriophage diversity is much greater than we ever imagined.

B. TAXONOMY OF MYCOBACTERIOPHAGES AND THEIR GENES
Bacteriophage genomes, including those of mycobacteriophage, are mosaic in
nature, meaning they often contain genes originating from various phylogenetic
backgrounds concatenated together into a sort of genetic mosaic [1]. This mosaicism
makes the classification of bacteriophages inherently difficult, especially under the
classical Linnaean paradigm, wherein new species are traditionally placed into the
framework based on shared physical characteristics. With the development of the field of
genetics and advent of wide-spread genome sequencing, it has become clear that this
system has its faults, particularly when attempts are made to use it for the classification of
microorganisms, particularly viruses like bacteriophage. Lawrence, Hatfull, and Hendrix
described these flaws as they relate to viral taxonomy at length in a paper published in
2002 [103]. Although there are plenty of phenotypic characteristics by which
bacteriophages can be grouped, including host range and morphology, these oftentimes
are not correlated with sequence similarities. For example, the phages T4 and Mu, as
members of the myoviridae group of phages, both have contractile tails, but the genes
encoding for their respective tails are completely unrelated. This would suggest that the
phages represented in the myoviridae group are not, in fact, recently derived from a single
common ancestor phage. Clearly, a fundamentally different paradigm is necessary to
classify bacteriophages in a meaningful way.
Two such paradigms have been developed for mycobacteriophage. One organizes
the mycobacteriophages themselves into groups called clusters on the basis of nucleotide
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similarity, while the other is a system for arranging mycobacteriophage genes into
“phamilies” of related genes. The system of phamilies, or phams, was first introduced by
Hatfull et al. in a 2006 paper [101] that explained how the 3,357 open reading frames
encoded in 30 mycobacteriophage genomes were organized into groups of related genes
dubbed phamilies. In order to be classified as a member of a particular pham, a candidate
open reading frame must code for a protein that shares at least 25% amino acid identity
with at least one other member of the phamily across its entire length. According to this
criterion, the open reading frames were classified into 1,536 phams of various sizes, with
the average pham containing 2.19 genes. Strikingly, 50.3% of the phamilies contained
just a single member, and 1,306 (about 85%) contained genetic sequences that had never
been identified before, hinting at the profusion of phage genes yet to be discovered. Three
phams contained representatives in all 30 of the mycobacteriophages examined. Thus,
these phams, which contain putative lysins and tail proteins, potentially correspond to
hallmark genes that may be conserved among most mycobacteriophage genomes. The
authors noted, however, that great sequence diversity still exists even among members of
a single phamily, as a candidate only has to match a single existing member with 25%
identity in order to be included.
Comparison of phage genes leads, in turn, to the identification of similar groups
of phages, called clusters. By grouping together phages that contain genes from the same
phamilies, the authors classified twenty-one of the phage genomes into six clusters,
designated A-F, with the remaining nine classified as singletons that did not share a close
enough relationship with any other mycobacteriophages at the sequence level to be
placed into a cluster. These clusters do not completely represent the evolutionary history
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of their member phages as the members are mosaics and may still contain instances of
genes common to phages of other clusters. However, later studies established that overall,
there is very little DNA sequence similarity between different clusters [102]. The exact
methods by which the clustering was accomplished were not made explicitly clear;
nevertheless, this paper proposed a feasible paradigm by which mycobacteriophages and
their genes, and perhaps all phages and phage genes, can be organized.
The clustering and pham systems have since been adopted by many researchers
investigating mycobacteriophages and have predictably been expanded as new
mycobacteriophages and genes have been added. In their 2010 paper that describes the
comparative analysis of sixty mycobacteriophages, Hatfull et al. added three new clusters
to the six previously established and rigorously described four methods by which cluster
membership was determined [100]. With new insights from these methods, they
additionally proposed alterations to a few of the previous classifications. The number of
singleton phage genomes was reduced from nine to five, and the number of phams
containing single members (orphams) was also lowered to 46.1% from 50.3%.
Interestingly, the increased sample size of 6,858 open reading frames resulted in 1,523
phams, slightly fewer than the 1,536 initially identified. This is perhaps due to the
bridging of former orphams by newly discovered genes. Taking the gene classification
system a step further, the three phams containing more than 250 members were further
subdivided into subphams, as were nine smaller phams, resulting in a total of 1723
distinct phams and subphams.
The authors took a more rigorous approach to the clustering process than
previously described, utilizing four different methods in an attempt to more completely
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address the three types of relationships they identified among the phage genomes. They
recognized one class of relationships containing genomes that are very closely related and
obviously belong to the same cluster, while another contained those having no observable
relationship and clearly belonging to different clusters. The third, more complex case
encompassed genomes where large but weakly similar genome segments, highly similar
but short genome segments, or divergent nucleotide sequences corresponding to similar
amino acid sequences are observed. Taking these relationships into account, they decided
on an explicit criterion for determining cluster eligibility; in order to belong to the same
cluster, two phage genomes must display sequence similarity spanning more the 50% of
the smaller genome in a dot plot analysis5. Dot plot analysis according to this criterion
resulted in nine clusters (designated A-I) with five singleton phages, which as noted
above was three more clusters and four fewer singletons than initially described in 2006.
Additionally, because some members of the same cluster display closer similarity to each
other than to other genomes within the cluster, five clusters were further subdivided into
a total of 12 subclusters.
The other three methods were largely used to confirm these classifications and
included comparison of average nucleotide identity values, gene content analysis using
the phamily classifications as was done previously, and performing pairwise genome
alignments of the genomes, which compare two or more nucleotide sequences while
showing gene locations simultaneously (Figure 12). These three additional methods
largely supported the classifications made based on the dot plot criterion. Finally, the
authors noted the reclassification of several phages based on their new methodology,
5

Dot plots are widely used in bioinformatics as a tool to visually compare two sequences. The sequences
are organized along the x and y axes, and a dot is placed on the graph wherever the two sequences match;
consecutive matches form lines that illustrate the relationship between the two sequences.
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including moving two phages previously excluded from cluster F and classified as
singletons into the cluster.

Figure 12: Pairwise Alignment of Two Mycobacteriophages. The figure depicts a section of a pairwise
nucleotide alignment of G cluster mycobacteriophages Hope and Angel generated by the program
Phamerator. The colored boxes represent putative genes, with colors and labels corresponding to the
phamilies each gene belongs to. The purple areas between the two genomes show areas of high nucleotide
homology, while white indicates little or no sequence homology. This particular segment shows evidence
of an insertion in the Hope genome (putative gene 57) that is not present in the Angel genome but which is
surrounded on both sides by areas of high sequence homology, a good example of the genetic mosaicism
observed among mycobacteriophages. Source: Pope WH, Jacobs-Sera D, Russell D, et al. 2011.
Expanding the diversity of mycobacteriophages: insights into genome architecture and evolution. PLoS
One. 6(1): e16329.

Since the publication of these papers, several additional clusters, subclusters, and
singleton

genomes

have been

added

to

the

rapidly-expanding

database

of

mycobacteriophage genomes. All of these are cataloged on the frequently-updated
Mycobacteriophage Database at phagesdb.org, created and maintained by the Pittsburgh
Bacteriophage Institute. As of May 2014, there were 21 clusters (A-U), variably divided
into a total of 37 subclusters, and eight singleton genomes contained in the database,
representing a total of 671 fully-sequenced mycobacteriophage genomes. Select
characteristics of each cluster are displayed in Table 4. There are also 3995 phages
contained in the database that have yet to be sequenced and thus cannot be rigorously
clustered, although recent efforts have focused on developing sets of primers unique to
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each cluster that would allow cluster assignment by Polymerase Chain Reaction (PCR),
thereby eliminating the express need for whole-genome sequencing [104].
A comparison of the average length and average GC content across each cluster is
shown in Table 4. These data clearly showcase the wide diversity present among
mycobacteriophages and highlights the utility of the clustering system in analyzing this
diversity. The clustering system has also allowed researchers to identify and further
investigate some of the unique characteristics specific to certain clusters. For example,
intron splicing has been explored in the Cluster J phages [105], and the evolutionary
history of a heteroimmune, exclusively virulent member of the K Cluster as well as the
potential utility of K1 subcluster phages as genetic tools for M. tuberculosis have been
elucidated through inter-cluster analysis [106].
The cluster and gene phamily systems, while not perfect, have become
conventional among the majority of mycobacteriophage researchers and will continue to
develop as new genomes are elucidated. At the same time, it is clear from the rapid
expansion of the clusters and prominence of singleton phages and orphams that
researchers have just scratched the surface of the cache of mycobacteriophages present in
the environment and that many more novel genes and genomes remain to be discovered
[95].
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Table 4: General Characteristics of the Mycobacteriophage Clusters. Source: phagesdb.org/clusters.
Cluster Subclusters Members

Avg Length
Oldest Newest
Avg GC%
(bp)
Found Found

A

11

248

51,539

63.3

1954

2014

B

5

119

68,661

67

2001

2014

C

2

46

155,504

64.7

1990

2013

D

2

10

64,795

59.4

2003

2013

E

-

44

75,487

63

2002

2013

F

3

70

57,414

61.5

2002

2013

G

-

14

41,845

66.6

2003

2013

H

2

5

69,469

57.3

2001

2013

I

2

4

49,954

66.5

2002

2012

J

-

16

110,332

60.9

2005

2013

K

5

33

59,720

66.8

1984

2013

L

3

13

75,177

58.9

2008

2013

M

2

3

81,636

61.3

2008

2011

N

-

7

42,888

66.2

2009

2013

O

-

5

70,651

65.4

2001

2012

P

-

10

47,784

67

2009

2014

Q

-

5

53,755

67.4

2005

2013

R

-

4

71,348

56

2009

2013

S

-

2

65,172

63.4

2009

2012

T

-

3

42,833

60.6

2008

2013

U

-

2

69,942

50.4

2009

2009

Singleton

-

8

66,405

66.2

1960

2013
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C. FURTHER INSIGHTS
ANALYSES

FROM

MYCOBACTERIOPHAGE

COMPARATIVE

The grouping of related mycobacteriophages into clusters and of related
mycobacteriophage genes into phamilies make it relatively straightforward to conduct
both inter and intra-cluster comparative analyses. Such comparative studies can reveal
much about the diversity and evolution of mycobacteriophages [100]. The morphological
and general genomic diversity of the mycobacteriophages, an important element of
preliminary comparative analyses, was discussed in detail in Section A.
The ubiquitous genetic mosaicism observed in the mycobacteriophages was also
touched upon briefly in the previous section; this mosaicism is clearly visualized by
pairwise genome alignments like the partial one shown in Figure 12 above. The genomes
of these two phages display high sequence homology overall but have this homology
interrupted intermittently by small, often single-gene regions of nucleotide sequence
divergence where one of the pair has presumably added a gene to its genome from an
outside source.
Genetic mosaicism is also illustrated well by phamily circles, in which userselected mycobacteriophage genomes are arranged around the periphery of a circle by
cluster (Figure 13). Lines whose thicknesses correlate with the strength of the
relationship then connect all of the different phages that contain genes belonging to the
pham under investigation. Phamily circles thus provide a visual depiction of evolutionary
relationships both within and across clusters. For example, the existence of clusteridentifier phams, i.e. phams represented in all genomes belonging to a particular cluster
but not in any other genomes, has been observed through phamily circle analysis [100].
Pham 1707 in Figure 13 is an example of such a pham.
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The construction of pairwise alignments and phamily circles as well as dot-plots
can be accomplished using a specialized bioinformatics tool called Phamerator [107]. The
program contains a database of protein-coding phage genes sorted into phamilies that it
draws upon to generate these comparative graphics, thereby greatly facilitating both
large-scale and more defined analyses.

Figure 13: Mycobacteriophage Phamily Circle Diagrams. Pham 1707 is an example of a pham whose
members are only observed in a single cluster, while pham 2942 is widely represented among the
mycobacteriophages and has members observed in six different clusters. These diagrams are generated the
program Phamerator. Source: Pope WH, Jacobs-Sera D, Russell D, et al. 2011. Expanding the diversity
of mycobacteriophages: insights into genome architecture and evolution. PLoS One. 6(1): e16329.

Besides the general genomic and genetic comparisons made possible through
Phamerator, several other more specific comparative studies have been reported in the
literature, including an investigation of the correlation between the isolation site and
cluster classification/sequence similarity, the exploration of superinfection abilities
among related phages, and the elucidation of possible mechanisms of host restriction
among mycobacteriophage. These topics are treated in more detail in the following
paragraphs.
Geographic Analysis
Mycobacteriophages have been isolated from geographic locations nearly as
diverse as the phages themselves, ranging from various sites across the U.S. to
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international sites in Canada, the Caribbean, China, Ireland, Finland, South Africa,
Mozambique, Algeria, India, and Japan. In fact, 334 of the 4666 currently described
mycobacteriophages were isolated outside the U.S., a small but important – and growing
–

group

(phagesdb.org,

May

2014).

In

their

2006

paper

comparing

30

mycobacteriophages, Hatfull et al. first suggested a lack of correlation between sequence
similarity and location of isolation [101], an observation reinforced in a 2011 paper by
Pope et al. that analyzed 80 mycobacteriophage genomes [95].
This observation has interesting implications for the study of phage evolution and
gene transfer, as it would seem likely that phages isolated from locations in closer
geographic proximity would be genetically similar and that those separated by a vast
geographical distance would be more divergent in accordance with decreased opportunity
for genetic exchange. The observed lack of correlation between these two parameters is
thus rather counterintuitive. The authors of the 2011 paper did take note of several
possible non-random distribution patterns, but conceded that much more data is necessary
to confirm these patterns. A more in-depth treatment of this topic as it relates specifically
to phages in the A4 subcluster is provided in Chapter 8.
Superinfection and Homoimmunity Studies
In the same paper, Pope et al. also described an experiment in which they
indirectly compared the immunity systems of Cluster A mycobacteriophages by
investigating the ability of each phage to superinfect lysogens of each of the other
members of the cluster. A prophage prevents expression of its lytic genes by the binding
of a repressor protein to specific regulatory sites in the genome; often, this repressor can
also block the expression of the lytic genes of closely related phages, barring them from
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undergoing replication and thereby making the lysogenic host immune to superinfection.
This phenomenon is known as homoimmunity. The observations made during this
experiment yield insights into which portions of the repressor system are important for
successful binding of the repressor as well as insights into bacteriophage immune
specificity in general. Similar immunity studies involving three Cluster G phages have
also been conducted [108].
Sequence comparisons also revealed a unique example of “repressor theft” by an
otherwise unrelated phage of Cluster C. This phage contains a putative repressor gene
that is more than 99% identical to one of the A1 subcluster repressor sequences, although
there is no binding site for the repressor within its genome and it is thus not utilized by
the phage to form its own lysogens. Noting that the Cluster C phage is capable of
superinfecting lysogens of the A1 subcluster phage, the authors came to the plausible
conclusion that this gene, probably picked up through a horizontal gene transfer event
somewhere in the phage’s evolutionary history, has been retained in the Cluster C
phage’s genome as a defense mechanism against superinfection by cluster A1-like phages.
If an A1-like phage were to superinfect a host already infected with the Cluster C phage,
the repressor would bind to the A1-like phage and prevent it from replicating while
allowing the Cluster C phage to continue replicating itself. The authors noted that this is,
as far as they are aware, the first example of repressor theft observed in any type of
bacteriophage.
Mechanisms of Host Range Constraint
Comparative analysis has also led to insights into phage-host interaction during
infection, specifically mechanisms by which host range constraints are established for
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mycobacteriophages. Several theories exist to account for the inability of a phage to
successfully infect bacterial strains outside its host range. These include restrictionmodification, availability of appropriate receptors, various processes that result in
abortive infection, Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPRs), and translational apparatus modification. In a 2012 Virology paper, JacobsSera et al. reported a series of experiments that strongly suggest host recognition or DNA
injection barriers determine the host range for mycobacteriophage [99].
As a prelude to these experiments, the authors first provided evidence for a
correlation between cluster or subcluster designation and host preference. They tested
221 sequenced mycobacteriophages representing clusters(subclusters) A(1-9), B(1-5),
C(1), D, E, F(1-2), G, H(1-2), I(1-2), J, K(1-5), L(1-2), M, N, and O as well as seven
singletons for ability to infect M. tuberculosis mc27000 and found that infective ability
was restricted to Cluster K phages and Subcluster A2 and A3 phages. Cluster G phages
were also found to form plaques on M. tuberculosis at a reduced efficiency relative to M.
smegmatis mc2155. Genome alignments yielded no obvious answers as to what merited
this difference in host preference.
Because M. tuberculosis is related rather distantly to M. smegmatis, it was not
unreasonable to find so few examples of mycobacteriophage able to infect both strains in
the almost exclusively M. smegmatis-derived database. Thus, to further probe patterns of
host preference, the authors also tested the same 221 phages for their ability to infect M.
smegmatis strains Jucho and MKD8 as well as the more distantly related M. aichiense,
which exhibits a similar growth profile to M. smegmatis. Although none of the phages
tested were able to infect M. aichiense, correlations between cluster/subcluster and
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infective ability were once again observed for the two M. smegmatis strains. It is
interesting to note that for these strains, differential plating efficiencies can be observed
even among presumably very closely-related phages of the same subcluster. For example,
the A4 Subcluster phages Peaches and TiroTheta9 share 99% sequence identity; however,
according to the data presented in the article, TiroTheta9 plates on Jucho with an
efficiency four orders of magnitude greater than Peaches (1.0 x 10-1 vs. 3.7 x 10-5,
measured relative to M. smegmatis mc2155), while the opposite is true for MKD8 (<10-9
vs. 1.1 x 10-5). A similar dichotomy is observed for MKD8 infection with Backyardigan
and Wile, another pair of highly homologous A4 phages.
With these host range constraints established, Jacobs-Sera et al. hypothesized that
the observed ability of several phages to form plaques with reduced efficiency on some of
the alternative hosts may be the result of mutations either expanding or altering the host
range. To test this, they isolated plaques of two Cluster G phages grown on M.
tuberculosis. Upon replating, the phages from these plaques were able to infect both M.
smegmatis and M. tuberculosis with equal efficiency, suggesting that a mutation had
occurred to expand the host range of the parent phages. The complete genome of one of
the isolates derived from Mycobacterium phage Halo was sequenced, and the mutation
was mapped to a non-synonymous point mutation within a gene belonging to a group of
putative minor tail proteins. This mutation was confirmed through sequencing the same
gene in the other isolates. The fact that mutations were exclusively found in a tail protein
suggests that hindered surface interactions, including phage adsorption and DNA
injection, rather than defects in the replicative process within the host are responsible for
the low efficiency of M. tuberculosis infection observed in Cluster G phages.
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Further support for this conclusion was provided by engineering two of the
observed substitutions into wild-type Halo. The engineered phage showed an ability to
infect M. tuberculosis equivalent to that of the mutants isolated previously. Additionally,
when M. tuberculosis cells transformed with either wild-type or expanded-host-range
mutant Halo DNA were plated on a lawn of M. smegmatis, equivalent numbers of
plaques were observed. This indicated that the phage DNA was able to replicate normally
within the M. tuberculosis cells, suggesting that replicative barriers are not what cause
the differential infection abilities of the wild-type and expanded-host-range mutants.
Unexpectedly, adsorption assays showed an increased ability of the mutant phage to
adsorb to M. smegmatis (but M. tuberculosis adsorption rates remained the same) – this
may suggest that the surface interactions affected by the mutation are not related to
receptor recognition, but that subsequent events requiring participation of tail proteins,
such as DNA injection into the host, somehow make the binding process irreversible. A
similar minor tail protein point mutation was implicated in the increased ability of Cluster
B2 phage Rosebush expanded-host-range mutants to infect M. smegmatis Jucho, and the
same adsorption phenomena were observed for these mutants as well.
The M. tuberculosis transfection results described above for Halo were replicated
in another phage from Cluster Q (Giles) that cannot normally infect M. tuberculosis.
Together, these results showed that it is largely surface interactions that prevent these
phages from crossing the species barrier. To determine whether surface interactions also
play a role in limiting cross-genus infections, the authors electroporated the DNA of the
Streptomyces phage Zemlya into electrocompetent M. smegmatis cells and plated them
onto a lawn of Streptomyces lividans, a known host of Zemlya. A small number of
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plaques were recovered, supporting the conclusion that Zemlya is able to replicate in M.
smegmatis post-DNA injection. Subsequently, twenty of these plaques were randomly
picked and plated on both M. smegmatis and S. lividans; all formed plaques on S. lividans
while none were able to do so on M. smegmatis, effectively ruling out the possibility of
contamination or host range mutation and therefore strengthening the argument that
surface interactions are responsible in large part for mycobacteriophage host range
constraints.

D. GENERATION OF MYCOBACTERIOPHAGE DIVERSITY
A prevailing theme throughout the comparative study of mycobacteriophage
genomes has been their striking mosaicism, with unique combinations of genes of clearly
distinct evolutionary histories composing each genome. This feature is not restricted only
to mycobacteriophages, but instead has been observed in all groups of double-stranded
DNA (dsDNA) bacteriophages that have been studied thus far. Hendrix et al. [1] propose
a model to explain these patterns in which all dsDNA phages share a common ancestor,
from which they have diverged through access by horizontal exchange to a global pool of
common genes; access is limited for each group of phages by parameters such as host
range, leading to the development of unique mosaic patterns and non-uniform relatedness
to other phages.
This model is well-supported by examples from various phage groups, and given
that there are an estimated 1025 phage infections, and thus opportunities for horizontal
exchange between different types of phages and their bacterial hosts, occurring every
second [96], it is also feasible. However, the model leaves the question of the precise
mechanisms by which this horizontal exchange occurs. Hatfull et al. estimate that if
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genetic exchange among mycobacteriophages occurred randomly, approximately 10350
distinct mycobacteriophage genomes would be possible [101]. As the total number of
global phage particles of all types is estimated at 1031, only a small portion of which are
mycobacteriophages, it follows that exchanges must be non-random. This makes sense if
one considers that in order to be viable, a genome would have to include all essential
genes for successful infection and replication. In addition, some genes must be paired or
co-translated with certain other genes in order to maintain functionality, and certain genes,
such as those encoding head and tail proteins, can generally not exist in duplicate within a
single genome. Two main models have been proposed to explain the majority of this nonrandom mosaicism; although these models were developed for the global phage
population in general, they apply to the generation of mycobacteriophage diversity, as
well. Both models are outlined in the following paragraphs.
In lambdoid phages, mosaic boundaries tend to occur close to boundaries between
genes [109], a tendency that has also been well documented in mycobacteriophages [98]
[93]. Stemming from these observations, in 1978 Susskind et al. proposed an early
“modular evolution” model in which they postulated the existence of short, conserved
linker sequences between genes [110]. These intergenic linker sequences were
hypothesized to facilitate recombination between modules of one or several genes
through homologous recombination or a site-specific recognition system. In the absence
of high-resolution DNA sequencing, these linker sequences seemed to provide a plausible
explanation for how “healthy hybrids” could be continually produced as phage genomes
recombine.
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As the availability of high-resolution bacteriophage DNA sequences, including
those of mycobacteriophages, increased, it became clear that this explanation was likely
not correct. The existence of bacterial genes within phage genomes [98] as well as
sequence evidence showing a lack of adequate space between genes to contain the
hypothesized linker sequences [111] were incongruous with the modular evolution model.
Additionally, little sequence similarity was observed among mosaic boundaries both
between phages and even on the same phage [111] [96], and a few examples of
recombination occurring not between genes but instead in the middle of single genes
were also described [111], providing further evidence against the earlier model.
Instead, a model of non-homologous, or illegitimate, recombination emerged to
account for these new insights [111]. This model suggests that recombination occurs
without discretion and essentially at random across the phage genome, giving rise to a
variety of recombinant genomes. Most of these are non-viable due to incorrect length for
packaging into the phage head or loss of essential gene function and thus are removed
from the population. This leaves behind for our observation only those rare recombinants
that have retained proper size and gene functions, the vast majority of which
consequentially display recombination junctions between genes. Pedulla et al. cite an
example of three recombination events in mycobacteriophages that occurred recently
enough in evolutionary history that the original sequences at the recombination junctions
are still well preserved [96]. Their observations provide definitive support for the
illegitimate recombination model.
Although illegitimate recombination has been widely accepted as the main
mechanism by which the diversity of mycobacteriophage and bacteriophage in general
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has been and continues to be established, there remain a few other mechanisms by which
genomic diversity may be propagated in mycobacteriophage. For example, a novel class
of small mobile elements apparently unique to mycobacteriophage genomes has been
identified [108]; the shuffling of these mobile elements could play a role in the generation
of new diverse mycobacteriophage genomes. Additionally, although transposons have
generally not been observed in mycobacteriophage genomes, a Cluster F phage appears
to include a transposon insertion 73% similar at the amino acid level to a putative
transposase from the soil bacterium Norcardia farcinia [93].
Recently, Jacobs-Sera et al. have proposed a new model that works alongside the
concept of illegitimate recombination but contains additional subtleties to explain the
diversity of mycobacteriophage in environments where there exists a diverse bacterial
population, such as in the soil [99]. Based on their studies of expanded-host-range
mutants described in the previous section, in which mutants with expanded host range
could be extracted after just one round of plating, the authors suggest that this switching
or expanding of host range through random mutation occurs with much greater frequency
than overall genetic exchange rates and much more quickly than changes in GC content
to adapt to a new host. While expansion to more similar hosts, such as different strains of
the same species, are more feasible, the authors present data that show cross-species
switches can also occur and suggest that even cross-genus switches are not impossible.
Given this model, different phages from a wide range of phylogenetic backgrounds (i.e.
evolved to efficiently infect a wide range of different host bacteria) can arrive at a
common host through a series of host range expansions in an environment of sufficient
host diversity.
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This model could explain the wide range of diversity observed among
mycobacteriophages, the majority of which were isolated from microbe-rich soil
environments; the distinct GC contents and genetic makeups observed among different
clusters may be the result of the “arrival” at M. smegmatis mc2155 after a series of host
expansion mutations by diverse phages originally adapted to infect other soil microbes.
The model thus predicts that the diversity of phages isolated on any bacterial host will
mirror the diversity of the bacterial population of the host’s natural environment. In line
with the proposed model, the fact that a broad range of GC contents has been observed
not only for mycobacteriophages but also for Pseudomonas and Staphylococcus phages
supports the idea of diverse phylogenetic origins for these phages. Furthermore, as the
model predicts, phages isolated from environments with restricted microbial diversity
exhibit a similarly restricted degree of diversity. This is exemplified by the low diversity
observed among phages of Propionibacterium acnes isolated from human sebaceous
follicles, an environment of limited microbial diversity. Given the fact that this model
allows expansion to extra-species and even extra-genus hosts, it highlights the great
potential of phage to facilitate genetic exchange between different bacteria in
environments of high microbial diversity, a concept introduced in Chapter 1D.

E. SUMMARY AND CONCLUSIONS
Comparative analysis of mycobacteriophage genomes has provided numerous
insights into the diversity and evolutionary mechanisms of this dynamic group of phages.
As covered in Section A, the observations reported in a number of papers indicate that the
average mycobacteriophage is a siphoviridae with a long, flexible, non-contractile tail
and isometric head about 55 nm in diameter and has a genome of approximately 114
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protein coding genes that is about 70 kbp in length with a GC content of around 63%.
However, enormous diversity has been observed among the mycobacteriophages, whose
genomes range from about 42 kbp to 165 kbp and which encompass a wide range of
morphologies including prolate heads, tail lengths spanning a more than two-fold range,
and both siphoviridal and contractile-tailed myoviridal morphotypes, although no stubbytailed podoviridae have been observed.
Section B discussed two novel taxonomic systems based on sequence similarity
and designed to alleviate some of the intrinsic difficulties in classifying phages by the
classical Linnaean paradigm. These systems have resulted in 1) grouping of
mycobacteriophages for which adequate sequence data exists into twenty clusters
(designated A-T) containing 35 subclusters, plus eight singleton genomes that do not fit
into any of the currently established clusters, and 2) the classification of
mycobacteriophage genes into roughly 1,500 gene phamilies. A high percentage (~46%)
of these are orphams containing only one member. These classification systems are not
perfect, but they provide a relatively sound idea of the relationships among
mycobacteriophage genomes and genes and greatly facilitate both intra and inter-cluster
comparative analyses.
Some examples of these analyses were detailed in Section C. Exploration of the
pervasively mosaic nature of mycobacteriophage genomes has been mediated by the
bioinformatics tool Phamerator. Geographic comparisons have revealed a distinct lack of
correlation between genome sequence and geographic area of isolation. Immunity studies
have yielded insights into immunity specificity and have described a unique instance of
repressor theft. Additionally, host range preference studies have implicated surface
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interaction barriers as the most likely mechanism for host range constraint among
mycobacteriophages.
Finally, Section D reviewed two major theories regarding the generation of the
highly diverse mosaic genomes observed among the mycobacteriophages; the early
“modular evolution” hypothesis, which maintains that short linker sequences between
genes facilitate homologous recombination to generate diversity, has been discarded in
favor of an illegitimate recombination model, whereby recombination happens randomly
across a phage’s genome and only the small fraction of recombinant genomes that retain
proper length and gene functions survive. Accordingly, most of these retained genomes
display recombination between genes rather than in the middle of genes as has been
observed in mycobacteriophages and bacteriophages in general. A new model of phage
diversification that suggests high-frequency host range expansion mutations are
responsible for the “arrival” of many different phages from diverse phylogenetic
backgrounds, and that the diversity observed among groups of phages isolated on a single
host strain accordingly reflect the bacterial diversity of the natural environment of that
host, has also been proposed.
Although much about the diversity and evolution of mycobacteriophages has been
elucidated, it is clear from the large number of singleton genomes and orphams that
researchers have only just begun to explore the enormous cache of undiscovered genetic
information contained in the global mycobacteriophage population. More insights will be
revealed through the isolation, characterization, and sequencing of additional
mycobacteriophages, including those which utilize hosts other than Mycobacteriophage
smegmatis. Illumination of the functions of the vast number of mycobacteriophage genes
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for which there is currently no known function will help researchers to better understand
the biology of these phages and make more accurate observations regarding their
evolutionary patterns. Finally, the continued analysis of mycobacteriophages has great
promise in terms of creating tools with which we can better understand and even
manipulate their mycobacterial hosts with the eventual aim of challenging devastating
pathogens like Mycobacterium tuberculosis. Although they are tiny in size, the advances
that wait just around the corner with the continued study of mycobacteriophages promise
to be immense.
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CHAPTER 7

ISOLATION AND SEQUENCING OF THE
NOVEL MYCOBACTERIOPHAGE TIROTHETA9

In this project, a novel mycobacteriophage, designated TiroTheta9 (TT9; see the
footnote at end of this chapter for etymology), was isolated from the environment and
completely characterized at both the phenotypic and genotypic levels. As covered
extensively in previous chapters, in order to further our understanding of
mycobacteriophage and bacteriophage in general, it is critical to develop a large database
of phage and phage genes available for comparison and study. The phage characterized in
this project, begun as a part of the previously described HHMI SEA-PHAGES program
in its inaugural year at Western Kentucky University, contributes to the growing number
of sequenced and characterized phages. The identity of TT9 as a mycobacteriophage
additionally renders this data potentially valuable in aiding the efforts of researchers
looking to develop phage-based tools for the study and treatment of Mycobacterium,
including such prominent pathogens as M. tuberculosis, the agent of tuberculosis, and M.
leprae, the agent of leprosy.

A. MATERIALS AND METHODS
Detailed recipes for all media, buffers, and reagents used in the following
procedures are included in Appendix A and can also be found in the Science Education
Alliance In Situ Resource Guide published by the HHMI [112].
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Soil Sample Collection
An environmental soil sample was collected by using a small spatula to scoop soil
into a 15 mL conical tube (VWR, catalog no. 21008-670). The sample was capped to
prevent drying and stored overnight at 4°C.
Bacterial Culture Techniques
The Mycobacterium smegmatis strain mc2155 used in the enrichment and growth
of phage was initially cultured from a frozen stock stored at -80°C. A sample was
streaked out for single conlonies on a standard Luria agar (L-agar) plate (Appendix A)
and allowed to grow for 4-6 days at 37°C. Liquid M. smegmatis P1FF (passage 1 from
frozen) stock cultures were prepared by using an inoculation loop to transfer M.
smegmatis from a single colony to 50 mL of Middlebrook 7H9 liquid media Complete
with Tween 80 (Appendix A) in a 250 mL baffled Erlenmeyer flask (Bellco, catalog no.
2543-60250). The flask was then incubated with shaking at 250 rpm for 48-72 hours at
37°C. New P1FF stock cultures were started weekly from the same agar plate. Liquid
cultures for use in phage experiments were prepared by adding a 1:1000 volume of P1FF
culture to 7H9 Complete without Tween 80 (Appendix A) in a 250 mL baffled flask and
incubating at 37°C with shaking at 250 rpm for 48 hours prior to use.
Enrichment of Mycobacteriophages
About one gram of soil was enriched for mycobacteriophages in a 250 ml baffled
Erlenmeyer flask containing 40 mL of deionized water, 5 mL of 10X 7H9/glycerol broth,
5 mL of AD supplement, 0.5 mL of 100 mM CaCl2, and 5 mL of late log/early stationary
phase liquid M. smegmatis culture. The flask was incubated for 48 hours at 37°C with
shaking at 220 rpm. The contents were then transferred to a 50 mL conical tube (VWR,
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catalog no. 21008-690) and centrifuged for 10 minutes at 1300 g. One mL of supernatant
was drawn off using a 1.0 mL luer-lock syringe (VWR, catalog no. BD-309628) and
filter-sterilized by pushing through a 0.22 μm syringe filter (VWR, catalog no. 28145501) into a 1.5 mL microcentrifuge tube (VWR, catalog no. 20901-551). The tube was
stored at 4°C.
The filtrate was serially diluted by transferring 10 μL of undiluted (100) filtrate to
a 0.2 mL microcentrifuge tube (Fisher, catalog no. AB-0620) containing 90 μL of phage
buffer (Appendix A). After mixing, 10 μL from this 10-1 tube was transferred another
tube containing to 90 μL of phage buffer, and so on until reaching 10-4 (Figure 14). Fifty
μL of each dilution (100–10-4) were added to 0.5 mL aliquots of overnight liquid M.
smegmatis culture in 9 mL glass culture tubes (VWR, catalog no. 47729-572) with caps
(VWR, catalog no. 16199-003). After incubating for 20 minutes at room temperature to
allow infection to occur, the aliquots were mixed with 4.5 mL of molten top agar
(Appendix A) at 55°C and plated onto pre-warmed L-agar plates (Appendix A). The
plates were inverted after the top agar was allowed to solidify for 20 minutes and
incubated at 37°C for 48 hours. The plates were then examined for plaques, which are
circular clearings where lysis of bacterial host cells has occurred as the result of lytic
phage growth.
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Figure 14: Phage Plating Protocol. A 100 phage stock is serially diluted by transferring 10 μL to 90 μL
phage buffer in a microcentrifuge tube, mixing, and repeating until reaching the desired dilution level (here,
10-4). Fifty μL of each dilution is transferred to 0.5 mL liquid M. smegmatis culture and incubated for 20
minutes. Four point five mL of molten top agar is added to each tube. The tubes are mixed and plated on Lagar plates. The plates are inverted after the top agar has cooled (~15 min) and incubated at 37°C. Petri dish
picture source: http://www.clker.com/clipart-red-petri-dish-open.html.

Purification of Single Phage Type
To isolate a single phage type from the plaques recovered through enrichment, a
sterile micropipette tip was used to pick phage particles from an isolated plaque on the
10-2 enrichment plate. The tip was swished in 100 μL phage buffer in a 0.2 mL
microcentrifuge tube to make a 100 phage solution. Serial dilutions to 10-4 were prepared
and plated as described above for the enrichment filtrate. After 48 hours incubation at
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37°C, an isolated plaque from these plates was picked, diluted, and plated as above; this
was repeated two more times for a total of four rounds of purification.
Obtaining a High-Titer Phage Stock
Plating assays of dilutions from an isolated plaque indicated that approximately
8,000 plaque forming units per plate formed a “webbing pattern” of plaques sufficiently
crowded so as to touch each other across the plate without achieving full lysis. Twenty
μL of a 10-3 dilution from an isolated plaque (calculated to contain approximately 80,000
plaque forming units, or 8,000 per plate) was added to 5.0 mL of liquid M. smegmatis
culture in a 50 mL conical tube. After incubating for 20 minutes at room temperature, the
contents were mixed with 45 mL of molten top agar and plated on 10 L-agar plates (5 mL
per plate). The plates were inverted after the top agar was allowed to solidify for 20
minutes and incubated at 37°C. After 24 hours, 4.5 mL of phage buffer was added to each
plate and allowed to sit undisturbed for 2 hours at room temperature. The lysate from
each plate was then collected in a 50 mL conical tube and sterilized by vacuum filtration
using a Steriflip-GP filter unit with a pore size of 0.22 μm (Millipore, catalog no.
SCGP00525). The filtered phage stock was stored at 4°C.
Transmission Electron Microscopy
To prepare phage particles for imaging under the TEM, 1.5 mL of high-titer
phage stock was added to a 1.5 mL microcentrifuge tube and centrifuged at 11,300 x g
for 1 hour. The pellet was resuspended in 50 μL of phage buffer and stored overnight at
4°C. Fine-point capillary tweezers (Pella, catalog no. 5620) were used to place a 3.0-mmdiameter, carbon-stabilized, formvar-coated copper EM grid (Pella, catalog no. 01813)
shiny-side-up on the edge of a sheet of Parafilm (Sigma-Aldrich, catalog no. P7668). A
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10-μL droplet of resuspended phage stock was placed on top of the grid and allowed to
adsorb for 2 minutes at room temperature. A Kimwipe (Kimtech, catalog no. 34120) was
used to wick off excess fluid. The grid was washed twice by adding a 10-μL droplet of
water, allowing it to sit for 2 minutes at room temperature, and wicking it off with a
Kimwipe. The grid was stained with 10 μL of a 1.0% uranyl acetate solution (Appendix
A), which was allowed to stain the grid for 2 minutes. After removing excess staining
solution with a Kimwipe, the grid was allowed to air dry. Phage particles were visualized
and photographed under a JEOL JEM 100CX TEM. The scale bar on the photographs
was used to determine the average head and tail length of the phage particles.
Isolation of Genomic DNA
Forty μL of nuclease mix (Appendix A) were combined with 10 mL of high-titer
phage stock in a 50 mL Oak Ridge tube with a screw cap (VWR, 21009-342) to degrade
nucleic acid contaminants in the stock. The solution was mixed by inversion, incubated at
37°C for 30 minutes, and incubated again at room temperature for 1 hour. Four mL of
phage precipitant (Appendix A) were added to the tube. The solution was mixed by
inversion and incubated overnight at 4°C. To pellet the phage particles, the tube was
centrifuged at 14,200 g for 20 minutes in a Sorvall SuperSpeed Centrifuge. After
decanting the supernatant, the pellet was resuspended in 2 mL of DNA Clean Up Resin
(pre-warmed to 37°C) from the Promega Wizard DNA Clean Up System (Fisher, catalog
no. PR-A7280). The manufacturer’s instructions for purification without a vacuum
manifold [113] were followed to isolate genomic DNA. DNA concentrations were
quantified using a Nanodrop and preparations were stored at 4°C.
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DNA Restriction Digests
Phage genomic DNA was digested with the restriction enzymes BamHI (NEB,
catalog no. R0136S), ClaI (NEB, catalog no. R0197S), EcoRI (NEB, catalog no.
R0101S), HaeIII (NEB, catalog no. R0108S), HindIII (NEB, catalog no. R0104S), SmaI
(NEB, catalog no. R0141S), ApaI (NEB, catalog no. R0114S), PstI (NEB, catalog no.
R0140S), XhoI (NEB, catalog no. R0146S), BglII (NEB, catalog no. R0144S), MspI
(NEB, catalog no. R0106S), and KpnI (NEB, catalog no.R0142S). Each digest was
prepared by combining 2 μL of the appropriate 10X reaction buffer (NEBuffer 1,
NEBuffer 2, NEBuffer 3, NEBuffer 4, or NEBuffer EcoRI; NEB catalog no. B7001S,
B7002S, B7003S, B7004S, B0101S) as detailed in Table 5, 0.5 μg phage genomic DNA,
10X BSA (NEB, catalog no. B9000S) where appropriate (Table 5), 10 units of restriction
enzyme, and deionized water to 20 μL in a 0.2 mL microcentrifuge tube. Digests were
mixed and incubated for 2 hours at 37°C, then place on ice or stored at -20°C.
Additionally, control digests of pUC18 plasmid DNA (Thermo Scientific, catalog no.
SD0051) and Lambda genomic DNA (Thermo Scientific, catalog no. SD0011) were
prepared to test the activity of BamHI, ClaI, EcoRI, HaeIII, and HindIII.
Point eight percent agarose gels were prepared from agarose gel powder (VWR,
catalog no. EM-2090) and 1X TBE buffer (Appendix A).Digests were run in 1X TBE
buffer at 100 V for approximately 45 minutes. Gels were stained in 0.5 μg/mL ethidium
bromide solution for 10 minutes before photographing under UV light.
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Table 5: Restriction Enzyme Reaction Conditions. Buffer and BSA requirements for each enzyme were
determined from the NEB website (https://www.neb.com/products/restriction-endonucleases).
Enzyme

Buffer

BSA

BamHI

NEBuffer 3

Yes

ClaI

NEBuffer 4

Yes

EcoRI

NEBuffer EcoRI

Yes

HaeIII

NEBuffer 2

Yes

HindIII

NEBuffer 2

Yes

SmaI

NEBuffer 4

No

ApaI

NEBuffer 4

Yes

PstI

NEBuffer 3

Yes

XhoI

NEBuffer 2

Yes

BglII

NEBuffer 3

No

MspI

NEBuffer 2

No

KpnI

NEBuffer 1

Yes

Genome Sequencing
To assess quality before sequencing, phage genomic DNA was run against Lamda
HindIII size standards (NEB, catalog no. N3012L) and Lambda DNA mass standards (15,
31, 63, 125, 250, and 500 ng/5 μL; prepared in the Science Education Alliance lab). One
percent agarose gels were prepared with Seakem LE agarose gel powder (VWR, catalog
no. 12001-868) and 1X TAE buffer (Appendix A). One μL of phage genomic DNA
(between 50 and 500 ng/μL; heated for 5 minutes in a 65°C heating block before loading)
and the Lambda size and mass standards were run in 1X TAE buffer at 120 V for
approximately 40 minutes. The gel was stained in 0.5 μg/mL ethidium bromide solution
for 10 minutes before photographing under UV light. After confirming DNA quality,
~10,000 ng of phage genomic DNA was sent to the sequencing facility at Virginia
Commonwealth University and processed by Roche 454 pyrosequencing technology
[114].
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Sequencing the Genomic Ends
a. Ligation of Phage Genomic DNA
Many dsDNA bacteriophage genomes include at each extremity a single-stranded
cohesive end, also referred to as a cos site. Usually around 10 base pairs in length, the cos
site allows the genome to circularize upon injection into a host bacterium. Often, this cos
site is not included in the raw genomic sequence data genome and must be sequenced
separately. To determine the sequence of the cos site, one primer located close to the
right end of the genome (P1) and two located close to the left end (P2, P3) were designed
(Table 6) such that they would frame the cos site if the genome were circularized.
Approximately 150 ng of phage genomic DNA was ligated overnight at 14°C in a 10 μL
reaction with 1 μL of T4 ligase (NEB, catalog no. M0202S), 1X ligation buffer (NEB,
catalog no. B0202S), and nanopure water to volume.
Table 6: Primers for Sequencing the Genomic Ends. One forward primer located near the right end of
the genome and two reverse primers located near the left end of the genome were designed to amplify
across the ends of the ligated genomic phage DNA. The sequence of the primers is in the 5’ to 3’ direction.
Primer

Direction

Sequence

Location

P1

Forward

CTGGTCACAGGGCGTGTC

51,059-51,076

P2

Reverse

CGCTGAACGCCGCTACTC

129-148

P3

Reverse

CTGTACATACCTTCCTATTC

191-208

b. PCR Reactions
Polymerase Chain Reaction (PCR) reactions were prepared by combining 2 μL of
ligated phage DNA, 2 μL of P1, 2 μL of either P2 or P3, 2 μL of dNTPs (10X stock
mixture; NEB, catalog no. N0446S), 20 μL 5X GC buffer (NEB, catalog no. B0519S), 1
μL Phusion polymerase (NEB, catalog no. M0530S), and nanopure water to 100 μL in a
0.2 mL microcentrifuge tube. The reaction was run under the following thermocycler
conditions: 1) 3 min at 98°C, 2) 10 s at 98°C, 3) 30 s at 55°C, 4) 2 min at 72°C, 5) Repeat
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steps 2) – 4) 34 times, 6) 10 min at 72°C, 7) hold at 4°C. Upon completion of the PCR
reactions, a 1% agarose gel prepared with 1X TBE buffer was run for approximately 1
hour at 100 V to confirm the presence of a product of expected size (~500 bp).
c. Gel Purification of PCR Products
The PCR product was purified from agarose gel by the phenol-freeze method
[115]. After electrophoresis and staining for 10 minutes in 0.5 μg/mL ethidium bromide
solution, the band of expected size was excised from the gel using a UV light table using
a razor blade. The extracted gel piece was placed in a 1.5 mL microcentrifuge tube and
cut into small pieces using a needle. After adding 900 μL of phenol, the solution was
vortexed and inverted to mix and frozen at -80°C for 10 minutes. The tube was
centrifuged at 12,100 g in a tabletop centrifuge, and the aqueous layer was transferred
into a clean tube. An equal volume of chloroform was added, mixed well by vortexting,
and then centrifuged at 12,100 g. The top layer was transferred into a clean tube, and the
chloroform process was repeated. The top layer was pipetted into a Microcon filter tube
(Millipore, catalog no. MRCF0R100), and water was added to 0.5 mL. The tube was
spun for 10 min at 550 g. Point five mL of water was added and the spin was repeated.
Finally, the Microcon tube filter was inverted in a fresh 1.5 mL microcentrifuge tube and
spun for 2 minutes at 550 g to recover the PCR product. Product recovery was verified on
a 1% agarose/1X TBE gel, and the product was submitted to GENEWIZ (South
Plainfield, NJ) for DNA sequencing.
Annotating the Genome
The FASTA-formatted DNA sequence file was uploaded to a bioinformatics
workstation containing two DNA analysis programs called Glimmer [116] and GeneMark
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[117]. These programs utilize different algorithms to identify genes ab initio in a DNA
sequence. Briefly, Glimmer, which stands for Gene Locator and Interpolated Markov
ModelER, utilizes an interpolated Markov model to call genes based on coding potential,
while GeneMark makes gene predictions based on similarities to a user-specified species
(the phage host M. smegmatis in this case). In addition to the gene predictions made by
Glimmer and GeneMark, tRNA genes were identified using a built-in program called
“tRNA Scanner,” and translation starts were identified by looking for ribosome binding
sites, known as Shine Dalgarno sequences, using another program called “SD finder.” A
Java program called Apollo [118], also accessed through the workstation, was used to
visualize Glimmer and GeneMark gene predictions simultaneously in order to locate
discrepancies between gene calls and add annotations to predicted genes.
The National Center for Biotechnology Information (NCBI) web-based Basic
Local Alignment Search Tool (BLAST) [119] returned nucleotide and protein matches
for each gene. Nucleotide BLAST (BLASTn) results, coupled with scores for possible
Shine Dalgarno sequences detected by the programs and other information such as length
and direction of the gene, were used to decide between Glimmer and GeneMark
predictions when the programs did not agree. BLASTn results were also used to assess
similarities between TiroTheta9 and other phages present in the database. Protein BLAST
(BLASTp) results yielded insights into putative functions for each gene. After calling the
most probable gene predictions and adding annotations regarding database matches and
putative functions where applicable, the completely annotated genome was saved as a
GenBank file for easy uploading to other mainstream bioinformatics programs such as
Geneious [120] as well as for submission to NCBI’s GenBank database, an open-access
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collection of all publically available DNA sequences [121]. Geneious and Phamerator
were used to perform several alignments with other closely related phages.

B. RESULTS AND DISCUSSION
Bacteriophage have a variety of promising applications in diverse fields such as
ecology, industry, and medicine. Because our current understanding of phage biology and
diversity is relatively limited, the isolation and characterization of novel bacteriophages is
essential for the continued development of these applications. Through the procedures
described above, a novel bacteriophage, TiroTheta9 (TT9), was isolated from the
environment

and

characterized

both

phenotypically

and

genotypically.

The

characterization of TT9 has enhanced our understanding of mycobacteriophages and their
unique properties. Additionally, the data collected has expanded the growing knowledge
base available to researchers and may contribute to groundbreaking discoveries in
medicine, molecular biology, genetics, evolution, and beyond.
Enrichment, Isolation, and Phenotypic Analysis
Mycobacteriophages were enriched from a soil sample collected from Fairview
Cemetery in Bowling Green, KY (GPS coordinates: 36° 59’ 34’’ N, 86° 25’ 15’’ W). A
single phage type was purified from the sample after four successive rounds of
purification by plating phage particles from isolated plaques on lawns of M. smegmatis.
The purified phage was named TiroTheta9 (TT9; see Footnote at end of chapter). TT9
forms clear, circular plaques with a diameter of 1-2 mm on a lawn of M. smegmatis
bacteria (Figure 15a) after 24 hours of incubation at 37°C. The clarity of the plaques
suggests that TT9 is primarily a lytic mycobacteriophage.
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TEM analysis shows that TT9 is a member of siphoviridae and has an icosahedral
capsid 58 ± 2 nm in diameter (average of 22 capsid measurements) and a noncontractile
tail 174 ± 5 nm in length (average of 13 tail measurements) as measured from the TEM images
shown in Figure 15b and c. TEM images were also useful in confirming the purity of the

phage stock, as all particles present in the sample appeared to be identical.

Figure 15: TiroTheta9 Plaques and TEM Micrographs. a.) TT9 forms clear plaques 1-2 mm in diameter
on a lawn of M. smegmatis after 24 hours of incubation. b.) and c.) TEM images show TT9 is a member of
siphoviridae, with an icosahedral capsid 58 ± 2 nm in diameter and a noncontractile tail 174 ± 5 nm in
length.
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Genotypic Analysis: Restriction Digest Results
Genomic DNA was isolated from a high-titer stock of TT9 phage particles, and
preliminary genotypic analysis was conducted by digesting the TT9 genomic DNA with
various restriction enzymes. This was done primarily to determine if TT9 was a novel
phage before sequencing by comparing the results with restriction patterns available for
other mycobacteriophages as well as to identify a characteristic restriction pattern for
TT9 DNA for future use in confirming DNA identity. The restriction patterns from
digestion with BamHI, ClaI, EcoRI, HaeIII, and HindIII, visualized using gel
electrophoresis, are shown in Figure 16. Additional digests were performed with XhoI,
BglII, MspI, KpnI, SmaI, ApaI, and PstI; the results of the SmaI, ApaI, and PstI digests
are shown in Figure 17a. The gel is badly smeared, which may be due to problems with
the electrophoresis buffer used to run the gel, but general cutting patterns can still be
discerned.
The patterns produced by BamHI, ClaI, EcoRI, HindIII, XhoI, BglII, MspI, KpnI,
SmaI, and ApaI all appear identical to the uncut genomic DNA, indicating that these
enzymes did not cut the DNA. This result suggests that the TT9 genome does not contain
the restriction sites for these enzymes. HaeIII, however, produced a multitude of
fragments too small to be individually distinguished. This result demonstrated that the
TT9 genome contains multiple instances of the HaeIII restriction site. Despite the
smearing, it is evident from Figure 17a that the PstI digest produced multiple bands large
enough to be individually discerned. As expected, subsequent genomic DNA stocks
analyzed in this manner gave a similar restriction pattern (Figure 17b).
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In order to confirm the functionality of the enzymes, digests of pUC18 plasmid
and Lambda genomic DNA, both of known sequence, were performed. The results of
these digests showed appropriate cutting patterns for each enzyme (results not shown),
verifying the activity of the enzymes and supporting the conclusion that the TT9 genome
does not contain restriction sites for the enzymes listed above. A comparison of the TT9
restriction patterns for BamHI, ClaI, EcoRI, HindIII, and HaeIII with analogous patterns
for 60 other mycobacteriophages yielded no matches to the patterns observed for TT9,
suggesting that TT9 is a unique, previously uncharacterized phage.

Figure 16: Restriction Digests of TiroTheta9 Genomic DNA. The contents of each lane are as follows:
1) 1-kb ladder (bands, top to bottom: 10.0, 8.0, 6.0, 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, 1.0, 0.7 kb), 2) undigested
TT9 genomic DNA, 3) BamHI digest, 4) ClaI digest, 5) EcoRI digest, 6) HaeIII digest, 7) HindIII digest.
Only HaeIII produced a restriction pattern different from that of undigested DNA; thus, it can be concluded
that the TT9 genome only includes the recognition site for this enzyme. Furthermore, the fragments
produced during the digestion are very small, indicating that the site is repeated many times throughout the
genome. Comparison with a database of the restriction patterns using these five enzymes for 60
mycobacteriophage genomes yielded no match, supporting the conclusion that TT9 is a unique and novel
mycobacteriophage. Note: The ladder is marked in base pairs.
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Figure 17: Additional Restriction Digests of TiroTheta9 Genomic DNA. a.) Additional restriction
digest analysis of TT9 genomic DNA. The lane contents are as follows:1) 1-kb ladder (bands, top to
bottom: 10.0, 8.0, 6.0, 5.0, 4.0, 3.0, 2.5, 2.0, 1.5, 1.0, 0.7, 0.5, 0.3 kb), 2) undigested TT9 genomic DNA, 3)
undigested TT9 genomic DNA, 4) SmaI digest, 5) ApaI digest, 6) PstI digest. The smearing is mostly likely
due to the compromised quality of the buffer used to prepare it. Lanes 4 and 5 ran identically to lanes 2 and
3, indicating a lack of recognition sites in the TT9 genome for either SmaI or ApaI. However, multiple
bands can be discerned in the PstI lane, leading to the conclusion that the TT9 genome contains several
recognition sites for PstI. b.) After TT9 genomic DNA was isolated from a second high-titer stock of the
phage, the DNA was digested with Pst1. The results of the digest were compared with the pattern produced
by a Pst1 digest of the originally isolated DNA to confirm its identity. The lane contents are as follows: 1)
1-kb ladder, 2) Pst1 digest of different preparation of TT9 genomic DNA, 3) Pst1 digest of original TT9
DNA. Although the poor quality of the original gel makes it difficult to distinguish each individual band,
overall they are discernable enough to confirm that the same pattern was produced by the digestion of both
DNA samples with Pst1. Thus, the two DNA samples were isolated from the same phage.

Genotypic Analysis: Sequencing and Genome Annotation Results
The sequenced TT9 genome consists of a single contiguous sequence, or contig,
and is 51,367 base pairs in length. Nucleotide BLAST (BLASTn) results returned 99%
sequence similarity to Mycobacterium Phage Peaches [122]. After analyzing each gene
prediction using BLAST and Apollo, the final TT9 genome was determined to contain 87
genes, 24 of which were assigned putative functions based on Protein BLAST (BLASTp)
matches. Spurred by the influx of phage genomic sequence information, functions for
seven additional genes have been assigned since the TT9 genome was first annotated in
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2010. Information for each predicted gene, including start and end position, gene length,
orientation, gene product designation, corresponding amino acid length, and putative
function where applicable, is summarized in Table 7, and the GenBank file showing the
complete annotated genomic sequence can be found online [123] and in Appendix B. The
data is also available on the Mycobacteriophage Database (http://phagesdb.org/
phages/TiroTheta9/). Based on sequence comparisons, TT9 was classified as a member
of the A4 subcluster of mycobacteriophages.
Identifying the Genomic Ends:
A 10 base-pair cos site with sequence CGGCCGGTAA was identified by
sequencing the PCR products amplified from ligated TT9 genomic DNA as shown in
Figure 18. The cos site sequence matches that of most of the A4 mycobacteriophages
included in the Mycobacteriophage Database as well as that of some phages from the A1,
A3, and A10 subclusters.
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Figure 18: Determining the TiroTheta9 cos Site Sequence. a.) Primers located at either end of the
genome were combined with ligated TT9 genomic DNA in a PCR reaction to amplify the region between
the ends of the ligated DNA containing the cos site. b.) The resulting PCR product was sequenced and
aligned with the TT9 genomic sequence in Geneious to generate the figure. The components of the
alignment are as follows: 1) the consensus identity across all sequences, 2) identity meter – green indicates
homology between the aligned sequences, while the gap indicates the position of the cos site, which is not
present in the genomic sequence data; 3) the sequence of the PCR amplified region containing the cos site
sequence, 4) TT9 Genomic sequence; the gap between the ends is where the cos site belongs, 5) sequence
verifying the left end of the TT9 genome. The peaks in 3 and 5 indicate that clear, unambiguous reads were
obtained across the cos site, supporting the accuracy of the sequencing results.
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Table 7: TiroTheta9 Gene Summary. Putative genes were located in the raw TT9 genomic sequence
using the ab initio gene calling programs Glimmer and GeneMark as well as NCBI’s BLAST. In total, 87
genes were called. The table summarizes the start and end position (given in base pairs from the 5’ end of
the genome), length in base pairs, direction, protein product designation (gp stands for gene product),
translated length of the predicted protein product in amino acids, and putative function based on BLAST
matches for each of TT9’s genes.
Gene

Start

End

Length

Direction

Designation

AA

Putative Function

1

672

457

216

3' → 5'

gp1

71

Protein coding

2

803

1234

432

5' → 3'

gp2

143

Protein coding

3

1326

1640

315

5' → 3'

gp3

104

Minor tail subunit

4

1645

2718

1074

5' → 3'

gp4

357

Protein coding

5

2722

3384

663

5' → 3'

gp5

220

Structural protein

6

3384

3755

372

5' → 3'

gp6

123

Protein coding

7

3784

3921

138

5' → 3'

gp7

45

Protein coding

8

3921

5423

1503

5' → 3'

gp8

500

LysA

9

5420

5881

462

5' → 3'

gp9

153

Protein coding

10

5881

6861

981

5' → 3'

gp10

326

LysB

11

6884

8581

1698

5' → 3'

gp11

565

Terminase

12

8578

10029

1452

5' → 3'

gp12

483

Portal Protein

13

10026

10886

861

5' → 3'

gp13

286

Capsid maturation protease

14

10939

11451

513

5' → 3'

gp14

170

Scaffolding protein

15

11479

12411

933

5' → 3'

gp15

310

Major capsid protein

16

12475

12681

207

5' → 3'

gp16

68

Protein coding

17

12685

13041

357

5' → 3'

gp17

118

Protein coding

18

13038

13205

168

5' → 3'

gp18

55

Protein coding

19

13202

13564

363

5' → 3'

gp19

120

Protein coding

20

13566

13958

393

5' → 3'

gp20

130

Protein coding

21

13958

14395

438

5' → 3'

gp21

145

Protein coding

22

14385

14975

591

5' → 3'

gp22

196

Major tail subunit

23

15095

15466

372

5' → 3'

gp23

123

Tail assembly chaperone

24

15095

15963

869

5' → 3'

gp24

289

Tail assembly chaperone

25

15882

18482

2601

5' → 3'

gp25

866

Tape measure protein

26

18487

19827

1341

5' → 3'

gp26

446

Minor tail protein

27

19824

21602

1779

5' → 3'

gp27

592

Minor tail protein

28

21624

22070

447

5' → 3'

gp28

148

Protein coding

29

22079

22525

447

5' → 3'

gp29

148

Protein coding

30

22515

22943

429

5' → 3'

gp30

142

Protein coding

31

22957

24813

1857

5' → 3'

gp31

618

Protein coding

32

25094

24876

219

3' → 5'

gp32

72

Protein coding

33

26634

25120

1515

3' → 5'

gp33

504

Serine integrase

34

26713

27132

420

5' → 3'

gp34

139

Protein coding

35

27801

27205

579

3' → 5'

gp35

198

Protein coding

36

27956

27798

159

3' → 5'

gp36

52

Deoxycytidylate deanimase

110

37

28108

27956

153

3' → 5'

gp37

50

Protein coding

38

28371

28105

267

3' → 5'

gp38

88

Protein coding

39

28454

28368

87

3' → 5'

gp39

28

Protein coding

40

28708

28451

258

3' → 5'

gp40

85

Protein coding

41

29061

28705

357

3' → 5'

gp41

118

Protein coding

42

29323

29048

276

3' → 5'

gp42

91

Protein coding

43

29553

29320

234

3' → 5'

gp43

77

Protein coding

44

29717

29550

168

3' → 5'

gp44

55

Protein coding

45

31564

29738

1827

3' → 5'

gp45

608

DNA polymerase I

46

31874

31572

303

3' → 5'

gp46

100

Protein coding

47

32047

31874

174

3' → 5'

gp47

57

Protein coding

48

32775

32056

720

3' → 5'

gp48

239

ThyX

49

33382

32843

540

3' → 5'

gp49

179

Protein coding

50

35442

33409

2034

3' → 5'

gp50

677

Ribonucleotide reductase

51

36323

35439

885

3' → 5'

gp51

294

Protein coding

52

37106

36339

768

3' → 5'

gp52

255

Metallophosphoesterase

53

37374

37099

276

3' → 5'

gp53

91

Protein coding

54

37678

37367

312

3' → 5'

gp54

103

Protein coding

55

38133

37474

660

3' → 5'

gp55

219

DNA primase

56

38362

37949

414

3' → 5'

gp56

137

DNA primase

57

38480

38346

135

3' → 5'

gp57

44

Protein coding

58

38972

38502

471

3' → 5'

gp58

156

Endonuclease VII

59

39860

39036

825

3' → 5'

gp59

274

Hydrolase

60

40237

39857

381

3' → 5'

gp60

126

Protein coding

61

40458

40234

225

3' → 5'

gp61

74

Protein coding

62

41052

40516

537

3' → 5'

gp62

178

Phosphoribosyltransferase

63

41878

41072

807

3' → 5'

gp63

268

DnaB-like helicase

64

41966

41886

81

3' → 5'

gp64

26

Protein coding

65

42157

41963

195

3' → 5'

gp65

64

Protein coding

66

42351

42154

198

3' → 5'

gp66

65

Protein coding

67

43152

42361

792

3' → 5'

gp67

263

AddAB recombination protein

68

43571

43149

423

3' → 5'

gp68

140

Protein coding

69

44165

43653

513

3' → 5'

gp69

170

Immunity repressor

70

44504

44376

129

3' → 5'

gp70

42

Protein coding

71

44874

44626

249

3' → 5'

gp71

82

Protein coding

72

45185

44871

315

3' → 5'

gp72

104

Protein coding

73

45342

45202

141

3' → 5'

gp73

46

Protein coding

74

45641

45342

300

3' → 5'

gp74

99

Protein coding

75

45796

45638

159

3' → 5'

gp75

52

Protein coding

76

45947

45804

144

3' → 5'

gp76

47

DNA methylase

77

46742

46158

585

3' → 5'

gp77

194

Protein coding

78

47253

46720

534

3' → 5'

gp78

177

Protein coding

79

47420

47250

171

3' → 5'

gp79

56

Protein coding
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80

47893

47423

471

3' → 5'

gp80

156

SprT

81

48060

47890

171

3' → 5'

gp81

56

Protein coding

82

48410

48057

354

3' → 5'

gp82

117

Protein coding

83

48583

48407

177

3' → 5'

gp83

58

Protein coding

84

48797

48585

213

3' → 5'

gp84

70

Protein coding

85

49095

48889

207

3' → 5'

gp85

68

Protein coding

86

50002

49118

885

3' → 5'

gp86

294

Protein coding

87

50150

50031

120

3' → 5'

gp87

39

Protein coding

Gene Content and Organization
A schematic diagram of the TT9 genome is shown in Figure 19. From the
diagram, it can be seen that TT9 has a very closely-packed genetic architecture, with little
to no space between genes and many genes overlapping with those adjacent to them. This
compact genomic structure is characteristic of phage genomes, as well as viral genomes
in general.
The overlap phenomenon is taken to a notable extreme in the case of gene 23,
which overlaps entirely with gene 24; the two genes share a start position, but gene 23
terminates 497 base pairs earlier than gene 24, resulting in a gene product 166 amino
acids shorter in length. Given the identification of these two genes as tail assembly
chaperones, this likely represents a unique frame-shift event that has also been
documented in the tail assembly chaperone genes of E. coli phage Lambda. In such a case,
the two genes would be transcribed together as a single transcript. Translation would
normally result in the production of the shorter gene product due to the presence of
translation terminators in the reading frame of gene 23. However, a “slippery” sequence
near the end of gene 23 would occasionally cause the ribosome to shift backwards or
forwards by a fixed number of bases (in Lambda, the shift is -1, but shifts of +1 and -2
have been observed in other phages [phagesdb.org/glossary]) and continue translating in

112

a different reading frame, resulting in the production of a longer gene product in
accordance with the entire length of gene 24.
The overall orientation of TT9’s genes is also of note. As reflected in Figure 19
and Table 7, except for gene 1, the first 31 TT9 genes are transcribed from the bottom
strand, while the remaining 56 plus gene 1 are transcribed from the complementary top
strand and are thus oriented in the opposite direction. This organization scheme is
common for phage genomes, where groups of genes of opposite orientation are often
expressed at different times during the phage replication cycle. For example, in the
Lactococcus phage sk1, middle and late transcripts are oriented opposite to early genes
[125]. A similar setup is observed in phage Lambda [41].
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Figure 19: Schematic Diagram of the TiroTheta9 Genome. The black line represents the 51,367 base pairs that make up the TT9 genome, while TT9’s 87
putative genes are indicated by green arrows that point in the direction of transcription. Figure generated by Geneious.

As noted above, putative functions have been identified for 31 of the 87 TT9
genes. Although this represents only 35.6% of the gene content, it allows several
important conclusions to be drawn regarding TT9’s genomic architecture. For example,
the genes involved in forming and assembling the phage capsid are grouped together, as
are those involved in forming the tail. In particular, genes 11, 12, 13, 14, and 15 have
been identified as a putative terminase 6 , portal protein 7 , capsid maturation protease 8 ,
scaffold protein 9 , and major capsid subunit respectively. Located downstream of the
capsid genes are genes 22, 23, 24, 25, 26, and 27, which comprise a putative major tail
subunit, two tail assembly chaperones 10 , a tapemeasure protein 11 , and two minor tail
proteins respectively. This organization reflects a synteny in structural and assembly
genes that is highly conserved among all siphoviridae, even among those with no
detectable nucleotide or amino acid sequence similarity [126].
An interesting anomaly that breaks from the traditionally tight grouping of related
structural genes is the presence of a putative minor tail subunit, gene 3, upstream of the
capsid genes. BLAST results yield nucleotide and protein matches to other A cluster
phages, including phages from the A4, A3, and A7 subclusters; however, these matches
6

The ATP-driven terminase enzyme is responsible for packaging genetic material into the capsid during
assembly.
7

Twelve portal proteins form a ring called the portal at one vertex of the phage capsid. During assembly,
the portal serves as a binding site for terminase and later for the tail to form a complete phage particle.
8

Capsid maturation protease functions to degrade intermediate scaffolding proteins as the capsid matures
during phage assembly.
9

Scaffolding proteins aid in the early formation of the capsid. They are degraded by capsid maturation
protease as the capsid matures and are thus not present in the mature phage particle.
10

The two tail assembly chaperones help to assemble the major tail proteins in a spiral pattern around the
core of the tail.
11

The tapemeasure protein, typically encoded by the longest gene in a siphoviridae phage genome, forms
the core of the tail and is thus directly proportional to the tail length.
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are located in a similar position apart from the other tail genes in these phages, as well,
suggesting that 1) the gene may have been acquired by a recent common ancestor of
these subclusters, and 2) the phage from which the gene originated has yet to be
discovered. Given its ambiguous evolutionary origins and anomalous position, it also
remains to be shown whether this gene actively functions as a minor tail subunit in the A
cluster phages that have it in their genomes.
Although the relative order of phage structural genes is highly conserved among
virtually all siphoviridae, the location of other genes tends to be more varied. Lysis genes
in the mycobacteriophages, for example, are generally found either upstream of the
capsid genes or downstream of the tail genes [126]. TT9 exhibits the former pattern, with
two putative lysin genes located immediately 5’ of the capsid genes. In particular, gene 8
is a putative Lysin A gene. LysA has been shown to function in peptidoglycan hydrolysis
and serves as the major lysis enzyme. Gene 9 is a putative Lysin B gene. LysB proteins,
found only in mycobacteriophage, function as mycolylarabingalactan esterases to
disconnect the unique mycobacterial outer membrane from the peptidoglycan cell wall
for efficient lysis [127].
Gene 33, a putative integrase gene, lies near the center of the genome. The
presence of this gene in conjunction with the putative immunity repressor represented by
gene 69 indicates that TT9 is a temperate phage capable of forming lysogens. Phenotypic
analysis of TT9 suggested a lytic classification for the phage, with clear plaques free of
the peripheral turbidity often associated with lysogen formation observed after incubation
at 37°C for 24 hours. It may be that the laboratory conditions were not optimal for TT9
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lysogen formation, or that 24 hours was not enough time for lysogens to grow in high
enough quantities to be observed.
Other genes of interest that have been identified in the TT9 genome are likely to
be involved in the synthesis of phage DNA during replication; these include DNA
polymerase I (gene 45); two DNA primases (genes 55 and 56); a DnaB-like helicase
(gene 63); and a deoxycytidylate deaminase (gene 36), the thymidylate synthase ThyX
(gene 48), and ribonucleotide reductase (gene 50), which function in the de novo
biosynthesis of deoxynucleotides. Unlike the structural genes, these genes are not
localized to a single region of the genome, but instead are scattered throughout the
second half of the genome and read in a direction opposite to that of the structural genes,
perhaps reflecting a distinct expression profile from the structural genes.
A putative endonuclease VII (gene 58) likely functions to resolve branch points in
newly synthesized DNA to prepare the genome for packaging, a function that has been
attributed to an analogous enzyme in E. coli phage T4 [128]. Gene 67 is a putative
AddAB DNA recombination protein that repairs double-stranded DNA breaks through
homologous recombination. A putative DNA methylase represented by gene 76 likely
constitutes an antirestriction mechanism to protect the phage DNA from digestion by the
host’s restriction-modification defense system. The specific roles of a putative
metallophosphoesterase (gene 52), hydrolase (gene 59), phosphoryltransferase (gene 62),
and SprT-like zinc metallopeptidase (gene 80) in the TT9 lifecycle have yet to be fully
elucidated. The function of these and the remaining 57 genes of unknown function that
comprise the TT9 genome could represent the subject of future investigations.
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Similarity to Other Mycobacteriophages
At the time of initial sequencing in 2010, TT9’s closest match in the BLAST
database was Mycobacterium Phage Peaches, another A4 phage. The Mycobacteriophage
Database local BLAST server contains an extended library of phage genomes, including
some that have not yet been published to GenBank. Unsurprisingly, current nucleotide
BLAST results of the entire TT9 genome on this server reveal closest similarity to other
A4 mycobacteriophages, with Broseidon, TygerBlood, and Flux making up the top three
matches. However, the top 100 matches also include, in order of first appearance in the
list, phages from the A10, A3, A1, A7, and A2 subclusters.
BLAST results for the entire TT9 genome on the general NCBI BLASTn server
show that TT9 displays 99% identity across 100% of its genome with six A4 phages
(Flux, Sabertooth, Dhanush, Meezee, Peaches, and Shaka). These genomes are nearly
identical at the nucleotide level, but the differences in their sequences could provide
tantalizing insights into the evolution of the phages as well as the structure of their
proteins. These and other important insights are derived from the comparative analysis of
related phage genomes, a topic that is explored for the A4 subcluster in the next chapter.
Footnote – What’s in a Name?
As bacteriophage are not considered living organisms due to the fact that they
require the assistance of a host cell to replicate, they are not assigned conventional
scientific names. Although several generally accepted guidelines have been put in place
by the Pittsburgh Bacteriophage Institute (phagesdb.org/namerules), novel phages can
more or less be named arbitrarily by their discoverers, which was the case for TT9. The
first part of TiroTheta9’s name, Tiro, is a Latin word meaning “beginner” or “new

118

recruit.” It denotes the beginning of the discoverer’s journey in the world of scientific
research. Theta is a Greek letter which was used to symbolize death in ancient Athens,
akin to the skull-and-crossbones symbol used today. It alludes to the graveyard site where
the soil sample that contained TT9 was collected, as well as to the deadly relationship
TT9 and all lytic phages share with their hosts. Theta also symbolizes the number 9,
which was included again as an Arabic numeral at the end of TT9’s name to represent the
month and year in which TT9 was discovered (September 2009).
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CHAPTER 8

COMPARATIVE ANALYSIS OF TIROTHETA9 AND THE A4 SUBCLUSTER

TT9, the novel mycobacteriophage described in the previous chapter, is a member
of the A4 subcluster of mycobacteriophages. Although the A4 phages necessarily share
many characteristics, they differ in important ways that may yield insights into phage
gene structure and function as well as the evolutionary history of the group that can be
extended to mycobacteriophage and even bacteriophage in general. The following
chapter outlines the general characteristics of the subcluster before delving into the
geographic distribution of the A4 phages and making genomic comparisons among them.

A. GENERAL CHARACTERISTICS OF THE A4 SUBCLUSTER
The A4 subcluster currently has 46 sequenced and verified members registered in
the Mycobacteriophage Database. It is the second largest subcluster of Cluster A, which
itself is the largest among the 20 mycobacteriophage clusters. The earliest member of the
subcluster was discovered in 2008, while the newest was added in 2013. All have the
siphoviridae morphotype, although a survey of the available micrographs on the
Mycobacteriophage Database server shows that capsid and tail dimensions vary. The
genome sizes and GC contents of members of the A4 subcluster are relatively consistent;
the genome sizes range from 51,131 bp to 51,813 bp and average 51,375 bp, and the GC
contents range from 63.7% to 64.1% with an average of 63.9%.
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Of the 46 sequenced and verified A4 phages, 18 have been annotated and
published on GenBank as of March 2014. Interestingly, although the genome size does
not differ dramatically among these 18 phages (51,236 bp-51,813 bp, ~600 bp difference),
the number of genes ranges from 85 to 91 (average 87.4). This suggests that the sizes of
individual genes may also vary rather significantly among subcluster members. TT9, with
87 genes, a genome size of 51,367 bp, and a GC content of 63.9%, falls right at the
average values for the subcluster. The names, genome lengths, GC contents, year of
isolation, and sampling location for all 46 A4 phages are summarized in Table 8; the
number of genes for each of the published phage genomes (indicated by bolded and
boxed names in Table 8) is also included along with statistics across applicable categories.
Table 8: Basic Characteristics of the A4 Subcluster Phages. The table includes the 46 members of the
A4 subcluster that have been sequenced and verified as of March 2014. The names of the 18 members that
have been published on GenBank are bolded and boxed. Source: phagesdb.org/subclusters/A4.
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Size
(bp)
51381

Achebe

51433

63.7

-

2012

KY

Arturo

51500

64.1

-

2011

VA

Backyardigan

51308

63.7

84

2009

KY

BellusTerra

51236

63.9

89

2012

PA
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51374

63.9

-

2011

MO
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51374

63.9
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2011

MA
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63.9
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63.9
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63.9
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64
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2011
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-

2012
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Gadost
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-

2012

NJ
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-

2012
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Name
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Year
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-
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-

2012
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51440
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2011
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51407
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-
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-
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63.9
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2009
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LittleGuy
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-

2011
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Maverick
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Medusa
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87
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Nyxis
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64
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63.9
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LA
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GA
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63.9
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2011

MO
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51369

63.9
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2008
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51367

63.9
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KY

TiroTheta9
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63.9

87

2009

KY

TygerBlood
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63.9

-

2011

AL

Wander

51366

63.9

-

2011

MA

Wile

51308

63.7

85

2009

VA

Average

51,375

63.9

87.6

-

-

Minimum

51,131

63.7

84

2008

-

Maximum

51,813

64.1

91

2013

-

Range

682

0.4

7

5

-

B. GEOGRAPHIC DISTRIBUTION
The A4 phages originate from a remarkable diversity of locations, as illustrated
by Figure 20. Although all current members were isolated in the United States, they
represent 16 states across about 2,200 km from Louisiana to Massachusetts and covering
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an area of about 1,840,000 km2. Even subsets of especially similar phages within the
subcluster display wide geographic diversity – for example, TT9 and the six phages with
which it shares 99% sequence identity (Flux, Sabertooth, Dhanush, MeeZee, Peaches,
and Shaka; red icons in Figure 20) were all isolated in different states (KY, PA, MO, AL,
NY, LA, and VA).
With so many miles between them, and given the huge diversity of the
bacteriophage population, it is remarkable that these seven phages, and the members of
the A4 subcluster in general, bear such strong sequence similarity, sharing a surprisingly
large amount of highly conserved sequence. In addition, the continued isolation and
characterization of new mycobacteriophages promises to uncover novel A4 subcluster
members from an increasing diversity of locations. These intriguing observations, which
reinforce previously published observations by Hatfull et al. in 2006 and Pope et al.in
2011, raise new questions about how phages evolve and are distributed. The observed
sequence similarity could be the result of convergent evolution to infect a common host,
but given the high degree of homology across the genomes of A4 phages, it is more likely
that A4 phages share a common ancestor. Where this putative ancestor first arose and
how it spread to the diverse locations from which its descendants have been isolated,
however, remains to be elucidated, as does the full extent of the geographic distribution
of A4 subcluster phages.
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Figure 20: Geographic Distribution of the A4 Phages. Despite their high degree of sequence similarity,
the A4 subcluster phages were isolated across a wide range of geographic locations, spanning from
Louisiana to Minnesota to Massachusetts. Even subsets of phages within the subcluster that display
particularly high homology – for example, TT9 and the six phages with which it shares 99% sequence
identity, indicated by the red icons in the figure – are found in diverse locations. These observations
indicate that there is little correlation between genomic sequence and geographic area of isolation. Figure
generated by Google Earth.

C. GENOME COMPARISONS
General Observations
As discussed earlier in this chapter, the 18 published genomes in the A4
subcluster vary somewhat in terms of genome size and number of genes. Despite these
minor variations, the general organization of the genome is very similar across the entire
subcluster. This is exemplified in Figure 21, which shows schematics of four
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representative A4 subcluster genomes. Given that there is a well-conserved relative order
for structural genes among all siphoviridae, one might suspect that perhaps a roughly
similar genome organization is observed for all mycobacteriophages and not just among
the A4 phages. However, a schematic comparison of these A4 genomes with the A1
subcluster phage Bxb1 and I1 subcluster phage Babsiella, also included in Figure 21,
shows that this is not the case. Although Babsiella is similar in length to the average A4
phage (48,420 bp vs. 51,375 bp), its genes are arranged in a very different manner. In
addition, despite belonging to the same cluster as the A4 phages, Bxb1 also shows
differences in genome organization, although much less dramatic than for Babsiella. This
suggests that the organization pattern observed for the A4 phages is subcluster-specific.
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Figure 21: Genome Organization is Conserved among the A4 Phages. An alignment of the A4 subcluster phages Eagle, Nyxis, TiroTheta9, and Wile
shows that the relative sizes and locations of genes is very similar across all four genomes. Comparison with the A1 phage Bxb1 shows deviations from this
organizational pattern, while comparison with the I2 phage Babsiella, which is similar in length but very different in seqeuence from the A4 subcluster phages,
reveals major differences in genome structure. This suggests that the general pattern seen for Eagle, Nyxis, TT9, and Wile is unique to the A4 subcluster.
Figure generated by Geneious.

Although the general organization of the genomes is similar across the A4
subcluster, there remains a considerable amount of sequence diversity. In general, this
diversity is spread across the genome, as can be seen in Figure 22, which shows an
alignment of TT9 and Flux. Although the two phages share 99% overall sequence
identity across 100% of their genomes, the figure clearly shows areas of sequence
divergence. Different divergence patterns are observed when TT9 is compared with each
of the other A4 members.
Many of these areas of divergence take the form of single nucleotide substitutions.
While most of these substitutions correspond to synonymous changes that do not alter the
amino acid sequence of the translated gene product due to the inherent degeneracy of the
genetic code, others are nonsynonymous, meaning the codons are translated into different
amino acids. Figure 23 shows a partial alignment of the TT9 and Flux tapemeasure
proteins. Of the 17 nucleotide differences shown, ten are synonymous while the
remaining seven are nonsynonymous.
As the substitution of even a single amino acid can radically alter the form and
function of the protein synthesized, these seemingly insignificant variations can
potentially produce two very different phage at the phenotypic level; an example of this
was discussed in Chapter 7C, where host range mutants were generated by the
substitution of a single amino acid in a minor tail protein. Alternatively, an amino acid
substitution may have little or no effect on the ultimate functioning of the resulting
protein, especially if the amino acids in question have similar properties. Studying these
small differences can thus unlock a new understanding of how evolution works to create

127

viable phages as well as enhance our knowledge of how amino acid sequence is related to
protein structure and function in general.
These single amino acid substitutions provide evidence for a vertical model of
phage evolution, whereby new phages diverge from a common ancestor through the
gradual acquisition of random mutations. The genomes of the A4 phages also show
evidence of evolution on a larger scale through horizontal gene transfer, whereby whole
genes from diverse evolutionary origins can be incorporated into the genome. Support for
both of these models will be presented in the following paragraphs.
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Figure 23: Synonymous and Nonsynonymous Nucleotide Substitutions in the Tapemeasure Protein of Flux and TiroTheta9. A partial alignment of the
nucleotide sequences of the tapemeasure genes and predicted amino acid sequences for the corresponding tapemeasure proteins of Flux and TiroTheta9 reveals
17 total nucleotide substitutions between the two phages. Of these, ten are synonymous at the amino acid level, while the remaining seven are nonsynonymous
and result in amino acid changes, indicated by black boxes in the figure. Depending on the chemical nature of each substituted amino acid, these changes could
have an effect on the structure and function of the resulting protein. Figure generated by Geneious.

Figure 22: Whole Genome Alignment of Flux and TiroTheta9. Although Flux and TT9 share 99% sequence identity across the length of their genomes, the
alignment shows many areas of sequence dissimilarity distributed throughout. Green in the identity lane indicates areas of homology, while yellow indicates
areas where the sequences differ. The phage genomes are represented by thick gray lines; the black stripes highlight sequence differences between them. Genes
are represented by green arrows that point in the direction of transcription. Figure generated by Geneious.

Evidence for Vertcal Evolution
The abundance of nucleotide substitutions that pepper the A4 genomes can
potentially offer clues into the evolutionary history of the subcluster. These substitutions,
which vary in location among different phages, are likely evidence of random mutations
acquired gradually in a vertical manner, similar to the way evolution proceeds in
macroscopic organisms such as animals and plants. A comparison of the putative
scaffolding and capsid proteins of TT9 with those of Flux, Shaka, and Peaches in Figure
24 illustrates this idea. Overall, the figure shows a high degree of sequence homology
among the two genes in TT9 and the analogous genes in each of the other three phages,
suggesting a common evolutionary origin. However, the genes vary in the number and
location of nucleotide substitutions they contain relative to TT9. Peaches differs the most,
displaying sequence differences in both genes. Fewer differences are seen for Shaka, and
they appear only in the capsid gene. Finally, Flux is identical to TT9 in both genes. If we
consider a model of vertical descent from a common ancestor, this would suggest that
Flux is most closely related to TT9, with Shaka a close second and Peaches a slightly
more distant relation as there has been more evolutionary time for random mutations to
accumulate.
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Figure 24: Evidence for Vertical Evolution in Peaches, Shaka, Flux, and TiroTheta9 Scaffolding and
Capsid Protein Genes. Alignments of the Peaches, Shaka, and Flux scaffolding and capsid protein genes
(genes 14 and 15 respectively) with the same genes in TiroTheta9 show varying degrees of sequence
divergence relative to TT9, with Peaches showing nucleotide substitutions in both genes, Shaka showing
fewer and only in the capsid gene, and Flux displaying complete sequence identity with TT9 across both
genes. If a vertical model of evolution for this set of genes is assumed, these observations would indicate
that Flux is most closely related to TT9, with Shaka a close second and Peaches more distantly related. In
the figure, phage genomic sequences are represented by gray lines. Black stripes on these lines highlight
areas of sequence dissimilarity for the pair of genomes under comparison. Genes are represented by green
arrows that point in the direction of transcription. Figure generated by Geneious.

A comparison of the minor tail proteins of TT9, Shaka, and Eagle reveals a
nucleotide sequence difference that is potentially related to the differential host
preferences of these phages. As discussed in the last chapter, Jacobs-Sera et al. identified
a single amino acid change in a minor tail protein of G cluster phages that allows hostexpanded mutants to infect M. tuberculosis with higher efficiency [99]. The same paper
also reported infection efficiencies on the Jucho and MKD8 strains of M. smegmatis for
eight A4 mycobacteriophages. Compared to TT9, Shaka and Eagle showed much greater
infectivity on both strains (for Jucho, 3.3 and 1.0 vs. 1.0 x 10-1, respectively, and for
MKD8 3.3 x 10-1 and 3.3 x 10-1 vs. <10-9, respectively; reported relative to infectivity on
M. smegmatis mc2155). The observations made by Jacobs-Sera et al. for G cluster phages
suggest that a difference in the structure of their minor tail proteins may be responsible.
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An examination of the two minor tail protein genes located downstream of the
tapemeasure gene in the three genomes (Figure 25) reveals a single nonsynonymous
amino acid change near the middle of the second minor tail protein (gp 26 in Eagle and
gp 27 in TT9 and Shaka). The same substitution – a methionine residue for a leucine
residue – occurs for both Shaka and Eagle, suggesting that this change may play a role in
their increased ability to infect the Jucho and MKD8 M. smegmatis strains. Although
methionine and leucine both have hydrophobic side chains, the structures of the two
amino acids differ rather significantly, meaning that such a substitution could have
significant effects on protein functionality. As Jacobs-Sera et al. showed through their
expanded host-range mutant experiments, single amino acid substitutions can occur
through random mutation as phage replicate; it is thus reasonable to suspect that such a
process also led to the divergence of Shaka and Eagle from TT9 in regards to the minor
tail protein gene.

Figure 25: A Nonsynonymous Amino Acid Substitution in Minor Tail Protein Genes of Shaka/Eagle
and TiroTheta9. An alignment of Shaka gene 27 and Eagle gene 26 with TiroTheta9 gene 27, all
identified as putative minor tail proteins, reveals the same nonsynonymous nucleotide substitution in Shaka
and Eagle relative to TT9. Reports indicate that TT9 exhibits a much lower plating efficiency on M.
smegmatis strains Jucho and MKD8 relative to Shaka and Eagle, which have a similar plating efficiency for
both strains [99]. Given that all other nucleotide substitutions between Shaka/Eagle and TT9 in the gene are
synonymous, the differential host range observed could be attributable to this change. Figure generated by
Geneious.
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Evidence for Horizontal Gene Transfer: Constructing a Genetic Mosaic
While much of the sequence diversity across the subcluster takes the form of
nucleotide substitutions as described above, other areas of difference encompass entire
genes. Offering a more generalized comparison than Geneious alignments, the
Phamerator program alignment of several representative A4 phages in Figure 26 shows
that genes bearing little or no similarity to the other A4 phages often appear sandwiched
between long stretches of highly homologous sequence. Although not found in other A4
phages, these genes are often homologous to sequences found in members of other
subclusters – for example, Wile gp62 matches genes found in several A2 subcluster
phages. This suggests that the genes were obtained through horizontal gene transfer
rather than derived from a common ancestor. This could potentially occur through a
coinfection event by two different phages.
These observations are consistent with the genetic mosaic model of phage
evolution proposed by Hendrix et al., which suggests that “all dsDNA phage genomes are
mosaics with access, by horizontal exchange, to a large common genetic pool” [1] (see
Chapter 6 for further background). A potent illustration of this mosaicism is given by the
following examination of the integrase genes of the A4 subcluster phages.
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Figure 2623: Phamerator Alignment of Four A4 Phages. The complete genomes of TiroTheta9, Wile,
Nyxis, and Eagle are compared in the figure. Purple shading between genomes indicates areas of high
sequence homology, while blue and orange indicate areas of less homology and white represents little or no
homology. Phage genomic sequences are represented by ruler-like lines, with colored blocks representing
genes placed above for genes transcribed in the forward direction and below for genes transcribed in the
reverse direction. The figure shows that although the four phages display a high degree of sequence
homology across the lengths of their genomes, there are several areas where one or more phages possesses
a gene not shared by the others. This observation is consistent with the mosaic model of phage evolution.
Figure generated by Phamerator.

Integrase Diversity in the A4 Subcluster
Figure 27 is a schematic of the 18 published A4 genomes generated through a
BLASTn nucleotide search using the full TT9 genome. This analysis shows a clear
sequence difference that occurs midway through the genomes. Closer examination
reveals that this region encompasses the integrase gene, and that the integrase genes
represented by members of the A4 subcluster can be divided into three groups of
apparently distinct evolutionary origin.
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Figure 27: Integrase Diversity in the A4 Subcluster as Visualized Through BLAST. BLAST results
using the entire TiroTheta9 genomic sequence as the query show a curious dichotomy located mid-genome
for the 18 published A4 subcluster phages. This divergence occurs in the integrase gene; the BLAST results
depicted in the figure indicate that that the integrase genes of Flux, Sabertooth, Dhanush, MeeZee, Peaches,
Shaka, Wile, and Backyardigan are similar to that of TT9, while those of Melvin, Medusa, Icleared,
BellusTerra, Eagle, Nyxis, Arturo, LHTSCC and Obama12 are not. Further examination reveals three
integrase groups of distinct evolutionary origin represented across the A4 subcluster, lending support to the
mosaic model of phage evolution. The phage genomes represented in the figure are as follows: 1) TT9, 2)
Flux, 3) Sabertooth, 4) Dhanush, 5) MeeZee, 6) Peaches, 7) Shaka, 8) Melvin, 9) Medusa, 10) ICleared, 11)
BellusTerra, 12) Eagle, 13) Nyxis, 14) Arturo, 15) Wile, 16) Backyardigan, 17) LHTSCC, 18) Obama12.
Figure generated by NCBI BLASTn.

In general, phage integrases work by facilitating site-specific recombination
between the attP attachment site on the phage genome and the attB site on the bacterial
chromosome (Figure 28). Although the attP and attB sites often differ significantly in
sequence, the attB site contains a short stretch of identity to attP, called the overlap
region, where crossing over occurs. Two major families have been identified for phage
integrases, the tyrosine integrases and serine integrases. These are named for the amino
acid responsible for effecting catalytic activity in each. The two families of integrase
operate by completely different mechanisms and also differ in other key aspects, detailed
in Table 9.
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Figure 28: General Mechanism of Phage Integrases. To integrate into a bacterial chromosome, a phage
integrase mediates site-specific recombination between the attP attachment site on the phage genome and
the attB attachment site on the bacterial chromosome. Excision requires an additional enzyme called
exisase. The specific mechanism by which integration occurs depends on the integrase family (Tyrosine or
Serine). Source: http://2010.igem.org/wiki/index.php?title=Team:Paris_Liliane_Bettencourt/Project/Memocell/Design&oldid=208629.
Table 9: Comparison of Tyrosine and Serine Integrases. Source: Groth AC, Calos MP. 2004. Phage
integrases: biology and applications. J. Mol. Biol. 335:667-78.
Characteristic

Tyrosine Integrases

Serine Integrases

Mechanism

Formation and resolution of
Holliday Junction

2-bp staggered cut followed by 180°
rotation and ligation

attP site

Short; overlap region flanked
by imperfect inverted repeats

Short; overlap region sometimes
flanked by imperfect inverted repeats

attB site

Extended; multiple binding
sites for cofactors

Short; overlap region sometimes
flanked by imperfect inverted repeats

Overlap region

6-8 bp

3-12 bp

Host factors required?

Yes

No
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Despite the fact that these two families of integrases operate by entirely different
mechanisms and have likely arisen from distinct evolutionary backgrounds [38], both are
represented in the A4 subcluster. Six of the 18 published genomes (33%) – Eagle,
BellusTerra, LHTSCC, Medusa, Melvin 12 , and Obama 12 – have tyrosine integrases,
while the remaining twelve (67%) have serine integrases. All six of the tyrosine
integrases are similar in sequence and closely resemble the integrases of primarily A3
subcluster phages, displaying 85% identity with 92% coverage to the A3 phage HelDan
among other A3 phages. However, BLAST analysis of the twelve serine integrases
reveals that they are comprised of two distinct groups. The first includes the integrase
genes of TT9, MeeZee, Peaches, Dhanush, Flux, Sabertooth, Shaka, Wile, and
Backyardigan, for which BLAST results show nucleotide matches only to each other.
This suggests that the integrase of these nine phages is currently unique to the A4
subcluster and perhaps originated from a phage ancestor that has yet to be discovered.
The remaining three integrases – those of Nyxis, Arturo13, and ICleared14 – are
also serine integrases based on protein matches, but interestingly do not display
significant sequence similarity to the other A4 serine integrases. This is clearly illustrated
in Figure 29, which shows a representative integrase from each of the three groups.

12

The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/KF841476) identify
Mycobacterium Melvin gp 33 as a serine integrase. However, BLASTp results for this gene reveal a
putative conserved domain associated with tyrosine phage integrases. In addition, BLASTn and BLASTp
matches are to tyrosine integrases. Thus, the gene is identified as a tyrosine integrase here.
13

The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/JX307702) identify
Mycobacterium Arturo gp 32 as a tyrosine integrase. However, BLASTp results for this gene reveal a
putative conserved domain from the serine recombinase superfamily. Furthermore, BLASTn and BLASTp
matches are to serine integrases. Thus, the gene is identified as a serine integrase here.
14

The annotations published on GenBank (http://www.ncbi.nlm.nih.gov/nuccore/JQ896627) do not classify
ICleared gp 33 as either a tyrosine or serine integrase. However, BLASTp results reveal a putative
conserved domain from the serine recombinase superfamily. In addition, BLASTn and BLASTp matches
are to serine integrases. Thus, the gene is identified as a serine integrase here.
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Instead, these integrases appear to be related to integrases from the A5 subcluster, with
which they display partial sequence identity; nucleotide BLAST results show
approximately 75% identity with 50% coverage to the A5 phage ElTiger69, Airmid, and
Benedict.
Figure 29 also shows that the sequences surrounding the integrase genes are
highly homologous. This strongly suggests that these diverse integrases were obtained
through horizontal gene transfer with phages of other subclusters, providing further
evidence in support of the mosaic model of phage evolution.

Figure 29: Phamerator Alignment of A4 Subcluster Phage Integrase Genes. A Phamerator alignment
of four A4 phages shows that three distinct groups of integrase genes, contained in the red box, are
represented in the A4 subcluster. TiroTheta9 and Wile have serine integrases that are very similar in
sequence, as indicated by the purple shading between them. Nyxis also has a serine integrase, but the
absence of purple shading shows that this integrase is distinct from that of TT9 and Wile. The gene is also
somewhat shorter than the TT9/Wile integrase. Eagle has a tyrosine integrase that is distinct from both the
TT9/Wile integrase and the Nyxis integrase. Figure generated by Phamerator.
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CHAPTER 9

CONCLUSIONS

This project resulted in the successful isolation and phenotypic and genotypic
characterization of a novel mycobacteriophage, designated TiroTheta9 (TT9), from an
environmental soil sample collected in Bowling Green, Kentucky. TT9 was found to be a
primarily lytic phage, forming clear plaques 1-2mm in diameter on a lawn of M.
smegmatis after 24 hours of incubation at 37°C. Although phenotypic analysis did not
yield evidence for TT9 lysogens, genomic analysis showed that TT9 contains an
integrase gene and is thus a temperate phage. This suggests that laboratory conditions
were not optimal for TT9 lysogen formation or that plates were not allowed to incubate
for long enough to observe plaque turbidity associated with lysogen formation. TEM
images revealed that the phage has an average capsid diameter of 58 ± 2 nm and a tail
length of 174 ± 5 nm. Its genome is comprised of 87 putative genes spanning 51,367 base
pairs, including a 10 base pair overhanging cos site.
Based on sequence similarities, TT9 was classified into the A4 subcluster of
mycobacteriophages, which currently contains 46 sequenced and 18 published genomes.
Comparative analysis of these genomes revealed a general lack of correlation between
geographic distribution and sequence similarity and provided insight into the
evolutionary mechanisms that govern the emergence of new phage types. In particular,
evidence for both vertical divergence from a common ancestor and acquisition of genes
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from distinct evolutionary origins through horizontal gene transfer from phages of other
clusters/subclusters was observed in the genomes of the A4 phages. The identification of
three groups of integrases of distinct origin among the otherwise highly homologous
members of the A4 subcluster provided strong support for the genetic mosaic model of
phage evolution proposed by Hendrix et al [1].
Notably, in their original 1999 paper proposing the mosaic model, the authors
comment that “the veracity of this view of bacteriophage population genetics and
evolution…will only be determined… after substantially more data are determined of
sequences and genetic organization of phages and their hosts.” Thus, the characterization
of TT9 adds an additional piece to this massive puzzle of phages, their hosts, and their
genes as we move closer to figuring out how these pieces integrate with each other.
Future Directions
Given that only 31 of TT9’s 87 genes (35.6%) are currently assigned putative
functions, elucidating the functions of the remaining genes and clarifying functions of
others that currently have only vague descriptions (such as gp 5, identified only as a
structural protein) is a logical direction for future experiments. Such experiments could
involve deleting, altering, or tagging the protein products of certain genes and observing
phenotypic effects. Such studies could potentially reveal new gene functions. These
products could be of potential use in basic or applied research and may contribute greatly
to our continued understanding of phage biology.
Comparative analysis of the A4 phages should also be continued as more
mycobacteriophages are added to the database. It would be interesting to observe which
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integrase group newly classified A4 members fall into. The expansion of the database as
a whole may reveal new links to other clusters.
Finally, the isolation and sequencing of additional phage genomes is another area
in which future efforts could be concentrated. To maximize chances of discovering
unique phages, different types of environmental samples beyond soil from a wide variety
of geographic locations and conditions could be considered. During the isolation process,
the purification of plaques with uncommon morphologies such as “bulls eye” patterns or
unusual size could yield diverse phage types. For instance, small plaques, while harder to
work with, are generally formed by larger phage that take longer to diffuse through the
agar when released upon cell lysis. Additionally, different isolation techniques could be
considered to potentially obtain phages with unique characteristics. This could potentially
include ssDNA and RNA phages.
Although TT9 and its analysis in the context of the A4 subcluster has yielded
important insights into mycobacteriophage genome structure and evolution, many
questions still remain. What is the function of the many unknown genes present in the
genomes of TT9 and other mycobacteriophages? How can such similar phages as the
members of the A4 subcluster be found in such geographically dissimilar areas?
Ultimately, can mycobacteriophages be developed into tools to manipulate and even
combat human pathogens such as M. leprae and M. tuberculosis? The answers to these
and many other important questions will only be revealed through the continued
expansion and study of this remarkably diverse group of phages.
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APPENDIX A

RECIPES FOR STOCK SOLUTIONS, MEDIA, AND REAGENTS

The following recipes were adapted from the Science Education Alliance In Situ
Resource Guide published by the HHMI [112].
I. Stock Solutions
AD Supplement (2 L)
Ingredient

Amount

Final Concentration

NaCl

17 g

145 mM

Albumin (Fraction V)

100 g

5.0%

Dextrose

40 g

2.0%

ddH2O

To 2 L

To Prepare
1

Weigh out NaCl and albumin and place in 4 L Erlenmeyer flask

2

While stirring, slowly add 1800 mL of ddH2O until the albumen
and NaCl are dissolved
While still stirring, slowly add the dextrose

3

To Sterilize

Once the dextrose is dissolved, transfer solution to 2 L graduated
cylinder and bring the volume to 2 L with ddH 2O
Filter-sterilize; do not autoclave

Store

at 4°C

20% Tween 80 (100 mL)
Ingredient

Amount

Final Concentration

Tween 80*

20 mL

20%

ddH2O
To Prepare

To 100 mL

4

1

Measure 60 mL ddH2O and place in a medium-sized beaker

2

Slowly add 20 mL Tween 90 while stirring

3
To Sterilize

Once the Tween 80 has completely dissolved, transfer to graduated
cylinder and bring to 100 mL with ddH2O
Filter-sterilize; do not autoclave

Store

at room temperature

*VWR, catalog no. 97063-806
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Carbenicillin (CB; 10 mL 50 mg/mL stock solution)
Ingredient
Amount

Final Concentration

Carbenicillin powder*

500 mg

50 mg/mL

ddH2O
To Prepare

10 mL
1

Weigh out carbenicillin and place in 15 mL conical tube

2

Add ddH2O and mix until dissolved

To Sterilize

Filter-sterilize (pore size 0.22 μm)

Store

at 4°C for ≤ 60 days

*VWR, catalog no. 101384-990
Cycloheximide (CHX; 10 mL 10 mg/mL stock solution)
Ingredient
Amount

Final Concentration

Cycloheximide powder*

100 mg

10 mg/mL

ddH2O
To Prepare

10 mL
1

Weigh out cycloheximide and place in 15 mL conical tube

2

Add ddH2O and mix until dissolved

To Sterilize

Filter-sterilize (pore size 0.22 μm)

Store

at 4°C for ≤ 60 days

*VWR, catalog no. 97064-724
40% Glycerol (1 L)
Ingredient

Amount

Final Concentration

Glycerol (glycerin)

400 mL

40%

ddH2O

To 1 L

To Prepare
1

Measure 500 mL ddH2O and place in a 1 L graduated cylinder

2

Slowly add 400 mL gycerol

3

To Sterilize

Place parafilm on the top of the cylinder and shake thoroughly to
mix
Once the glycerol has completely dissolved, bring the volume to 1
L with ddH2O and mix
Filter-sterilize or autoclave in 250 mL or 500 mL bottles

Store

at room temperature

1 M Tris, pH 7.5 (1 L)
Ingredient

Amount

Final Concentration

Trizma base*

121.1 g

1M

ddH2O
To Prepare

To 1 L

4

1

Weigh out Trizma base and place in a large beaker
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2

Add approximately 975 mL of ddH2O and stir

3

Once the Trizma base has dissolved, bring the pH to 7.5 with HCl

4

Transfer to a graduated cylinder and add ddH2O to 1 L

To Sterilize

Autoclave in 250 mL or 500 mL bottles

Store

at room temperature

*Sigma-Aldrich, catalog no. T1503-500G
50X Tris-Acetate-EDTA (TAE; 1 L)
Ingredient

Amount

Final Concentration

Trizma base*

242 g

2M

500 mM EDTA

100 mL

50 mM

Glacial acetic acid

57.1 mL

1M

ddH2O
To Prepare

To 1 L
1

Weigh out Trizma base and place in a large beaker

2
3

Add approximately 800 mL of ddH2O and stir until the Trizma base
is dissolved
Add the EDTA stock while stirring

4

Slowly add the glacial acetic acid while stirring

5

If necessary, adjust the pH to 8.5 with additional glacial acetic acid
and trasfer to a graduated cylinder
Bring the volume to 1 L with ddH2O

6
To Sterilize

No sterilization necessary; do not autoclave

Store

at room temperature

*Sigma-Aldrich, catalog no. T1503-500G
10X Tris-Boric Acid-EDTA (TBE; 1 L)
Ingredient

Amount

Final Concentration

Trizma base*

108 g

890 mM

Boric acid

55 g

890 mM

EDTA disodium salt dihydrate

7.44 g

20 mM

ddH2O
To Prepare

To 1 L

2

Weigh out Trizma base, boric acid, and EDTA and place in a large
beaker
Add 980 mL of ddH2O and stir until all ingredients are dissolved

3

Adjust the pH to 8.3 and transfer to a graduated cylinder

4

Bring the volume to 1 L with ddH2O

1

To Sterilize

Autoclave

Store

at room temperature

*Sigma-Aldrich, catalog no. T1503-500G
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II. Media
Middlebrook 7H9 Liquid Medium, Neat (900 mL)
Ingredient
Amount
7H9 broth base*

4.7 g

40% glycerol stock**

5 mL

ddH2O
To Prepare

To 900 mL

Final Concentration
0.2%

1

Place broth base and 850 mL of ddH2O in an Erlenmeyer flask

2

While stirring, add the glycerol and stir until the broth base powder
is completely dissolved
Transfer to a graduated cylinder and bring up to 900 mL with
ddH2O
Aliquot into 90 mL, 450 mL, or 900 mL portions as needed

3
4
To Sterilize

Autoclave

Store

at room temperature

*VWR, catalog no. 90003-876
** Recipe included in this appendix
Middlebrook 7H9 Liquid Medium, Complete without Tween 80 (100 mL)
Ingredient
Amount
Final Concentration
7H9 liquid medium, neat*

89 mL

1X

AD supplement*

10 mL

CB stock*

100 μL
100 μL

10%
50 μg/mL

CHX stock*
100 mM CaCl2
To Prepare

10 μg/mL
1 mM

1 mL
1

Add all ingredients to sterile bottle or flask aseptically and mix

To Sterilize

All ingredients sterile; do not autoclave or filter sterilize

Store

at 4°C

*Recipe included in this appendix
Middlebrook 7H9 Liquid Medium, Complete with Tween 80 (100 mL)
Final
Ingredient
Amount
Concentration
7H9 liquid medium, neat*

89 mL

1X

AD supplement*

10 mL

CB stock*

100 μL
100 μL

10%
50 μg/mL

CHX stock*
100 mM CaCl2

1 mL
250 μL

20% Tween 80 stock*
To Prepare
1
To Sterilize

10 μg/mL
1 mM
0.05%

Add all ingredients to sterile bottle or flask aseptically and mix
All ingredients sterile; do not autoclave or filter sterilize
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at 4°C

Store
*Recipe included in this appendix

10X 7H9/Glycerol Media (500 mL)
Ingredient
Amount
7H9 broth base*

23.5 g

40% glycerol stock**

25 mL

ddH2O
To Prepare

To 500 mL
1
2
3
4

Final Concentration
2%

Place broth base and 400 mL of ddH2O in an Erlenmeyer flask
While stirring, add the glycerol and stir until the broth base
powder is completely dissolved
Transfer to a graduated cylinder and bring up to 500 mL with
ddH2O
Aliquot into 50 mL or 100 mL portions as needed

To Sterilize

Autoclave

Store

at room temperature

*VWR, catalog no. 90003-876
** Recipe included in this appendix
Middlebrook Top Agar (TA; 1 L)
Ingredient
Amount
7H9 broth base*

2.35 g

Agar**

4g

ddH2O

0.5 L

7H9 liquid medium, neat***

0.5 L

100 mM CaCl2
To Prepare

10 mL

Final Concentration
0.8%

1 mM

1

Place broth base, agar, and ddH2O in an Erlenmeyer flask

2

Stir until broth base powder is complete dissolved

3

Autoclave the flask

4

Once cooled to handling temperature, aliquot in 25 mL volumes
into sterile 100 mL bottles and add 25 mL 7H9 liquid medium
(neat) to each bottle
Before use, heat to boil in microwave and cool to 55°C in water
bath
Add 0.5 mL 100 mM CaCl2 to each bottle

5
6
To Sterilize
Store

Add all ingredients aseptically after autoclaving in step 3; do not
autoclave or filter-sterilize final medium
in 55°C water bath ≤ 7 days

*VWR, catalog no. 90003-876
** VWR, catalog no. 100370-088
***Recipe included in this appendix
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Luria Agar (L-Agar) Plates (1 L)
Ingredient
Amount
L-Agar base*

30.5 g

CB stock**

1 mL
100 μL

CHX stock**
ddH2O
To Prepare

Final Concentration
50 μg/mL
10 μg/mL

To 1 L
1
2
3

Add L-Agar base to 1 L ddH2O and stir to mix
Heat while stirring and boil for up to 1 minute to completely
dissolve the L-Agar base
Autoclave at 121°C for 10 minutes

5

Cool to 55°C in a 55°C water bath
Aseptically add the CB and CHX stock solutions

6

Mix well by swirling, avoiding bubbles

7

Use aseptic technique to pour agar into Petri dishes

4

To Sterilize

Plates sterile after autoclaving; keep lids on to maintain sterility

Store

at 4°C

*VWR, catalog no. 90003-250
**Recipe included in this appendix

III. Reagents
Phage Buffer (PB; 1 L)
Ingredient

Amount

Final Concentration

1 M Tris, pH 7.5*

10 mL

10 mM

1 M MgSO4

10 mL

10 mM

NaCl

4g

68 mM

100 mM CaCl2

10 mL

1 mM

ddH2O
To Prepare

970 mL
1

Place all ingredients except CaCl2 in Erlenmeyer flask

2

Stir until the NaCl is completely dissolved

3
4

Autoclave and cool to 55°C in 55°C water bath
Aseptically add the CaCl2 and mix well by swirling

5

Aliquot into sterile bottles or tubes in 50 mL or 100 mL portions

To Sterilize

Autoclave

Store

at room temperature

*Recipe included in this appendix
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Phage Precipitation Solution (100 mL)
Ingredient
Amount
Polyethylene glycol (PEG)
30 g
8000*

Final Concentration
30%

NaCl

19.3 g

3.3 M

ddH2O
To Prepare

To 100 mL
1
2
3

Place NaCl and 60 mL ddH2O in a glass bottle with a screw cap
and swirl until NaCl is completely dissolved
Slowly add PEG 8000 a few grams at a time, alternatively
swirling and heating in a microwave until all the PEG is dissolved
Add ddH2O to 100 mL and stir until homogeneous

To Sterilize

Filter-sterilize

Store

at room temperature

*Sigma-Aldrich, catalog no. P2139-500G
Nuclease Mix (10 mL)
Ingredient

Amount

Final Concentration

0.088 g
500 μL of 5 mg/mL stock

150 mM

DNase I*
Rnase A**

250 μL of 10 mg/mL stock

68 mM

Glycerol

5 mL

50%

ddH2O
To Prepare

4.25 mL

NaCl

1
2
3
4

10 mM

Dissolve the NaCl in the ddH2O in a sterile 15 mL conical tube
Add the Rnase and DNase stock solutions and mix with gentle
inversion
Add the glycerol slowly to a final volume of 10 mL and mix with
gentle inversion until the solution is homogeneous
Aliquot into microcentrifuge tubes

To Sterilize

No sterilization necessary

Store

at -20°C

*Sigma-Aldrich, catalog no. D4527-40KU
**Sigma-Aldrich, catalog no. R6513-10MG
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1.0% Uranyl Acetate Stain (10 mL)
Ingredient
Amount

Final Concentration

Uranyl acetate*

0.1 g

1.0%

ddH2O
To Prepare

To 10 mL
1

Weigh out the uranyl acetate and place it in a beaker

2

To Sterilize

Add approximately 9 mL ddH2O and stir
When the uranyl acetate has dissolved, bring the final volume up
to 10 mL with ddH2O
Filter-sterilize (0.22 μm pore size)

Store

at room temperature in the dark

3

*SPI Supply, catalog no. 02624-AB

159

APPENDIX B

GENBANK PROFILE AND COMPLETE GENOMIC SEQUENCE OF
MYCOBACTERIOPHAGE TIROTHETA9

The following is the GenBank profile for Mycobacterium TiroTheta9 as
determined through the procedures described in this work and published on GenBank
under accession number JN561150.1 (http://www.ncbi.nlm.nih.gov/nuccore/JN561150).

Mycobacterium phage TiroTheta9, complete genome
GenBank: JN561150.1
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
CONSRTM

TITLE
JOURNAL
PUBMED
REFERENCE
AUTHORS

TITLE

JN561150 51367 bp DNA linear PHG 03-FEB-2012
Mycobacterium phage TiroTheta9, complete genome.
JN561150
JN561150.1 GI:343197866
.
Mycobacterium phage TiroTheta9
Mycobacterium phage TiroTheta9
Viruses; dsDNA viruses, no RNA stage; Caudovirales; Siphoviridae.
1 (bases 1 to 51367)
Hatfull,G.F.
the Science Education Alliance Phage Hunters Advancing Genomics and Evolutionary
Science Program; the KwaZulu-Natal Research Institutefor Tuberculosis and HIV
Mycobacterial Genetics Course Students; the Phage Hunters Integrating Research and
Education Program
Complete Genome Sequences of 138 Mycobacteriophages
J. Virol. 86 (4), 2382-2384 (2012)
22282335
2 (bases 1 to 51367)
Schrader,S.M., Parthasarathy,P.T., King,R.A., Rinehart,C.A., Serrano,M.G., Lee,V.,
Hendricks,S.L., Sheth,N.U., Buck,G.A., Bradley,K.W., Khaja,R., Lewis,M.F.,
Barker,L.P., Jordan,T.C., Russell,D.A., Pope,W.H., Jacobs-Sera,D., Hendrix,R.W. and
Hatfull,G.F.
Direct Submission
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JOURNAL

COMMENT

FEATURES
source

gene

cds

gene

cds

Submitted (05-AUG-2011) Pittsburgh Bacteriophage Institute and Department of
Biological Sciences, University of Pittsburgh, 365 Crawford Hall, Pittsburgh, PA 15260,
USA
Isolation, DNA preparation, and annotation analysis performed at Western Kentucky
University, Bowling Green, KY
Sequencing performed at Virginia Commonwealth University, Richmond, VA
Supported by Science Education Alliance, Howard Hughes Medical Institute, Chevy
Chase, MD and The Gatton Academy for Mathematics and Science, Bowling Green,
KY.
Location/Qualifiers
1..51367
/organism="Mycobacterium phage TiroTheta9"
/mol_type="genomic DNA"
/strain="TiroTheta9"
/isolation_source="soil"
/db_xref="taxon:1074829"
/lab_host="Mycobacterium smegmatis mc2 155"
/country="USA: Bowling Green, KY"
/lat_lon="36.99 N 86.42 W"
/collection_date="01-Oct-2009"
/collected_by="S. Schrader"
/identified_by="S. Schrader"
complement(457..672)
/gene="1"
/locus_tag="TIROTHETA9_1"
complement(457..672)
/gene="1"
/locus_tag="TIROTHETA9_1"
/codon_start=1
/transl_table=11
/product="gp1"
/protein_id="AEM05952.1"
/db_xref="GI:343197950"
/translation="MAAVARCLEIAATVVVAAPDVVNIGCLPEATGTLNLTLVARCFEH
GLPVVLVPVRREPAGAVGGAPAPPRI"
803..1234
/gene="2"
/locus_tag="TIROTHETA9_2"
803..1234
/gene="2"
/locus_tag="TIROTHETA9_2"
/codon_start=1
/transl_table=11
/product="gp2"
/protein_id="AEM05869.1"
/db_xref="GI:343197867"
/translation="MGERGPIGKRSDQRVRRNKTDNPVTKLPARGPVKQPQIGIPDAHP
VVTQLWDSLAHSAQAQFYEPSDWAYARMALHFANQLLWSEKPNGQILATVNS
MLNGLLVSEGDRRRVQLEIERNQADAVVVDVAAMFAQQLGAQQRSG"
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gene

cds

gene

cds

gene

cds

1326..1640
/gene="3"
/locus_tag="TIROTHETA9_3"
1326..1640
/gene="3"
/locus_tag="TIROTHETA9_3"
/note="minor tail subunit"
/codon_start=1
/transl_table=11
/product="gp3"
/protein_id="AEM05870.1"
/db_xref="GI:343197868"
/translation="MPVIGAQLESDTLVLTRGRDFKWSFENLDATGQPVAFPAGSLFFEF
ENGTKWTFSIEGALATIKIESEQVALIAARTKWQLVFLPEGEELGGDPIALGQVQ
IQG"
1645..2718
/gene="4"
/locus_tag="TIROTHETA9_4"
1645..2718
/gene="4"
/locus_tag="TIROTHETA9_4"
/codon_start=1
/transl_table=11
/product="gp4"
/protein_id="AEM05871.1"
/db_xref="GI:343197869"
/translation="MRLRGFPTDGRPAVSYVGSPTGSILGIPQNLIGKVSVSQQRPRSLLSI
PTDTPRGVISRHPTTGRLLAVPGRPGPQGPQGPKGDGLRIDGQVPTYAELPGSAS
DGDVWLAGGKLYRYDNGWPDESAGTQVQGQEGPRGPQGIAGPQGPVGPQGP
QGLKGDTGPRGPEGPEGPEGPRGLQGEQGVQGPQGPKGDTGSQGPKGDVGPQ
GERGLQGIQGPVGPKGDKGDKGDTGNQGPQGPQGPRGFTGDTGQTGDDGPPG
PEGPPGPEGPQGPAGPKGDLGPQGPQGLQGPKGDKGDKGDTGSQGPQGIQGPQ
GIQGPQGPYGYLSSDATVLDFRRMTQAQYNALGAGRPATTFYVIVG"
2722..3384
/gene="5"
/locus_tag="TIROTHETA9_5"
2722..3384
/gene="5"
/locus_tag="TIROTHETA9_5"
/note="structural"
/codon_start=1
/transl_table=11
/product="gp5"
/protein_id="AEM05872.1"
db_xref="GI:343197870"
/translation="MPVRIGDATPSGFRFGDLTATKIYLGDVLVFPAFTVVSQTFSTVGN
WTFNIPAECGAIDIILLGGGGGGSSGNAGLGNGGGGDGGLWETLTLIRGIDFPST
ALQITGTVGDGGTGGAGGWIPINGADGNPTTANIPGVGLVQALGGGGGVWTSG
SRPGKGPGNRVHNGINYTGGANTGDSAANGNPPGGGAGGGNSGFFGFPAGGG
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GKGARGQAWVRAYV"
3384..3755
/gene="6"
/locus_tag="TIROTHETA9_6"
3384..3755
/gene="6"
/locus_tag="TIROTHETA9_6"
/codon_start=1
/transl_table=11
/product="gp6"
/protein_id="AEM05873.1"
/db_xref="GI:343197871"
/translation="MTQTAPYPTELEELVDGVRYRPGWAFQLVEAPRNDGVNGLALVI
VVQTVDAYGEETHRPVSIYFPFMVPPEVRSRDGWKRWLYDRIEDAERHERGEF
FEVDGEKPFAPRHYPEADGYLRLPPT"
3784..3921
/gene="7"
/locus_tag="TIROTHETA9_7"
3784..3921
/gene="7"
/locus_tag="TIROTHETA9_7"
/codon_start=1
/transl_table=11
/product="gp7"
/protein_id="AEM05874.1"
/db_xref="GI:343197872"
/translation="MTALQGKLAVFALKQGVKFLKNHPDLIPGEIDDAIVKVLALALGV
"
3921..5423
/gene="8"
/locus_tag="TIROTHETA9_8"
3921..5423
/gene="8"
/locus_tag="TIROTHETA9_8"
/note="LysA"
/codon_start=1
/transl_table=11
/product="gp8"
/protein_id="AEM05875.1"
/db_xref="GI:343197873"
/translation="MARRLFRGRAFSENGWPYVDQGSCTWDEVVPGVWLQIQNGAPFT
IMRAFARDFHAHVEPLRDYDSACWTQDNTVDTSNHPGGTGMDLNWNGADQK
TFRYGITKERAYPGDKARKLDELLAFYEDVIYCGGYWSIRDWMHFQMGYGTY
DSKADRPTEKTLDFIRRKIRPDGFSTFNRGGGTTVPNGASVLARATGIPLDRAERI
LPALREGLILAECNTFPRIAMFLAQTCWESDQYRATEEYANGPAHEERWIYKGR
TWIQLTWRSAYEGFGKWCHARGLVNDPMVFVNNPRSLADLKWAGLGAAYY
WTTTVRNTRKYPTLNQASDARDVLVATQIVNGGTNHLAERTAIYNRAIALGDE
LLQLVQEEDGFLSALNSAEQREVLDLLRWLAAPEYGELRKLFASRAMYRDSDD
RFETLAGFVLACDAMQWEDRVEGAAMLGEPEYLERVLRLAAGRGPGAKNPDG
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SPRQWAINHARAVLADIEAKNPQALQRYLAQKGAA"
5420..5881
/gene="9"
/locus_tag="TIROTHETA9_9"
5420..5881
/gene="9"
/locus_tag="TIROTHETA9_9"
/codon_start=1
/transl_table=11
/product="gp9"
/protein_id="AEM05876.1"
/db_xref="GI:343197874"
/translation="MSPKVRQTIYYLGTIIPGVLGIALIWGGIDAGAAQSIGDIIAGAVALL
GASAPAVAAKKVNEQRKDGTLVPQAPVEQVVNGVQAVIAAQQAAQAELDRV
RDVVTGAIGIVPGIVPQLGPLAQQAVDALNSFAPPTAYSQAAQFADPYRAPWDR
"
5881..6861
/gene="10"
/locus_tag="TIROTHETA9_10"
5881..6861
/gene="10"
/locus_tag="TIROTHETA9_10"
/note="LysB"
/codon_start=1
/transl_table=11
/product="gp10"
/protein_id="AEM05877.1"
/db_xref="GI:343197875"
/translation="MLKLGSSGLMVSAWTAVMRLRFASYALGVNGQPIKVDGYFGYDE
EKVQKEYQLRTGQFPSGQVSREDLHRLGLLPTLLSIHGTGQADPFGIGYPADIAR
RVLDLYWWQPVGNWPAKAVPMNGSVDAGERECVRLISNPLIVPGPTAFVDYS
QGSVIGGRVRNRMRRKELRGELVAAASFGNPMRLRGHYAGNVDPGGEGIDPR
QELAAEPFRIELAAKGDLYTTCPGGQSGEMERAIYHAVFSRFIGEDSLIEQVWEL
ARNPWVEVPAAVKAIVRGGMFAIRGTGPHVRYHIDECPGTGMTYYEYAIKHLR
DTAEARLRRIVASVT"
6884..8581
/gene="11"
/locus_tag="TIROTHETA9_11"
6884..8581
/gene="11"
/locus_tag="TIROTHETA9_11"
/note="terminase"
/codon_start=1
/transl_table=11
/product="gp11"
/protein_id="AEM05878.1"
/db_xref="GI:343197876"
/translation="MSLANHHPVPLLPQPPHKIGPVWQVREDGSWHLPERTLGWGILN
WLAKYVRSPAGGGPFLPTLEQARFILWWYAVDERGVYAYREGVLRRMKGWG
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KDPLCAAIALAELCGPVAFSHWDLEGNPVGQTRHAAWITIAAVSQDQTKNTFSL
FPVMISKDLKTDYGLDVNKFVIYSEVGGRIEAATSSPASMEGNRPTLVIENETQ
WWGVGPDGNVNDGVDMDDVIEGNVAKIPGARKLAICNAHIPGNDTVAEKAYD
HWQDVQTGKAVDTGILYDALEAPADTPVSEIPSEKEDPEGYAEGIAKLMDGLQ
VARGDSYWLPLEEILGSVLNTRNPVSESRRKFLNQVNAHEDSWIAPTEWDRLAL
TDKVFCLKKNDRITLGFDGSKSNDWSALVACRVEDGMLFVLKTWNPEDHPHN
EVPREDVDAYVRSAFQRYDVVGFRADVKEFEAYVDQWGRDFKRKIKVNATPG
NPIAFDMRGQTKRFALDCERFLDAVLEREVYHDGNPVLRQHVLNARRHPTTYD
AISIRKESKDSSKKIDAAVCAVLAYGARQDFLMSKKSRTGRAVVIR"
8578..10029
/gene="12"
/locus_tag="TIROTHETA9_12"
8578..10029
/gene="12"
/locus_tag="TIROTHETA9_12"
/note="portal"
/codon_start=1
/transl_table=11
/product="gp12"
/protein_id="AEM05879.1"
/db_xref="GI:343197877"
/translation="MTSPTEQQNVNPEERLEPLLNAFEEKIRPLADNTAYYESERRPDAI
GIAVPPEMRKLLAHVGYPRLYVNSIADRLELEGFRIAGESDADEQLWDWWSAN
DLDVESTLGHVDALVHGRSFVTVSAPDPAIDLGVDPTVPMIRVEPPTNLHAVIDP
RTRQVKEAIRAIYDEEGNEIVGATIYLPNATAYFDKVEGEWTQGRPTVNHGLEM
VPVVPIPNRNRLSDLYGTSEITPELRSVTDAAARTLMLMQSTAELMGVPLRLLF
GIKRSEIGLPDDPDEPVSPRQAFEAYYARILGFEDEMGKAYQFDAAELRNFVDA
LDALDKKAAAYTGLPPQYLSFSSDNPASAEAIRSSESRLVMNCERKARIFGGAW
EQVMRVAYRVMNPGAEIPPNMYRLEALWADPSTPTYAAKADAATKLYGQGM
GVIPREQARIDMGYSVETRRQMREWDKEENPVGQLAGLYAPTDKTGGSETPNE
PAAEEVPEE"
10026..10886
/gene="13"
/locus_tag="TIROTHETA9_13"
10026..10886
/gene="13"
/locus_tag="TIROTHETA9_13"
/note="capsid maturation protease"
/codon_start=1
/transl_table=11
/product="gp13"
/protein_id="AEM05880.1"
/db_xref="GI:343197878"
/translation="MNAEEYAARQAVVSAAVANYILQIGKLFLGPRLSVQDWIGFLQAL
YPEVYRHRLEAAELARQFHDSERRRHGKAFQPRFLVEYDFKEFVKDMEPTRDR
MSRELAPQSALGDVALRAVRSVENAGRKQIIRAVEDDSETGTVKGWARVATGR
ETCAWCLMLISRGPVYSSAESAGLDLDDQSAADVFRASGGDLNKLAAYVDENE
LMKEWHTGCDCKVVPVYDRANWPGRDAYKRAEQFWIEATKEARRLIDSGKSK
SDNLNREAQNALRRRLERGDLSMTRFALAA"
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10939..11451
/gene="14"
/locus_tag="TIROTHETA9_14"
10939..11451
/gene="14"
/locus_tag="TIROTHETA9_14"
/note="scaffolding"
/codon_start=1
/transl_table=11
/product="gp14"
/protein_id="AEM05881.1"
/db_xref="GI:343197879"
/translation="MADNDTQTPDTTPGNDGGTDTGQAPAPEVFSREYVEELRRENAK
ARTSKNQAVEDAKAEVRKEYEAKLAEKDTAYTELQNQLGEAWIELEKVYTTID
AKVPSDRVRAFAAILQGSDKESISESAKSAKQLFGGMTGTVPAVDPTQGSGGGK
HTPLNGDPILDALRKAVGA"
11479..12411
/gene="15"
/locus_tag="TIROTHETA9_15"
11479..12411
/gene="15"
/locus_tag="TIROTHETA9_15"
/note="major capsid"
/codon_start=1
/transl_table=11
/product="gp15"
/protein_id="AEM05882.1"
/db_xref="GI:343197880"
/translation="MAQGTTFQVDHAQIAQTGDSMFKGYLEPEQAQDYFAEAEKTSIVQ
RVARKIPMGSTGVKIPHWTGDVAAAWIGEGDMKPITKGDMTVNQVEPHKIATI
FIASAETVRANPANYLGTMRVKVGTAIALAFDDAALHGTDSPFDQFVDQTTKS
VDITPAAPATTYDAIGVNALSLLVNDGKKWQATLLDDIAEPVLNGAKDANGRP
LFVESTYEGLTTPYREGRILGRTTILSDHVATGTTVGYQGDFSQIVWGQVGGLSF
DVTDQATLNLGTMEEPKFVSLWQHNLVAVRVEAEFGLLINDVEAFVKLTNA"
12475..12681
/gene="16"
/locus_tag="TIROTHETA9_16"
12475..12681
/gene="16"
/locus_tag="TIROTHETA9_16"
/codon_start=1
/transl_table=11
/product="gp16"
/protein_id="AEM05883.1"
/db_xref="GI:343197881"
/translation="MKIRNKDNGGVAEVTEDYGKALIELGRWEPADAPRRQRAKKSSP
KPPEPAPAEAPEPETPTEVTTTEE"
12685..13041
/gene="17"
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/locus_tag="TIROTHETA9_17"
12685..13041
/gene="17"
/locus_tag="TIROTHETA9_17"
/codon_start=1
/transl_table=11
/product="gp17"
/protein_id="AEM05884.1"
/db_xref="GI:343197882"
/translation="MAIATAQDVENRWVRELSEEETTLVNTRLNDAERMLKRRIKNLD
AVDPEDVKQVEADMVLRLLRNPEGYTQETDGNYTYMLSQALASGKLEVLPEE
WEALGIRRSGMFVLTPTFEMPT"
13038..13205
/gene="18"
/locus_tag="TIROTHETA9_18"
13038..13205
/gene="18"
/locus_tag="TIROTHETA9_18"
/codon_start=1
/transl_table=11
/product="gp18"
/protein_id="AEM05885.1"
/db_xref="GI:343197883"
/translation="MSASDRQPPGPYPEGFTEAVRPEDVDVSKCDHEFGVCFCVHDWRI
HWGNLDRSGL"
13202..13564
/gene="19"
/locus_tag="TIROTHETA9_19"
13202..13564
/gene="19"
/locus_tag="TIROTHETA9_19"
/codon_start=1
/transl_table=11
/product="gp19"
/protein_id="AEM05886.1"
/db_xref="GI:343197884"
/translation="MSLLDHCPDDVIVYPQVVTTDDDGNTITKPSDEGIPTKARLQVLGQ
SGTSSRRQEQDNEGFESERVYTIRFTRKFDREHGILGMQSQVEWEGVRWALFGE
PAYYNSSRRTRHITYTVKRY"
13566..13958
/gene="20"
/locus_tag="TIROTHETA9_20"
13566..13958
/gene="20"
/locus_tag="TIROTHETA9_20"
/codon_start=1
/transl_table=11
/product="gp20"
/protein_id="AEM05887.1"
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/db_xref="GI:343197885"
/translation="MAKLIPRRRLNHIVAHLAETKAAIRREAREVEGRARRNLAEARAS
TTHSKIVGPGHLTKIGSAADDPDVLVYMDAPNPMAIEYGHGPSGYFDPDKYGK
VTKAPAGLYILNRAAGIAGSMVTPSMGRRGVK"
13958..14395
/gene="21"
/locus_tag="TIROTHETA9_21"
13958..14395
/gene="21"
/locus_tag="TIROTHETA9_21"
/codon_start=1
/transl_table=11
/product="gp21"
/protein_id="AEM05888.1"
/db_xref="GI:343197886"
/translation="MTFPRIQSVVIPLLRDALVPDKAKKVGSWIENIDYREFPLVNVRRIG
GGRHPNRPTQFATPVIELTVYHTKGLIECEQLYEDCLDVLYDAVKTQKQTPKGY
LHSIRETMGATQFSSPFMDSWRVQGLIALGLRPPRNKGVTPNGT"
14385..14975
/gene="22"
/locus_tag="TIROTHETA9_22"
14385..14975
/gene="22"
/locus_tag="TIROTHETA9_22"
/note="major tail subunit"
/codon_start=1
/transl_table=11
/product="gp22"
/protein_id="AEM05889.1"
/db_xref="GI:343197887"
/translation="MALNDEAVLTAAVGYVYTGPVGTAAPSAAELDDLDLESPSSWTA
TSWDSIGHTSRGDMPEFGFDGGDSEIKGTWQRKKLREVTTEDPVDYLTLFLHQF
DEDALSLYYGKNASTTAGEFAVSGKSDPTEKAFFVVIEDGDVRIGFHSAKASVK
RDDAIQLPVDDFASLPIRATFLDHPGFPLFKWVNEDLFPNVQTP"
15095..15963
/gene="24"
/locus_tag="TIROTHETA9_24"
join(15095..15442,15442..15963)
/gene="24"
/locus_tag="TIROTHETA9_24"
/ribosomal_slippage
/note="tail assembly chaperone"
/codon_start=1
/transl_table=11
/product="gp24"
/protein_id="AEM05891.1"
/db_xref="GI:343197889"
/translation="MSNVFTLDSLREEADKQFAPFKVRLSDGTEVVLRNLLRLNKNDRK
TVLASIEALKTEDESEEGRTLDDIDRMVDTVSKILELAAGKDSRKLLKELDGDL
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GLLMGVLEGWLEATSPGGSAELAGLIDRYGEHLVPDLKHYYGIDLRELFSEANP
LSPQYVLIHIKHLPIESAFVAAIRGGQEFRGWNADRYALAAIINSIRAGNYMFVM
ANSDPRKGKPPLPSPWPVPQENKAEKKYAPNSFAGIVAAQVIAARKRKQQKKE
AEWQAQEASKSAGFLSGSSQTSTGSTES"
15095..15466
/gene="23"
/locus_tag="TIROTHETA9_23"
15095..15466
/gene="23"
/locus_tag="TIROTHETA9_23"
/note="tail assembly chaperone"
/codon_start=1
/transl_table=11
/product="gp23"
/protein_id="AEM05890.1"
/db_xref="GI:343197888"
/translation="MSNVFTLDSLREEADKQFAPFKVRLSDGTEVVLRNLLRLNKNDRK
TVLASIEALKTEDESEEGRTLDDIDRMVDTVSKILELAAGKDSRKLLKELDGDL
GLLMGVLEGWLEATSPGEAQNSPA"
15882..18482
/gene="25"
/locus_tag="TIROTHETA9_25"
15882..18482
/gene="25"
/locus_tag="TIROTHETA9_25"
/note="tapemeasure"
/codon_start=1
/transl_table=11
/product="gp25"
/protein_id="AEM05892.1"
/db_xref="GI:343197890"
/translation="MAGAGGVEVGRISIRVVPDLDGFYRELKTKLEGIEKTLKAKIKVEP
DMDGFAGVVAQKAKNLKAKVKLDGDSTDLQKAVDAVNAKGPKKIKLELDPE
FDYRLRQRLAKLKPKVEVDVDFKRGMLDRLSNSLSKIQMPSFGSGINPMGWAV
ILAGVAAVTPLISGLLGAITTAIVALPGLITSILVPVAALALGMDGLKKAAEVLK
GPFDDLKATMSSAVEEQFTPVFEKLGTIFPMLKEALPGVTDGLAAMAQSFADA
VTSPQGMEKVRGVIDDIANALKQAAPGIGDFTTGLLDLVKGFTGNLPSVADWF
NDTGKSFKDWAKDFTEKGPDGTSKFDRALEGLGWTLKELGGGLVDIGGKALD
FFSDPEKIRSFKTELDGVVATVSTLVDLSNQLASNMSKIPGFRDGEANGPMDFAP
IQIQLIKEQFDKIDWSGIWGNMKSTAAGAFAEVTMFAANTAITIGAKFRGIWDGI
STNAGTAWNGVVTIVSGVIANILRIAAQLPGQIASVWANIPSMTAGVWNTVVST
AAPIITQILTTFINVGVGVMNEVSSWPGKIVGALGSLASTLAEIGSRAAQALVSA
LAAGIRAGIGPIGQAVGALMSAARALIPNSPAKEGPFSGSGWRAVEGFGDALGD
ALASGIPGQEDKIVSKIRAIMQAIKDVFGDASKLNLNFNFGSLESGLNSVASAAT
DTSRALGNTVSGAMPNKLSDEAKQQKDLLELKKDELEVERQKLQNQKNGLDP
KDKAGRAAIQQQIDQLNLQKKQIDLEKEQLDYAGKYTDQVAETDSVMGDMGK
KIYDATKNVAQAASGQLMSDLGISGNGALSQFLEQGLALGEQFIFNVGSMDDA
VAGQQTIQNKKALQFDRR"
18487..19827
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/gene="26"
/locus_tag="TIROTHETA9_26"
18487..19827
/gene="26"
/locus_tag="TIROTHETA9_26"
/note="minor tail protein"
/codon_start=1
/transl_table=11
/product="gp26"
/protein_id="AEM05893.1"
/db_xref="GI:343197891"
/translation="MDTLVELEGVNGEWFTLAGPGEGDRGVYLGTDVKGLYDPPVKV
VYEEPGNYPGARYLNHRILRRDITFGVEILNDAAIGPNSWLSRESEWRKAWAFD
RDCKLYITTPESGTRYLKVRLGESPEVSWFTDPRGNKINRTVMVVIAGDPFWYQ
DDVVYSAVTQTDTTFDPNPLPWPWPQEALPTETLSITVDPADGKGGLNPTDQYS
WVKWILPGSTQVPAEPYVPGIPWLGAPKSPAVIWTVPDYSFEDESLSNRRVRMP
GLIGGLRTAEVQIVSLIGDPKSGTFKLGRDSSLTSSIAYNATAATMKTRLEAVYG
AGNIRVDGGPTLLSPRQPWRVSFIGALAGSPQPLMLTESSLGNGGRVQVTRATE
GATAPAENALIDTDPREEQVTSENGSQLWARMNGVRFRHPIPPWTKSATFELTV
SGAVPGQMAVLRIPRAWTRPWGLE"
19824..21602
/gene="27"
/locus_tag="TIROTHETA9_27"
19824..21602
/gene="27"
/locus_tag="TIROTHETA9_27"
/note="minor tail protein"
/codon_start=1
/transl_table=11
/product="gp27"
/protein_id="AEM05894.1"
/db_xref="GI:343197892"
/translation="MSTSTITSLEDAERVWNTAMARRALREQERLKPVLTRLWDGDMR
LRGHVAGERGGDFEFIENDTGTASLQLSLDHHLAKWVMNFRGREKRNVIVTFD
KQGARWSGFMDHYRVVREENGDVYLDIVFKHDYEQAKHILCWCNPFLRPELQ
FPKLWIIFGPAKWCLLLTLFVNILRLETSLWTLPDNPLDPTEWMPLSFNISNWRNI
VKPFPLIGDNSNLTMVFSRFQSFHDIAKSTLEDAQLTIVCRRYLKGEDPHPFEDL
RGELNIGPLEDLLSLIPIRHGCLVWDIVDNSGWGSETSFGGSWLTGFIRAVVNIAS
DGMTEGVDVFTGDPTFPGEYYTPWFLGTSPQAPWIVFEEGPYTGIKSSEFKYFE
ATDTSFVAGGESMPGVNEGISAGVNMGGDFLTSMINQALGGFIDLPPLGGTMD
AIAKPLYENVFLAFQEWPTLRAMGSPIPIPLLEASQNGLGDFHYYEGWVENATK
AFTLSAFLATRAKIYATRAHTAHTIKVSDAAPYYVGEPGYGHFWLGSRVGTSVL
GFPIPHTVFVERVSKISYSWGADGPKGWELDIGYRDPKDPLLKLFELVMRFNGA
MGQLGIL"
21624..22070
/gene="28"
/locus_tag="TIROTHETA9_28"
21624..22070
/gene="28"
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/locus_tag="TIROTHETA9_28"
/codon_start=1
/transl_table=11
/product="gp28"
/protein_id="AEM05895.1"
/db_xref="GI:343197893"
/translation="MIKPQEEVDWNKPEEHFAWALRNMPMLAGVGAVTHPGFLVQWS
KHLWECGFAHRDYLERLADEDGNIHVSKLPKQRIRWQAPFRGPRSNYNNAAR
WVSKNTPAPQPVRLPDVSKMTQQEQEFMLGQFRELGLIQDYIPQPDVAQELND
22079..22525
/gene="29"
/locus_tag="TIROTHETA9_29"
22079..22525
/gene="29"
/locus_tag="TIROTHETA9_29"
/codon_start=1
/transl_table=11
/product="gp29"
/protein_id="AEM05896.1"
/db_xref="GI:343197894"
/translation="MTFRYVPAWGLRGLQLAVLFEAAMRGLMYLLMPQMALSSDSLTE
LERSAPLYVWGLVFVAAAAFGLFGETLMSGTENYMGSSSQNNPRAWPSFVAH
AALMILYVTLALAYGASLYDAGAAHFAIIPYDLLMIAYLHWLFARRRKSHVH"
22515..22943
/gene="30"
/locus_tag="TIROTHETA9_30"
22515..22943
/gene="30"
/locus_tag="TIROTHETA9_30"
/codon_start=1
/transl_table=11
/product="gp30"
/protein_id="AEM05897.1"
/db_xref="GI:343197895"
/translation="MSTEILQYLPQQWVGLFAVIMFIGYITMQVIEKYPTFAKIMPFGTW
WHERQKTKRGKRNAWVAEDNEVIQALQAQVSAIAADLAAVNEKVRTFTAWS
VYDARWHHKVSVTWAGSETCLLPDHLDYFAFERLWRDDPVGASRL"
22957..24813
/gene="31"
/locus_tag="TIROTHETA9_31"
22957..24813
/gene="31"
/locus_tag="TIROTHETA9_31"
/codon_start=1
/transl_table=11
/product="gp31"
/protein_id="AEM05898.1"
/db_xref="GI:343197896"
/translation="MTTPHQIPDQGVLEKWLGSGAFELGGGDSSWGQDYTENAVRALF

171

gene

cds

gene

cds

gene

EVPIGSVLTAFDVLEEQLLKLPLEALRYFKPLIPGATENDFVDVYTAVAKIIDNLT
DLPMALLKGEFLEWLGGTYAVLSTEVRQILEILSGLIVTPINAAVQGVKDWWNL
ITGKTSKLGTDGKLAADQLTGTVPTDKVGGFGGTANLADGLTTLVDNTVKAA
GNILGSGFGLQDLFDSLKGMQSNIADANAALAQLQADWAGSVNSGKKFFVNFG
DFDNANSVPSILTEVVNTGPGSVATVDGQLQWLDSGNAFAQRMYLYNVEPLM
DDYFEVQFVMPRRSEDELFGFANPPYNYAIGRSNASGSRFCFARVGYQRARIGC
MVDGTMTLFGTQDISYQAPAGARIKFRGGTSGGVRVFQLLVNNQIIGTVTDTGN
VSYAGAGYRMIGIGFEAQPRGNGQGTPGTISALSANDNTPQAVVGTSFRAYRA
ATGSISKGSGANVLPANCIDTLDHISSDLTWTPATQRLTYNGERPKTFLVGMRV
KSNSIIPSGGTWRQVLYKNGSLYARLEGHEGMVDTSTNNDNENRLSFVGGGTP
MVQMNPGDYISFGFENTSSVGIVGSGDGSQTWVNAIGLG"
complement(24876..25094)
/gene="32"
/locus_tag="TIROTHETA9_32"
complement(24876..25094)
/gene="32"
/locus_tag="TIROTHETA9_32"
/codon_start=1
/transl_table=11
/product="gp32"
/protein_id="AEM05951.1"
/db_xref="GI:343197949"
/translation="MSNPVPYPYPVPSKRKPAPNPLFLTLSILSGFPTAFFLLLFVTGGTSI
FVMIGFLWSAMWTWVWALMANRYR"
complement(25120..26634)
/gene="33"
/locus_tag="TIROTHETA9_33"
complement(25120..26634)
/gene="33"
/locus_tag="TIROTHETA9_33"
/note="integrase (S-int)"
/codon_start=1
/transl_table=11
/product="gp33"
/protein_id="AEM05950.1"
/db_xref="GI:343197948"
/translation="MPQPLRALVGARVSVVQGPQKVSQQAQLETARKWAEAQGHEIVG
TFEDLGVSASVRPDERPDLGKWLTDEGASKWDVIVWSKMDRAFRSTKHCVDF
AQWAEERQKVVMFAEDNLRLDYRPGAAKGIDAMMAELFVYLGSFFAQLELNR
FKSRAQDSHRVLRQTDRWASGLPPLGYKTVPHPSGKGFGLDTDEDTKAVLYD
MAGKLLDGWSLIGIAKDLNDRGVLGSRSRARLAKGKPIDQAPWNVSTVKDALT
NLKTQGIKMTGKGKHAKPVLDDKGEQIVLAPPTFDWDTWKQIQDAVALREQA
PRSRVHTKNPMLGIGICGKCGATLAQQHSRKKSDKSVVYRYYRCSRTPVNCDG
VFIVADEADTLLEEAFLYEWADQPVTRRVFVPGEDHTYELEQINETIARLRRESD
AGLIVSDEDERIYLERMRSLITRRTKLEAMPRRSAGWVEETTGQTYGEAWETED
HQQLLKDAKVKFILYSNKPRNIEVVVPQDRVAVDLAI"
26713..27132
/gene="34"
/locus_tag="TIROTHETA9_34"
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26713..27132
/gene="34"
/locus_tag="TIROTHETA9_34"
/codon_start=1
/transl_table=11
/product="gp34"
/protein_id="AEM05899.1"
/db_xref="GI:343197897"
/translation="MLSPVRVATAGTVAVGGLAFALSFTALSELSADNGVSQAWMVPL
VVDGGIIVATTATLALRTQWYAWTLLIVGSLVSVAGNVAHASPHGAIAMVIAAI
PPLWLLAATHLTVLLYRGTQESRSASISEPLFSRAFAENAA"
complement(27205..27801)
/gene="35"
/locus_tag="TIROTHETA9_35"
complement(27205..27801)
/gene="35"
/locus_tag="TIROTHETA9_35"
/note="deoxycytidylate deaminase"
/codon_start=1
/transl_table=11
/product="gp35"
/protein_id="AEM05949.1"
/db_xref="GI:343197947"
/translation="MRPTWDEYFLGIARAAAERSDCERSKVGAVVVKDRRVRATGYNG
APAGRPGCGTCPRRTSNARPGVDSYSSGGTRCVAVHAEANALLYCDREDLRGA
ALYITRAPCGDCSKLIDAAGIERVVYPFEWEKPEGCVCAGPTDPYHGWCDPCSK
LPKIVVQEQDRWERNEYTVRMEPGMLPDEPWRLGFINLRDEVGKTIE"
complement(27798..27956)
/gene="36"
/locus_tag="TIROTHETA9_36"
complement(27798..27956)
/gene="36"
/locus_tag="TIROTHETA9_36"
/codon_start=1
/transl_table=11
/product="gp36"
/protein_id="AEM05953.1"
/db_xref="GI:343197951"
/translation="MAKHRFDTPRSANTPVVFRYGGRANGTGGVFVRYKNGNLEPLVG
PWVPRRPR"
complement(27956..28108)
/gene="37"
/locus_tag="TIROTHETA9_37"
complement(27956..28108)
/gene="37"
/locus_tag="TIROTHETA9_37"
/codon_start=1
/transl_table=11
/product="gp37"
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/protein_id="AEM05948.1"
/db_xref="GI:343197946"
/translation="MKLVTALVLLALVLGLTACEGDSGGSDYDGPNGVIFMPVQGNPV
GIPIFF"
complement(28105..28371)
/gene="38"
/locus_tag="TIROTHETA9_38"
complement(28105..28371)
/gene="38"
/locus_tag="TIROTHETA9_38"
/codon_start=1
/transl_table=11
/product="gp38"
/protein_id="AEM05947.1"
/db_xref="GI:343197945"
/translation="MSAGDVYLQIVEDDKGRPIMHFNGREFGVLEEPRIEFNSVPYGIYG
RARADISVSIRAVLIEPEPTPPPKPKRTWASAMGLRKPRGNR"
complement(28368..28454)
/gene="39"
/locus_tag="TIROTHETA9_39"
complement(28368..28454)
/gene="39"
/locus_tag="TIROTHETA9_39"
/codon_start=1
/transl_table=11
/product="gp39"
/protein_id="AEM05946.1"
/db_xref="GI:343197944"
/translation="MKGVIVLLYLLAWLIVGFGVPITLDALL"
complement(28451..28708)
/gene="40"
/locus_tag="TIROTHETA9_40"
complement(28451..28708)
/gene="40"
/locus_tag="TIROTHETA9_40"
/codon_start=1
/transl_table=11
/product="gp40"
/protein_id="AEM05945.1"
/db_xref="GI:343197943"
/translation="MTVQATSIESYHQIKPLLPKREVEALAWLQRGRPLCNLELAGLLDL
PINSVTPTVFRLRERGLVVESHRAKYEPTNRTVIYWTAA"
complement(28705..29061)
/gene="41"
/locus_tag="TIROTHETA9_41"
complement(28705..29061)
/gene="41"
/locus_tag="TIROTHETA9_41"
/codon_start=1
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/transl_table=11
/product="gp41"
/protein_id="AEM05944.1"
/db_xref="GI:343197942"
/translation="MEDRDFFDLLYQQWSKTTGAQDTYWMVEEDTEHYAGGPGTFLV
LAVDKENERKFIASFEREEDADFIAGLHGCLADLVRKLHMALDEADNADYDRD
SRECRIAELELENAELRKELGR"
complement(29048..29323)
/gene="42"
/locus_tag="TIROTHETA9_42"
complement(29048..29323)
/gene="42"
/locus_tag="TIROTHETA9_42"
/codon_start=1
/transl_table=11
/product="gp42"
/protein_id="AEM05943.1"
/db_xref="GI:343197941"
/translation="MKWMHGGEGDSPAIAPLRPPSTTVELYITLPDQSSIPEFGENHRLTV
QKLALGVENMSQVERNWAIRTLIESVVEAAITELEEKGILRGGS"
complement(29320..29553)
/gene="43"
/locus_tag="TIROTHETA9_43"
complement(29320..29553)
/gene="43"
/locus_tag="TIROTHETA9_43"
/codon_start=1
/transl_table=11
/product="gp43"
/protein_id="AEM05942.1"
/db_xref="GI:343197940"
/translation="MKAAVALPAPDGLTEELMGKAIYELNKLGTIMPHPLSGEGALEVY
LIPDAMKPAGAPKELTFLRFVADLMPYVGKRP"
complement(29550..29717)
/gene="44"
/locus_tag="TIROTHETA9_44"
complement(29550..29717)
/gene="44"
/locus_tag="TIROTHETA9_44"
/codon_start=1
/transl_table=11
/product="gp44"
/protein_id="AEM05941.1"
/db_xref="GI:343197939"
/translation="MDGIKLTLTVENGKRTATAEAVIDRLWLNEVFVDLAYDAAVAAM
KEALKAEGVLP"
complement(29738..31564)
/gene="45"
/locus_tag="TIROTHETA9_45"
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complement(29738..31564)
/gene="45"
/locus_tag="TIROTHETA9_45"
/note="DNA pol I; DNA polymerase I"
/codon_start=1
/transl_table=11
/product="gp45"
/protein_id="AEM05940.1"
/db_xref="GI:343197938"
/translation="MIEHRHEVDGDEVVINVVDRESDLDGFMDFIRAHQGFLGLDSETT
GLDIYNDGFRCRLVQFGTPSEAWVVPVERGGPYAGDVKRALEMVQGFVLHNA
AYDLQVFERTLGVPMETMWPKVKDTRILAHLIDPRGKDEGGSGHSLEDLTRRYI
DSAVADNVKTLMADLAKANKTTKVNVWKKVPFEDPHYQLYSGMDPILAARLI
QKLAPLVKVSDELVDNEHKLAAICSYMERTGFLLDVEYTEELSLDLQVKESHY
NEIALNYGCEKVNSTDQVADVLESMGVRIKGRTPSGKRKVDDAVLSELTEHEK
AGEFATAVIEAKKAGKWRKTWVDGFLKQRDSQNRCHAAINPLRARTARMSIT
GIPAQTLPAGDSTIRRCFLADEGHRIASVDYQAQELRVLAALSKDQRMIQAFLD
DADLHLMTARAAFGEHIQKDDPERKYAKVVNFGRVYGGGAKTVAEQTGLDM
ATAQKVVAGFDRAYPEVQKLSQRLQREAIRNGYITTPFIDGLGGRRLPVDPQRA
YSALNYLIQSSSRDVTCRALLRLHDAGFTPYLRLPIHDEILASVPAEQAEWGANR
IGELMAEQMGPVLIGTDPEVGGRSWGSLYGANY"
complement(31572..31874)
/gene="46"
/locus_tag="TIROTHETA9_46"
complement(31572..31874)
/gene="46"
/locus_tag="TIROTHETA9_46"
/codon_start=1
/transl_table=11
/product="gp46"
/protein_id="AEM05939.1"
/db_xref="GI:343197937"
/translation="MRKKELKRALREANLSIDALASSNTTLWEQREELARQNRELRAKL
ETKGPNRPNRPKLDKTEVAFIKDLVRAGVSRRDVARSFDVNPSTISRIVRGQYH
R"
complement(31874..32047)
/gene="47"
/locus_tag="TIROTHETA9_47"
complement(31874..32047)
/gene="47"
/locus_tag="TIROTHETA9_47"
/codon_start=1
/transl_table=11
/product="gp47"
/protein_id="AEM05938.1"
/db_xref="GI:343197936"
/translation="MKEVTVLLIDGTIIRTQGEVNVDPIENTLVITGDSGAYLSFYRPNLM
YYAVSPLEGI"
complement(32056..32775)
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/gene="48"
/locus_tag="TIROTHETA9_48"
complement(32056..32775)
/gene="48"
/locus_tag="TIROTHETA9_48"
/note="ThyX"
/codon_start=1
/transl_table=11
/product="gp48"
/protein_id="AEM05937.1"
/db_xref="GI:343197935"
/translation="MKVKLIAATEVDPYVLESLGYKPSPYETAGGIGDWDADELAEFAG
RNCYRSFDRPNPATRENEDYLAHILEVGHESVLEHASATFYIEASRSVLTELERH
RHLSFSVVSQRYVDPTPLGGHTPPVVWELPENQYRDAAHFLAEAWDSAESYYK
RLLAVLENAGLPRKKAREAARAVLPNMTNSPMVVTGNHRAWRYVIKARYHEA
ADAEIRELAGELLAQLREIAPNTYQDIPNEPYSY"
complement(32843..33382)
/gene="49"
/locus_tag="TIROTHETA9_49"
complement(32843..33382)
/gene="49"
/locus_tag="TIROTHETA9_49"
/codon_start=1
/transl_table=11
/product="gp49"
/protein_id="AEM05936.1"
/db_xref="GI:343197934"
/translation="MQDPFASAPATDEAQAAPEPQESAFDAPPPEAPKKAPAKKAAAKA
APKPAAAPGEGKVVLTFKGGSGFDAPWIVIHAEDLDDALDQVTNQGATLGAL
MERVQNAGQHFAGMAPAKASGGNSGGGGGGRSNAPRGAQEPPAGTPPAPGPD
WVYKSGTGKNGKPWSAWMPPRGSDEKPVWL"
complement(33409..35442)
/gene="50"
/locus_tag="TIROTHETA9_50"
complement(33409..35442)
/gene="50"
/locus_tag="TIROTHETA9_50"
/note="ribonucleotide reductase"
/codon_start=1
/transl_table=11
/product="gp50"
/protein_id="AEM05935.1"
/db_xref="GI:343197933"
/translation="MTTEVNWGPTGEIVYNRTYSRVKPDGSSETWPETVERVVDGNLA
LVDARYQQPGEREELIRLITEFKMLPAGRHLWASGVKNAQHLFNCWVSGWTE
KPSDHFEFTFMRLMEGGGVGANYSNRFIDYGPVPQELYVHIVCDEEHPDYQAM
KDAGVLSTEYDPEWAGAFVIEDSREGWAAALVDLIDTHYRDEVSHFQRVYDVS
RVRPFGAKLKTFGGRASGPLPLARMLIDVCEVLSEIATVGGSLNGIAAMEIDHAI
AQCVVAGGVRRSARMSMMHWQDPQIEEFVRCKQETGKHWTTNISVVVDDLF
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WTALNMPNQVSIMVRDQAHKALTWITDGMVANGEPGFWDSSLSNQGEPNEVV
CTNPCGEITLQEWEPCNLGHINLAAFVKDNGKVDTIDLIRSHRLMARFLIRATFS
PVGDPKSREVLDRNRRIGVGHLGVASYLAMTGRRYSKAPLDKHFRKTLRELAK
EVEQSAQQFSHELRIPVPVKTRTVAPTGTIAKMPGVSEGIHPIFAKYFYRRIRFSK
GDPQIEELREQGYEVEDDLYAQNTVVVTIPTKDTLVQEVVDRFGRDAEEIVESA
EDLTLNQLLAFQAMYQMLWADNAVSFTANVDPDRYKPHVVGEQLRTFGGLLK
GATIFPESSMPQAPYERITKKQFEAATAQAVADSVDEECASGACPIR"
complement(35439..36323)
/gene="51"
/locus_tag="TIROTHETA9_51"
complement(35439..36323)
/gene="51"
/locus_tag="TIROTHETA9_51"
/codon_start=1
/transl_table=11
/product="gp51"
/protein_id="AEM05934.1"
/db_xref="GI:343197932"
/translation="MVKVMEAAAKSALVTWGREGGLDDLVQDLWVWYLERPATQRK
LEELSKPEAIATVRRAAIQILTEQVLAGNKFNGRNLYSSEAVKDVLKDRSNNRY
LKDIMPTAMAALEKQHAVYAEALRSRYDDGVIPQDGPSQDALKNAHKAITEHV
NIIVITAGDVSSAAVQAETRKSSGGRSDPTADAAIALIEKGDEELELTDQEGNVT
GTTTYRTELANVFDDWITQSTGDSSEVRLDIFDGMFNGDDRMAMYRAQVFPEL
FPDEKPMLIDNWPAEDRELYCGGEYTPGYLRLVKGGK"
complement(36339..37106)
/gene="52"
/locus_tag="TIROTHETA9_52"
complement(36339..37106)
/gene="52"
/locus_tag="TIROTHETA9_52"
/note="metallophosphoesterase"
/codon_start=1
/transl_table=11
/product="gp52"
/protein_id="AEM05933.1"
/db_xref="GI:343197931"
/translation="MSKRIVIVSDTQIPYEDRRAVRAVLRFIGDYQPDQVIHIGDLMDFPQ
PSRWNKDTRGEFEGSVFTDAEKAKLRFLAPLRTIYVGPVGVHEGNHDERPRTYL
SKYAPALAESKAFHLETLLDFDGFGIDLLPEFYKVAPGWVTTHGHRGQISLSRIA
GNTALNAARKFDTSVIMGHTHRQGILSHTSGYGGISKKIVTGVEVGNLMDMRQ
ADYLKGGTGNWQSGFGLLTIEGRHVKPEIIPITNGRFTVDGHTWEV"
complement(37099..37374)
/gene="53"
/locus_tag="TIROTHETA9_53"
complement(37099..37374)
/gene="53"
/locus_tag="TIROTHETA9_53"
/codon_start=1
/transl_table=11
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/product="gp53"
/protein_id="AEM05932.1"
/db_xref="GI:343197930"
/translation="MSESILEEAQRLIHGERNKNYGHPRENFSDIAALFSGYLERPISDIDV
ANLMILMKIARVKGTGYHRDSFTDIAGYAGCVERIYEEEPEVE"
complement(37367..37678)
/gene="54"
/locus_tag="TIROTHETA9_54"
complement(37367..37678)
/gene="54"
/locus_tag="TIROTHETA9_54"
/codon_start=1
/transl_table=11
/product="gp54"
/protein_id="AEM05954.1"
/db_xref="GI:343197952"
/translation="MEALHARAVHRIPNRLRPRGRRRARSRVRQPCGTDPAEQQGDPDA
TWRGCQLASHQQRQIRSAGKDVMTQPNEYTETEFLGLDPDAPWWEGIHDYVH
EGEDDE"
complement(37474..38133)
/gene="55"
/locus_tag="TIROTHETA9_55"
complement(37474..38133)
/gene="55"
/locus_tag="TIROTHETA9_55"
/note="DNA primase"
/codon_start=1
/transl_table=11
/product="gp55"
/protein_id="AEM05931.1"
/db_xref="GI:343197929"
/translation="MQRLSESQKSFLREATERYRRSLNGSPAEEYLATRGLMFDSVRDE
VDRFMLGYVDDPLPGHEMFRGFMAIPYLRWSREHGWIVVAIRYRCIQDHDHRG
HGKYMTAPGDQPWLYNTLALLREVPDVAITEGEIDAITAQVCGLPAVGVPGAN
MWKPYMRELFIGYRTVYVLADGDEPGAEFANRVALTLPNSRVIPMPPGEDVNS
LVISRGKSALLERMS"
complement(37949..38362)
/gene="56"
/locus_tag="TIROTHETA9_56"
complement(37949..38362)
/gene="56"
/locus_tag="TIROTHETA9_56"
/note="DNA primase"
/codon_start=1
/transl_table=11
/product="gp56"
/protein_id="AEM05955.1"
/db_xref="GI:343197953"
/translation="MPSTDEPLIVQAIHRYHPDWEPPKDTGKDWIKCLCPFHAEEVPSAA
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VSFVRQAFNCLACGVKGDVLGLIKKQEEVSYAEAERIAEELSPGGNRTVPAKSE
RQSSRRVFGDKGTDVRQRQGRSRPVHARVRGRPTPWS"
complement(38346..38480)
/gene="57"
/locus_tag="TIROTHETA9_57"
complement(38346..38480)
/gene="57"
/locus_tag="TIROTHETA9_57"
/codon_start=1
/transl_table=11
/product="gp57"
/protein_id="AEM05930.1"
/db_xref="GI:343197928"
/translation="MRYRVEAIIRSDEDEAKFAEKFDELINDTYKTGVEDTVVYAING"
/gene="58"
/locus_tag="TIROTHETA9_58"
/note="Endo VII; endonuclease VII"
/codon_start=1
/transl_table=11
/product="gp58"
/protein_id="AEM05929.1"
/db_xref="GI:343197927"
/translation="MTTTRRKPTVRSQDRAHKRKPCIDCTAEGIVTKRKAPHPGPRCVT
HHRAKRLQRRTLTQEQRWMDVYGITADEYWAIYEHQGGCCYICRRANGKRKR
LSVDHDHATGIVRGLLCTACNRNVLGHLRDSVEAAQRIIDYLDDPPAVQAIGER
VVPDP"
complement(39036..39860)
/gene="59"
/locus_tag="TIROTHETA9_59"
complement(39036..39860)
/gene="59"
/locus_tag="TIROTHETA9_59"
/note="hydrolase"
/codon_start=1
/transl_table=11
/product="gp59"
/protein_id="AEM05928.1"
/db_xref="GI:343197926"
/translation="MNLKHQTLVLDDGYRVAVTTAGHSAGVPLVFMHGLSVSAIAYEE
LFEELSYLGFYVIAPDAANHGDSGSLPWGHTVEDMANIIARALTSLKVDKAVIA
GHSMGGAMAVEFSAMFPDRVHAAILIDAAAGKEHHEGIAIAPGRNLPTRAARF
AVGGLVDILGDGYRAMRSRTRRERLSLLSSLQESVSGLRFVRAAYALTKADTVP
LLEKMRANSVPTAVLHAECDQIVPYAAGVSAAALAGGKLFTVKGFHSWLLVD
PEFAADLIKTAMWDVIA"
complement(39857..40237)
/gene="60"
/locus_tag="TIROTHETA9_60"
complement(39857..40237)
/gene="60"
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/locus_tag="TIROTHETA9_60"
/codon_start=1
/transl_table=11
/product="gp60"
/protein_id="AEM05927.1"
/db_xref="GI:343197925"
/translation="MRRVLVTGSRDWRDRPEVWRTLQDELDKSPDGIVVVHGAARGA
DDIADRWAWGMHQMGYKVEPEDHPADWDTYGKSAGHRRNAEMVALGADV
CHAFPLEESIGTFGCMELAEAAGIPVVNHGYIKE"
complement(40234..40458)
/gene="61"
/locus_tag="TIROTHETA9_61"
complement(40234..40458)
/gene="61"
/locus_tag="TIROTHETA9_61"
/codon_start=1
/transl_table=11
/product="gp61"
/protein_id="AEM05926.1"
/db_xref="GI:343197924"
/translation="MPKPTPKMNIIHQQALSALIATKPVSWDRKSLVKDENGKESVVKT
KVTREGLRFPLAQNVSEFNVDLAARRWVP"
complement(40516..41052)
/gene="62"
/locus_tag="TIROTHETA9_62"
complement(40516..41052)
/gene="62"
/locus_tag="TIROTHETA9_62"
/note="phosphoribosyltransferase"
/codon_start=1
/transl_table=11
/product="gp62"
/protein_id="AEM05925.1"
/db_xref="GI:343197923"
/translation="MTLADAIFAPWDTVQYQAVAPRPEKKVLDLTDETYLRVVHKPDR
LLELANQYLSNVDYDTLVGTGLSGTIAATTLARLLDKNYLVVRKPNDGSHTSM
KAEGRIGKRWVFVDDLVATGRTFGRVWDAVHLITQDWKFETKFVGSFLYSDG
GWYDHDFVPADDERTERWLMNNSEYYSQP"
complement(41072..41878)
/gene="63"
/locus_tag="TIROTHETA9_63"
complement(41072..41878)
/gene="63"
/locus_tag="TIROTHETA9_63"
/note="DnaB-like helicase"
/codon_start=1
/transl_table=11
/product="gp63"
/protein_id="AEM05924.1"
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/db_xref="GI:343197922"
/translation="MYTPMQSLRVKGSAGDPLPPVFQALEMKGTRFLRGQLALVCAGP
GTGKSAFVLTYALKARVPTLYFSADSDAFTQLNRMVSIQTAWSMERSARAVRN
SDLTEVAEEFEDIPIRFNYNASPSLDQIEDSMKAYCQGYGDYPDLVVVDNITNVR
SGGGEDDDPFSGLESMMDYLHTMARNTGACVVGLHHVTGSYNDADKPIPLSG
VKGQITRVPELVLTLHRVSEEFGPEALRVSTVKNRAGRMDPSGLDFVELEFIGDT
MQIRDPSNQ"
complement(41886..41966)
/gene="64"
/locus_tag="TIROTHETA9_64"
complement(41886..41966)
/gene="64"
/locus_tag="TIROTHETA9_64"
/codon_start=1
/transl_table=11
/product="gp64"
/protein_id="AEM05923.1"
/db_xref="GI:343197921"
/translation="MIAEVIVFGFIIALGALGGWLCFTKL"
complement(41963..42157)
/gene="65"
/locus_tag="TIROTHETA9_65"
complement(41963..42157)
/gene="65"
/locus_tag="TIROTHETA9_65"
/codon_start=1
/transl_table=11
/product="gp65"
/protein_id="AEM05922.1"
/db_xref="GI:343197920"
/translation="MRNVQMEMNVAKQRRKLTQLCAEAPPSHQGYIEHLIRLFDKDCE
AGLPRPASEFIPMYHEEFGL"
complement(42154..42351)
/gene="66"
/locus_tag="TIROTHETA9_66"
complement(42154..42351)
/gene="66"
/locus_tag="TIROTHETA9_66"
/codon_start=1
/transl_table=11
/product="gp66"
/protein_id="AEM05921.1"
/db_xref="GI:343197919"
/translation="MTQSYRKSLTLSTESEYWFVELGSGDSEYPFPSVAAATRFAQGHT
HRAPVIRYPDGRRWNGKEWV"
complement(42361..43152)
/gene="67"
/locus_tag="TIROTHETA9_67"
complement(42361..43152)
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/gene="67"
/locus_tag="TIROTHETA9_67"
/codon_start=1
/transl_table=11
/product="gp67"
/protein_id="AEM05920.1"
/db_xref="GI:343197918"
/translation="MTEERKHRSVSQLKQYEKCPYSYKLSRLDKAWQRPAAWTAQGSA
VHEAIEAWERSGRTMSLEAAQAVFRESYQKYINAACAITPNFEYWFASGRYGG
RLDIARRYDIGLEQVGKYIDWATSHTEEVIWIAPDGTPGIELGFDIDLDGVLVRG
FIDAVIETDEGLIVRDHKTGKQPGDDFQLAVYAVALAEEYGIEPPELGDYWMG
QSGKATYPYNLTDWTKEAITEKFKELDANVRAGKFDPNPSEDNCRFCDVSFAC
EFSAG"
complement(43149..43571)
/gene="68"
/locus_tag="TIROTHETA9_68"
complement(43149..43571)
/gene="68"
/locus_tag="TIROTHETA9_68"
/codon_start=1
/transl_table=11
/product="gp68"
/protein_id="AEM05919.1"
/db_xref="GI:343197917"
/translation="MPLAIVCHQLALAAPVIRVARPGWLFAESINLLGVTLLLTYRSSAV
RDTDPMFADVKALLDRAKAVKRICLQSLPDQGIMFGEGYWESSLVYDGALDPT
EPLDPRAQAVVDFITKGKYPVHPTEVPAQIRKHLHTLEVAS"
complement(43653..44165)
/gene="69"
/locus_tag="TIROTHETA9_69"
complement(43653..44165)
/gene="69"
/locus_tag="TIROTHETA9_69"
/note="immunity repressor"
/codon_start=1
/transl_table=11
/product="gp69"
/protein_id="AEM05918.1"
/db_xref="GI:343197916"
/translation="MKTDKPYKNQPELTLAVVEDLKGKGYTQSEIARMYGVTRQYVSW
IKHYYGGRLTPREIVLQHFPFQVPVPMQQGVSPYRRLREHGEYMATGGVGMDD
LKLKRLRGFYNKLRDHVLEFDPNIPPEEGVSKAGGWAYRPRRPEDKDLLIRVND
YTDLTEEGAMIWRFPPREP"
complement(44376..44504)
/gene="70"
/locus_tag="TIROTHETA9_70"
complement(44376..44504)
/gene="70"
/locus_tag="TIROTHETA9_70"
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/codon_start=1
/transl_table=11
/product="gp70"
/protein_id="AEM05917.1"
/db_xref="GI:343197915"
/translation="MYVEDMDLDEAIEWEAELSGSDDPQDIMDLEDVRARIEELEG"
complement(44626..44874)
/gene="71"
/locus_tag="TIROTHETA9_71"
complement(44626..44874)
/gene="71"
/locus_tag="TIROTHETA9_71"
/codon_start=1
/transl_table=11
/product="gp71"
/protein_id="AEM05916.1"
/db_xref="GI:343197914"
/translation="MRKLAFALAMAGIGVAIVATPPYAEAAPGMCANHGTGPGLIYKH
ACASGRGGWGWVDISETQQEYKSPSGQSQTPPRVRDKG"
complement(44871..45185)
/gene="72"
/locus_tag="TIROTHETA9_72"
complement(44871..45185)
/gene="72"
/locus_tag="TIROTHETA9_72"
/codon_start=1
/transl_table=11
/product="gp72"
/protein_id="AEM05915.1"
/db_xref="GI:343197913"
/translation="MAVTLVDDTVQGLNARIEELEAELALARAVREAHIPEEPSVDGTVI
RFVKYNLSYTFAAIRVLGRWYITQDGTRSPRQGHAPKAWDELLAWIGERNWH
RIEVLS"
complement(45202..45342)
/gene="73"
/locus_tag="TIROTHETA9_73"
complement(45202..45342)
/gene="73"
/locus_tag="TIROTHETA9_73"
/codon_start=1
/transl_table=11
/product="gp73"
/protein_id="AEM05914.1"
/db_xref="GI:343197912"
/translation="MKLTKSDIAYREALGLSTTDPLPAEIGMVTRRANRLKRPRKTARFR
"
complement(45342..45641)
/gene="74"
/locus_tag="TIROTHETA9_74"
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complement(45342..45641)
/gene="74"
/locus_tag="TIROTHETA9_74"
/codon_start=1
/transl_table=11
/product="gp74"
/protein_id="AEM05913.1"
/db_xref="GI:343197911"
/translation="MKARYILAGLCGAIVLGNAPAIIAEARADVTAECYAHLSDKQSHT
TPAADRRFHLERGEPSPCTEQDAKDGLPKASSDSGKPKEDRDKKSRHCRKHWY
C"
complement(45638..45796)
/gene="75"
/locus_tag="TIROTHETA9_75"
complement(45638..45796)
/gene="75"
/locus_tag="TIROTHETA9_75"
/codon_start=1
/transl_table=11
/product="gp75"
/protein_id="AEM05912.1"
/db_xref="GI:343197910"
/translation="MSNIHREDWHLGVDDEFNVGESRPKTPRWLTNAVNGPEYYKDRK
FQRRKRTR"
complement(45804..45947)
/gene="76"
/locus_tag="TIROTHETA9_76"
complement(45804..45947)
/gene="76"
/locus_tag="TIROTHETA9_76"
/codon_start=1
/transl_table=11
/product="gp76"
/protein_id="AEM05911.1"
/db_xref="GI:343197909"
/translation="MARNYRRRPYGSKYKPKTHTIVLNSGAVLSVNAKGRCEDAPCCG
CCT"
complement(46158..46742)
/gene="77"
/locus_tag="TIROTHETA9_77"
complement(46158..46742)
/gene="77"
/locus_tag="TIROTHETA9_77"
/codon_start=1
/transl_table=11
/product="gp77"
/protein_id="AEM05910.1"
/db_xref="GI:343197908"
/translation="MPTPVATDAKGTRNSTANRTPKEVPAHAGDTLTDAMWKLFPTPA
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ARDGKGPNPNKREGGMDLPGAVALLPTPLTTDSQGGGHHGDGGMDLRTTATH
LYGTSEWGKFEPAIRRWEGIVGREVPVPTEPNKNGNPRLNAAFSEWMMGWEE
GWVTDLIETSGRRAPEGKISRTAAMKIIGNGVVVQQAAAAIRDLLA"
complement(46720..47253)
/gene="78"
/locus_tag="TIROTHETA9_78"
complement(46720..47253)
/gene="78"
/locus_tag="TIROTHETA9_78"
/note="DNA methylase"
/codon_start=1
/transl_table=11
/product="gp78"
/protein_id="AEM05909.1"
/db_xref="GI:343197907"
/translation="MSHGPRIGSLFSGAGGLDLAVEEVFGGQTIWQVEVEKAAATLLAK
RFGVPNLGDVSKVNWHEVPAVDILCGGFPCQDVSPAGLKAGIGQGTRSGLWAH
FAEAIDILRPRVVVIENVRGLLSAKATDASGLQMRAMGRVLRDLSDLGYDAKW
KTLAAGAIGAPHKRERVFIVAHPGRD"
complement(47250..47420)
/gene="79"
/locus_tag="TIROTHETA9_79"
complement(47250..47420)
/gene="79"
/locus_tag="TIROTHETA9_79"
/codon_start=1
/transl_table=11
/product="gp79"
/protein_id="AEM05908.1"
/db_xref="GI:343197906"
/translation="MAPDATLEELRLLMSDYDRHGLAVGQEAIDRMVELMTALDEWIT
KGGFLPADWRAA"
complement(47423..47893)
/gene="80"
/locus_tag="TIROTHETA9_80"
complement(47423..47893)
/gene="80"
/locus_tag="TIROTHETA9_80"
/note="SprT"
/codon_start=1
/transl_table=11
/product="gp80"
/protein_id="AEM05907.1"
/db_xref="GI:343197905"
/translation="MTAMLDRPTTMTPPQARFQARSLMDEHGLDDWHLRFDNAKRRA
GQCNYRTRTISLSLHLMRLRSAEDTMQTITHEIAHALVGGSHGHDAVWAAKHR
ELGGNGQRCFEMEDIDPTAPWIGTCSHGKQFARYRQPKRLEGWRCRCRPSSSPV
VWKKRG"
complement(47890..48060)
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/gene="81"
/locus_tag="TIROTHETA9_81"
complement(47890..48060)
/gene="81"
/locus_tag="TIROTHETA9_81"
/codon_start=1
/transl_table=11
/product="gp81"
/protein_id="AEM05906.1"
/db_xref="GI:343197904"
/translation="MTSHKEQAMSTRATPEQLEARLGLRQSNAAQPHRNRKREMKRPG
KGHRKAWKRDEQ"
complement(48057..48410)
/gene="82"
/locus_tag="TIROTHETA9_82"
complement(48057..48410)
/gene="82"
/locus_tag="TIROTHETA9_82"
/codon_start=1
/transl_table=11
/product="gp82"
/protein_id="AEM05905.1"
/db_xref="GI:343197903"
/translation="MRVFVYFNLHKHMWSVKALEGPDKGRVITRSHYVILRNVEGKVS
EAGRQRVLREGRKNVHAGLVGELVQGEAVDLDVNARLVTYNPRKYSTFVYAD
DETPFAGADLAVMTHKRVYAA"
complement(48407..48583)
/gene="83"
/locus_tag="TIROTHETA9_83"
complement(48407..48583)
/gene="83"
/locus_tag="TIROTHETA9_83"
/codon_start=1
/transl_table=11
/product="gp83"
/protein_id="AEM05904.1"
/db_xref="GI:343197902"
/translation="MSDAAFKQWMRLVDAQLLKRMGVTTRDIADRCYRDMHDDGLRP
FEVVSEIMSEGIDAL"
complement(48585..48797)
/gene="84"
/locus_tag="TIROTHETA9_84"
complement(48585..48797)
/gene="84"
/locus_tag="TIROTHETA9_84"
/codon_start=1
/transl_table=11
/product="gp84"
/protein_id="AEM05903.1"
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/db_xref="GI:343197901"
/translation="MIIAALIALGIGPTVDLSDIDIDMLPECVEEDCSDQPGQVGMWLDE
DTGNWYLSLGESSVLVVDDTVEEG"
complement(48889..49095)
/gene="85"
/locus_tag="TIROTHETA9_85"
complement(48889..49095)
/gene="85"
/locus_tag="TIROTHETA9_85"
/codon_start=1
/transl_table=11
/product="gp85"
/protein_id="AEM05902.1"
/db_xref="GI:343197900"
/translation="MKRDTIVQITGKSSTGSPHGLLVEAEPTGGLRFTVTGHDGKKRHA
AVILPVGEVSAALVSIIDHLTES"
complement(49118..50002)
/gene="86"
/locus_tag="TIROTHETA9_86"
complement(49118..50002)
/gene="86"
/locus_tag="TIROTHETA9_86"
/codon_start=1
/transl_table=11
/product="gp86"
/protein_id="AEM05901.1"
/db_xref="GI:343197899"
/translation="MTTRVETILSKADFGAAVIAGLEGSTDVRWARQVWAELRESVGY
RKASAALLTSGASQQKLSKNSLPSFGLMLTPERGMMAASLRDVREAFGLSGAIN
LCPMASKGCAAACLSRSGQSGMPAQQRAQAVRTAFLLSHPVLAGLLIGAEIRSA
LRRHGRINLRLNTTSDIRWEIVAPHMVQALAEAGVLMYDYTAWSPRDRAESSD
YSLTYSAKEPSHTSDEYLQGILASGGNVAMPFTTRRGEALPEEWNGYRVIDGDE
SDERRNDPRGVVVGLRAKGHEWKKDNTAGFIRATA"
complement(50031..50150)
/gene="87"
/locus_tag="TIROTHETA9_87"
complement(50031..50150)
/gene="87"
/locus_tag="TIROTHETA9_87"
/codon_start=1
/transl_table=11
/product="gp87"
/protein_id="AEM05900.1"
/db_xref="GI:343197898"
/translation="MDVYGKHRVISQNAQGNVLRVLVEDIETGERSYRVIPLP"

ORIGIN
1 tgcgcctggc cgatcatgta cgggttttca gatttgagtc acaggagtcc cgccaggcac
61 gcgagggaaa agcccaggtc gacgttccat gcgcggtgat ccgcgccaca cttgtcatct
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121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
2101
2161
2221
2281
2341
2401
2461
2521
2581
2641
2701
2761
2821
2881
2941
3001
3061
3121
3181
3241
3301
3361
3421
3481
3541
3601
3661
3721
3781
3841

cacacgccga
ggagggggtt
ccggccgctg
aatcggcgcg
gaggtcgaag
ggctgcctct
tcctccgacc
ctcgaagcag
gatgttgacc
aaccgctgcc
gcaatgagga
cttttcaccc
gcgcgtccga
gaagcaaccg
cctggcgcat
ggcgctgcac
gaccgtcaac
actcgagatc
tcagcagttg
gcgcgtttcc
atcccatgcc
gcgacttcaa
ccgggtccct
cactcgccac
ggcagctcgt
aagtccagat
gcggtctcct
ggcaaggtct
cctcgcggcg
ccgggcccgc
cccacgtatg
aagctgtacc
caggagggac
gggccgcagg
gagggcccgc
gacaccggct
ggcattcagg
caaggcccgc
gatgacggtc
ggaccgaagg
aagggcgaca
atccaggggc
cgcaggatga
tacgtgatcg
cgcttcggtg
ttcactgtgg
gaatgcggtg
gcgggcctcg
cgcgggatcg
accggtggtg
aacatccccg
ggcagccgtc
ggggcgaata
ggcaactcag
gcatgggtga
agctggtcga
gcaacgacgg
gcgaagagac
gctcccgcga
agcgcggcga
aagcggacgg
caaatgacgg
ctcaagaacc

ataggaaggt
gagtagcggc
ccgacaggga
ggccgactag
acctccttct
actagggagg
gcgccagcag
cgggctacca
acatcaggcg
acggcagaaa
ggcgacctat
aggaggtgtc
cgcaacaaga
cagatcggta
tcagcgcagg
ttcgccaacc
tcgatgttga
gagcggaacc
ggcgctcagc
tctcggcgca
agtcatcggc
gtggtcgttc
gttcttcgag
gatcaagatc
cttcctcccc
tcaggggtga
acgtcggctc
cggtgtcgca
tcatcagccg
aaggaccaca
cagagcttcc
gctacgacaa
cgcgaggacc
gtctcaaggg
gtggtctgca
cccagggacc
ggccggtcgg
aagggccgca
ctcccggacc
gcgacctcgg
agggtgatac
cgcagggccc
cgcaagccca
tggggtgaca
acctgacggc
tcagccagac
ccatcgacat
gtaacggcgg
actttccgtc
ctggcggctg
gcgtcggctt
ccggcaaggg
ccggcgattc
gcttcttcgg
gggcatacgt
cggtgtccga
ggtcaacggc
ccaccgaccg
cggctggaaa
gttcttcgag
ctacctcagg
ccctacaagg
acccggacct

atgtacaggg
gttcagcgcc
gcgccccgca
acatagtaca
cagtcggtct
tactcaaatt
gctcccgcct
gtgtcagatt
cggcgacgac
gtcatccgca
cgagcgccat
aagtgggcga
cagacaaccc
tccccgacgc
cgcagttcta
agctcctctg
acggtctgct
aggccgacgc
agcgttccgg
gctccctcct
gctcagcttg
gagaacctcg
ttcgagaacg
gaatccgagc
gagggtgagg
tcgcatgagg
ccccaccggt
gcagcggccc
ccacccgacc
aggtcccaag
tggttcagcc
cggctggccc
gcaaggtatc
tgataccggt
gggtgagcag
taagggtgac
cccgaagggc
gggcccgcgt
cgaaggccca
accgcaagga
gggatcgcag
ctacggctac
gtacaacgcg
catgccagtt
caccaagatt
gttctccacg
catcctgctc
cggcggtgac
taccgcgctg
gattccgatc
ggtgcaggcg
ccccggcaac
ggctgccaac
cttcccggcc
ctgatgacgc
taccggccag
cttgccctgg
gtgtcgatct
cgctggctgt
gtcgacggcg
ctgcctccga
caaactcgcc
gatccccggc
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tagaggccca
gccccaggag
gggcgctcgg
agggaccgcc
tctccctgtc
tcaccctcag
gactgggacg
cagggtcccg
cacagtcgcc
gaaggccacg
cccggctctc
aagaggccct
ggtcaccaag
acacccggtc
cgagccgagc
gtctgagaag
cgtgtccgaa
cgtcgtggtc
ctgagcccac
ccggggatag
agtccgacac
acgcgaccgg
gcacgaagtg
aggtcgcgct
agctcggcgg
ctgcgcggat
tccatcctcg
cgcagcctgc
acaggtcgac
ggcgacggcc
tcggacggag
gacgagtctg
gcgggcccgc
cctcgaggcc
ggtgtccaag
gtaggccccc
gacaaaggcg
ggcttcacag
ccaggaccgg
cctcagggcc
gggccacagg
ttgtcctcgg
ctcggagcag
cgcatcggtg
tacctcggcg
gtcggcaact
ggcggtggtg
ggcggtctgt
cagatcaccg
aacggcgcag
ctgggcggcg
agggtccaca
ggtaacccgc
ggtggaggcg
agacggcacc
gctgggcgtt
tcatcgtcgt
acttcccgtt
acgaccgcat
agaagccgtt
cttgacatcg
gtcttcgcgc
gagattgacg

acgtaagggg
gcagcggcct
gtaagtaaga
tcagagcggt
ggcagccgcc
atgcgaggag
agaactaccg
gttgcctcag
gcaatctcca
cccgcaagcg
ggtagcgggc
atcggcaagc
ctcccagcgc
gtcacgcagt
gactgggcct
cccaacgggc
ggcgaccgcc
gacgtagcgg
agacccccgg
accccccacc
cctcgtcctg
tcagccggtg
gaccttcagc
gatcgctgcc
cgatcccatc
tcccgactga
gaatccctca
tgtcgatccc
tgctcgcggt
tccgcatcga
atgtgtggct
ccggaaccca
agggcccagt
cggaaggtcc
ggccgcaagg
agggtgagcg
acaagggcga
gcgacaccgg
aaggtccaca
tgcagggtcc
gcattcaggg
acgcaacggt
gaaggccagc
atgccacccc
acgttctggt
ggaccttcaa
gtggcgggtc
gggagacact
ggacggtcgg
acggtaaccc
gtggcggtgt
acggcatcaa
ctggcggcgg
gtaaaggagc
gtatccgacc
tcaactggtc
gcagacggtc
catggtgccg
cgaggacgcc
cgccccacgc
tacacaatga
tgaagcaagg
acgccatcgt

gaacctctaa
tcacccccca
gaggcccgcg
cccgttggtt
gcccacaggc
gagctggagc
gcagcccgtg
gaaggcaacc
ggcagcgtgc
gcagttacga
caggtgcccg
gatcggatca
gtggaccggt
tgtgggactc
acgcccgcat
agattctcgc
gacgggtgca
cgatgttcgc
agggggttga
tttgaaagga
actcgcggcc
gccttcccgg
atcgaaggcg
cgcacgaagt
gcgctcggcc
cggtcggccg
gaacctgatc
gactgacacg
gcccggtaga
cggccaggtc
cgcgggcggc
ggtccaaggc
cggcccgcag
ggaaggaccg
cccgaagggt
aggtctccaa
cacgggcaac
tcagaccggc
aggtcctgcg
gaagggtgat
tccgcaaggt
tctcgacttc
aacgacgttc
ctcggggttc
cttccccgcg
catcccggcc
gtcaggcaac
gacgctcatt
tgacggcggt
caccactgcc
gtggacatcc
ctacacgggc
cgctggcggc
gagaggacag
gagctcgaag
gaggccccac
gacgcatacg
cccgaggtgc
gaacgccacg
cactaccccg
aaggagggcc
tgtgaagttc
caaggttctg

3901
3961
4021
4081
4141
4201
4261
4321
4381
4441
4501
4561
4621
4681
4741
4801
4861
4921
4981
5041
5101
5161
5221
5281
5341
5401
5461
5521
5581
5641
5701
5761
5821
5881
5941
6001
6061
6121
6181
6241
6301
6361
6421
6481
6541
6601
6661
6721
6781
6841
6901
6961
7021
7081
7141
7201
7261
7321
7381
7441
7501
7561
7621

gcgctcgcgc
acggttggcc
ggctgcagat
acgcccacgt
tcgacaccag
agaagacatt
agctcgatga
tccgcgactg
cgaccgagaa
tcaatcgcgg
gtatcccgct
ctgagtgcaa
atcagtaccg
acaaggggcg
ggtgccacgc
tggccgacct
acacgcggaa
cacagatcgt
ccatcgccct
cactcaactc
aatacgggga
ggttcgagac
tcgaaggcgc
ctggccgagg
acgcacgagc
tagcgcagaa
catcatcccc
gcaatccatc
cgtcgccgcc
ggtggagcag
tgagctcgac
tccgcagctc
cacggcctac
atgttgaagc
cggttcgcca
ggctacgacg
gggcaggtct
cacggcaccg
gtgctggacc
aacggttcgg
gttccgggcc
cggaacagga
aacccgatgc
gacccgaggc
ctgtacacga
gtcttcagcc
aacccgtggg
atccgtggca
acctactacg
atcgtcgcgt
ccatccggtg
ggaggacggc
ggctaagtac
ccgcttcatt
cgtccttcga
ggaactctgt
gacccgccac
gttctcgctg
gaacaagttc
cgcgtcgatg
cgtcggtccg
cgtcgccaag
cgacaccgtg

tgggcgtctg
ctacgtcgac
acagaacggc
agagccgctc
caaccacccc
ccgctacggc
gctgctggcc
gatgcacttc
gacgctcgac
tggcggcacc
ggacagggcc
cacgttcccc
ggcgaccgag
cacctggatt
ccgagggctg
gaagtgggct
gtacccgacg
caacggcggc
tggcgatgag
ggctgagcag
gctccgcaag
cctcgccggc
ggccatgctc
tccaggagcc
ggttctggct
gggggccgca
ggtgtccttg
ggtgacatca
aagaaggtga
gtcgtcaacg
agggtccggg
ggtccgctcg
agccaggcag
tgggctccag
gctacgcgct
aggagaaggt
cacgagaaga
gccaggccga
tgtactggtg
tcgacgctgg
cgacagcgtt
tgcggcgcaa
ggctgcgggg
aagagctcgc
cctgccccgg
ggttcatcgg
tcgaggttcc
ccggcccaca
agtacgcaat
ctgttacttg
ccgctcctcc
tcctggcacc
gtgaggtcgc
ctttggtggt
cgcatgaagg
ggcccagttg
gcggcgtgga
ttcccggtga
gtcatctact
gagggtaacc
gacggcaacg
attcccggcg
gccgagaagg

atggcacgcc
caaggatcgt
gctcccttca
cgcgactacg
ggtggcaccg
atcacgaagg
ttctacgagg
cagatgggct
ttcatcaggc
acggtaccca
gaaaggattc
cggatcgcga
gagtacgcca
cagctcacct
gtcaacgacc
ggcctcggcg
ctcaaccagg
acgaaccatc
ctcctgcaac
cgcgaggtcc
ctattcgctt
ttcgtcctgg
ggtgagcccg
aagaaccccg
gacatcgagg
tgagcccgaa
gtatcgccct
tcgcgggcgc
acgagcagcg
gcgtgcaggc
acgtggtgac
cgcagcaggc
cgcagttcgc
cggcctcatg
tggcgtcaac
ccagaaggag
cctgcaccgc
cccgttcggg
gcagccggta
cgagcgtgag
cgtggactac
ggagctccgt
ccactacgcc
ggccgagccg
tgggcagtcc
tgaggacagc
ggcagccgtg
cgtccgctac
caagcacctt
acatcgcacg
cccaaccgcc
tacctgagag
cagccggtgg
acgccgtcga
gctggggcaa
cgttctcgca
tcacgattgc
tgatctcgaa
cggaggtcgg
gcccgacgct
tcaacgacgg
cacgcaagct
catacgacca
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ggctcttcag
gtacatggga
cgatcatgcg
actccgcgtg
ggatggacct
aacgcgccta
acgtgatcta
acggcaccta
gcaagatcag
acggcgcgtc
tgcccgccct
tgttcctcgc
acggtcctgc
ggcgctcggc
cgatggtgtt
ctgcgtacta
catcggacgc
tggccgaacg
tcgtccaaga
tcgacctcct
ctcgcgcaat
cctgcgatgc
agtacctcga
acggcagccc
ccaagaaccc
agttcgacag
gatctggggc
tgtggcgctc
caaggacggc
agtcatcgcc
cggtgccatc
ggtcgacgct
ggacccgtac
gtcagtgcct
ggccagccga
taccagctac
ctcgggctgc
atcggctacc
ggcaactggc
tgcgttcggc
tcccaaggca
ggtgagctcg
ggcaacgtcg
ttccgcatcg
ggtgagatgg
ctgatcgagc
aaggccatcg
cacattgacg
cgagacaccg
gaagggagga
ccacaagatc
gactctcggc
cggtccgttc
tgagcgcggc
ggacccgctc
ctgggacctc
cgccgtctcg
ggacctcaag
tggccggatc
ggtgatcgag
cgtcgacatg
cgcgatctgc
ctggcaggac

gggtcgggca
cgaggtcgtt
ggcgttcgct
ctggacccag
gaactggaac
ccccggcgac
ctgcggcggc
cgactcgaag
gccagacggg
ggtgctcgct
gcgcgagggc
acagacgtgc
acacgaggaa
ctatgagggc
cgtcaacaac
ctggacgacg
ccgcgacgtg
gactgccatc
ggaggacggc
gcgctggttg
gtatcgcgac
gatgcagtgg
acgggtactg
gcgtcagtgg
gcaagcacta
acgatctact
gggatcgacg
ctcggcgcgt
actctggtgc
gcgcagcagg
ggcatcgtcc
ctcaacagct
cgggctccct
ggacggcggt
tcaaggtcga
ggacaggtca
tgcccacgct
ccgccgacat
ctgcgaaggc
tgatcagcaa
gcgtgatcgg
tcgctgcggc
atccgggcgg
agctcgcggc
agcgtgcgat
aggtctggga
tgcgcggtgg
agtgccctgg
ccgaggcacg
ggagtgagcc
gggccggttt
tggggcattc
ctgccgactc
gtgtacgcct
tgcgcggcca
gaaggcaacc
caggaccaga
accgactacg
gaggccgcga
aacgagaccc
gacgatgtca
aacgcccaca
gtacagaccg

ttctcggaga
cccggtgtct
cgggacttcc
gacaacaccg
ggcgctgacc
aaagcccgca
tactggagca
gccgaccggc
ttctcgacgt
cgagccaccg
ttgatcctcg
tgggagtccg
cgctggattt
ttcggcaagt
ccacggtcgc
accgtccgga
ctggtggcga
tacaaccggg
tttttgtctg
gccgctcccg
agcgacgacc
gaggaccgcg
cgtctcgccg
gcgatcaacc
caacgctatc
acctcggcac
ctggcgcagc
cggctcccgc
cgcaggctcc
ccgcacaggc
ccggcatcgt
tcgcaccgcc
gggaccgctg
gatgcggctc
cgggtacttc
gttcccgagc
gctgtcgatc
cgctcggcgg
cgtcccgatg
cccgctgatc
tggccgtgtc
cagcttcggt
tgaaggtatc
caagggcgac
ctaccacgcg
gctcgcccgc
gatgttcgcc
aacgggcatg
acttcggcgc
tcgcgaatca
ggcaggtacg
tgaactggct
tggaacaggc
accgcgaagg
tcgcgctcgc
cggtgggcca
cgaagaacac
gccttgacgt
cttcgtcgcc
agtggtgggg
tcgagggcaa
tccccggcaa
gtaaagcggt

7681
7741
7801
7861
7921
7981
8041
8101
8161
8221
8281
8341
8401
8461
8521
8581
8641
8701
8761
8821
8881
8941
9001
9061
9121
9181
9241
9301
9361
9421
9481
9541
9601
9661
9721
9781
9841
9901
9961
10021
10081
10141
10201
10261
10321
10381
10441
10501
10561
10621
10681
10741
10801
10861
10921
10981
11041
11101
11161
11221
11281
11341
11401

cgatacaggc
tccctccgag
cctgcaggtc
cctgaacacc
ccacgaggat
gttctgcctc
ctggagcgcc
gaaccccgag
gtcggcattc
atacgtcgac
caacccgatt
attcctcgac
acacgtcctg
gagcaaggac
gagacaggac
acgagcccca
gcgttcgagg
cgtccggacg
ggttaccccc
atcgcaggcg
gatgtcgagt
gtctcagccc
gtcgagccgc
gcgatccggg
cccaacgcca
gtgaaccacg
gacctctacg
cggacgctga
ttcggtatca
cgtcaggcgt
gcgtaccagt
aagaaggcag
ccggcctcgg
aaggcacgca
aaccccggtg
agcaccccga
ggcgtcatcc
cagatgcggg
ccgaccgaca
gaggagtgaa
actacatcct
tcggcttcct
tcgctcgcca
tcttggtcga
tgtcccgaga
gcgtcgagaa
ggacggtcaa
tgctgatctc
accagtcagc
atgtcgatga
cggtctacga
ggatcgaagc
acctcaaccg
tgacgagatt
gcccaggagg
aatgacggag
gtcgaggagt
gacgccaagg
tacaccgagc
accatcgacg
tctgacaagg
acgggcaccg
ctcaacggag

atcctgtacg
aaggaggacc
gcccgtggcg
cgcaacccgg
tcgtggatcg
aagaagaacg
ttggtggcgt
gaccatccgc
cagaggtacg
cagtggggcc
gccttcgaca
gcggtcctcg
aacgcccgcc
agcagcaaga
ttcctgatga
ccgaacagca
agaagattcg
ccatcggtat
ggctgtacgt
agtccgacgc
cgacgctggg
ctgaccccgc
cgaccaacct
cgatctacga
cggcgtactt
ggctggagat
ggacatcgga
tgctgatgca
agcgatccga
tcgaggcgta
tcgacgctgc
ccgcctacac
ctgaggccat
tcttcggtgg
ccgagattcc
cgtatgccgc
cgagggagca
agtgggacaa
agaccggggg
cgctgaagag
ccagataggg
gcaggctttg
gttccatgac
gtacgacttc
gctggcaccc
cgccggtcgg
gggctgggcg
acgaggcccc
ggcagatgtg
gaacgaactg
cagggccaac
cacaaaggag
agaggcgcag
cgccctcgcg
caaacagtat
gcaccgacac
tgaggcgtga
cagaagtccg
tgcagaacca
ccaaggtccc
agtcgatctc
tcccggccgt
acccgatcct

acgcgctgga
cggaaggcta
actcgtactg
tgtcggagtc
ctcccaccga
accggatcac
gccgggtcga
acaacgaggt
acgtggtcgg
gggacttcaa
tgcgcggtca
agcgagaggt
gacatccgac
agatcgacgc
gtaagaagag
gaacgtcaac
gcctctcgcg
cgccgtaccg
caactcgatt
cgacgaacag
ccatgtggac
catcgacctc
gcacgcggtc
cgaagagggc
cgacaaggtc
ggtcccggtc
gatcactccg
gtcgacggca
gatcggtctc
ctacgcccgc
agagctccgc
cggcctgcct
ccggtcgtct
ggcctgggaa
accgaacatg
caaggctgac
ggcccggatc
ggaggagaac
gtccgagacc
tacgccgcca
aagctgttcc
tacccggagg
agcgagcgtc
aaggagttcg
cagtccgctc
aagcagatca
cgagtagcga
gtgtactcct
ttccgcgcca
atgaaggagt
tggcccggac
gctcgtcgcc
aacgcgcttc
gcgtaactca
ggctgacaac
gggtcaggca
gaacgccaag
caaggagtac
gctcggagag
gtctgatcgc
cgaatcggcc
cgatcccacc
cgacgcgctt
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agcgcctgcc
cgccgagggc
gctgccgctg
ccgacgcaag
gtgggaccgg
gctcgggttc
ggacgggatg
gccccgcgag
cttccgggcc
gcggaagatc
gacaaagcga
ctaccacgac
tacctacgac
tgccgtctgc
ccgcacgggc
cccgaagagc
gacaacaccg
cccgagatgc
gcggaccgac
ctctgggact
gcactcgtcc
ggtgtggacc
atcgacccgc
aatgagattg
gagggtgagt
gtgccgatcc
gagctgcggt
gagctcatgg
cccgacgacc
atcctcggct
aacttcgtgg
ccgcagtacc
gagtcccgac
caggtcatga
tatcggctgg
gcagccacga
gacatgggct
ccggtgggcc
ccgaatgagc
ggcaggcggt
tcgggcccag
tctaccggca
ggcggcacgg
tgaaggacat
tgggcgatgt
tccgagcggt
ccggtcgaga
cagcggagag
gcggtggtga
ggcatacagg
gggacgcata
tcatcgactc
gtcgtcgtct
acaccacgac
gacactcaga
cccgcaccgg
gcacgcacct
gaggccaagc
gcgtggatcg
gtccgcgctt
aagtcagcca
cagggctctg
cgcaaggccg

gacaccccgg
atcgccaagc
gaggagattc
ttcctgaatc
ctggctctga
gacggctcga
ctgttcgtcc
gacgtggacg
gacgtgaagg
aaggtcaacg
ttcgctcttg
ggcaatcccg
gcgatttcca
gcggtcctgg
cgagcggtgg
ggcttgagcc
cctactacga
ggaagctgct
tggagctgga
ggtggtctgc
acggccggtc
ccacggtccc
gtacccgcca
tcggcgcgac
ggacgcaggg
ccaaccggaa
cggtcaccga
gcgtgccgct
cggacgagcc
tcgaggacga
atgcccttga
tgtcgttcag
tggtgatgaa
gggtggccta
aagcactctg
agctgtacgg
actccgtcga
aactcgccgg
ctgccgccga
cgtctcggca
attgtctgtg
ccgtctggag
aaaggcgttc
ggagccgact
cgcgctgcgg
cgaggacgac
aacgtgcgcc
cgcggggttg
cctcaacaag
ctgcgactgc
caagcgtgcc
aggaaagtcg
cgaacgaggc
cccctggtgg
cccccgacac
aggtcttcag
cgaagaacca
tggccgagaa
agctggagaa
tcgcggccat
agcaactgtt
gtggtggcaa
tcggggcgta

tctcggagat
tgatggacgg
tcgggtcggt
aggtgaacgc
ccgacaaggt
agtccaacga
tcaagacgtg
cctacgtccg
agttcgaggc
ccactccggg
actgcgagag
ttctgcgaca
tccgcaagga
cgtatggcgc
tgatccgatg
gctgctgaat
gtccgagcgt
ggcgcacgtc
gggtttccgg
caacgacctc
gttcgtgacg
gatgatccga
ggtgaaggaa
gatctacctg
ccgtcccacc
ccggctgtcg
cgcagcggcc
ccgactcctg
ggtgtcgccg
gatgggcaag
cgcgctggac
ctcggacaac
ctgcgagcgc
ccgggtcatg
ggctgacccg
ccagggcatg
gacacgacgg
cctctacgcc
ggaggttcct
gcagtcgcga
caggactgga
gccgctgagc
cagccccgct
cgggaccgca
gcagtacgca
tccgagaccg
tggtgtctga
gacctcgatg
ctcgccgcct
aaggtggtgc
gagcagtttt
aagagcgaca
gacctttcaa
ggtccaacac
cacgccgggc
ccgggagtac
agcggtcgaa
ggacacggcg
ggtctacacg
cctgcagggg
cggcggtatg
gcacacgccg
atccccacta

11461
11521
11581
11641
11701
11761
11821
11881
11941
12001
12061
12121
12181
12241
12301
12361
12421
12481
12541
12601
12661
12721
12781
12841
12901
12961
13021
13081
13141
13201
13261
13321
13381
13441
13501
13561
13621
13681
13741
13801
13861
13921
13981
14041
14101
14161
14221
14281
14341
14401
14461
14521
14581
14641
14701
14761
14821
14881
14941
15001
15061
15121
15181

cgacaagaaa
gcgcagaccg
ttcgcggaag
tcgaccggcg
ggcgacatga
atcgccacga
ggcaccatgc
cacggcaccg
accccggccg
gtcaacgacg
aacggtgcca
accacgccgt
gccaccggca
ggcggtctgt
cccaagttcg
ggtctgctca
gacatcgcac
attcgcaaca
atcgagctgg
tcccccaaac
gtaacgacca
tgggtccgtg
gagcggatgc
caggtcgagg
acggacggca
cttcccgaag
acattcgaga
ggttcacgga
gcgtgtgctt
tatgagcctc
cgacgacgac
gctgcaggtt
gttcgagtcg
cattctcggg
gcccgcgtac
ctgacatggc
agacgaaggc
tggccgaggc
agatcggttc
tggcaatcga
tcacgaaggc
tggtgacacc
ggtggtgatc
gtggatcgag
cggtcgtcat
ccacaccaag
cgacgccgtg
gatgggcgct
cgcattgggc
aagcggtgtt
cgagcgccgc
gctgggacag
gtgattccga
acccggtcga
actacggcaa
ccaccgagaa
gcgccaaggc
cactgcccat
acgaggacct
atgtccgagt
accactggcc
cctccgagag
ggaggtcgtg

gtagcatcat
gcgactcgat
cggagaagac
tcaagattcc
agcccatcac
tcttcatcgc
gggtcaaggt
acagcccgtt
cgccggccac
gcaagaagtg
aggacgccaa
accgcgaggg
ccacggtcgg
ccttcgacgt
tgtcgctgtg
tcaacgacgt
ggcggggggc
aggacaacgg
gccgctggga
cgccagagcc
ccgaggagta
agctctccga
tcaagcgtcg
ccgacatggt
actacacgta
agtgggaggc
tgccgacatg
ggcggttcgt
ctgcgtgcat
ctcgatcact
ggcaacacga
ctgggtcagt
gagcgtgtgt
atgcagtcgc
tacaactcgt
gaagctgatt
ggcgatccga
acgggcatca
tgccgcagac
gtacggccac
cccggcaggg
gtcgatgggt
ccgctgctgc
aacatcgact
ccgaatcgac
gggctcatcg
aagacccaga
acgcagttca
ctccgacccc
gaccgctgca
cgagctggac
catcggccac
gatcaagggc
ctacctgacg
gaacgcctcc
ggcgttcttc
gtctgtgaag
ccgggcgacg
gttcccgaac
gactaggggg
cgcctaccca
gaagccgaca
ctccgcaacc

ggcacaagga
gttcaagggc
ctccatcgtc
gcactggacc
caagggcgac
ctcggctgaa
cggcaccgcc
cgaccagttc
cacctacgac
gcaggcgacc
cggccgtccg
ccgcatcctg
ctaccagggc
gacggaccag
gcagcacaac
ggaagcgttc
ccttcggggc
cggcgtagcc
gccagccgac
agcaccggcc
agacatggcg
ggaggagacc
gatcaagaac
ccttcggctg
catgctgagc
gctgggcatc
agcgccagcg
ccggaggacg
gactggcgca
gcccggacga
tcaccaagcc
ccggtacgtc
acacgatccg
aagtcgagtg
ctcgtcgtac
ccccgtcgca
cgagaagcac
acgacgcact
gatcccgacg
ggtccttccg
ctctacatcc
aggaggggcg
gggatgcact
accgcgagtt
cgacgcaatt
agtgtgagca
agcagacgcc
gctcgccatt
ctcgcaacaa
gtcgggtacg
gacctggacc
acgagccggg
acctggcagc
ctgttcctgc
accacggctg
gtggtcatcg
cgcgacgacg
ttcctggatc
gtacagactc
gaggggttta
acgaaaggtc
agcagttcgc
tgctgcggct
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accacgttcc
tacctcgagc
cagcgtgtcg
ggcgatgtcg
atgacggtca
accgttcgtg
atcgcgctgg
gtggatcaga
gccatcggcg
ctgctcgatg
ctgttcgtgg
ggtcgtacca
gacttctccc
gcgaccctga
ctcgtcgcag
gtcaagctca
cccctgccaa
gaagtcaccg
gccccgaggc
gaggcccctg
attgcgactg
accctcgtca
ctggacgcgg
ctccgcaacc
caggcgctcg
cggcgtagtg
accggcagcc
ttgacgtgtc
ttcactgggg
cgtgatcgtc
gtccgacgag
gtcccgtcgc
gttcacccgg
ggaaggcgtg
ccggcacatc
ggctgaacca
gcgaggtcga
cgaagatcgt
tgttggtgta
gctacttcga
tgaaccgcgc
tgaagtaatg
ggttccggac
ccctctggtg
cgcaacgccg
gctctacgag
caagggctac
catggactcc
aggagtaacg
tctacaccgg
tggaatcccc
gcgacatgcc
ggaagaagct
accagttcga
gtgagttcgc
aagacggcga
cgatccagct
accccggttt
cctgagtctg
ccttggcggg
cgctatgtca
tccgttcaag
gaacaagaac

aggtcgatca
ccgagcaggc
ctcgcaagat
ccgccgcgtg
accaggtcga
cgaacccggc
ccttcgatga
ccacgaagtc
tcaacgcgct
acatcgctga
agtcgaccta
cgatcctgag
agatcgtctg
acctgggcac
tccgtgtgga
ccaacgcctg
gcggaaaggg
aggactacgg
gtcagcgggc
aacccgagac
cacaagacgt
acacgcggct
tcgaccccga
cggagggcta
catccggaaa
gaatgttcgt
gcctggtccg
caagtgcgac
caacctggat
tacccgcagg
ggcatcccca
caggagcagg
aagttcgacc
cggtgggctc
acctacacgg
catcgtcgcc
aggcagggct
cggtcccggc
catggacgcg
cccggacaag
agccggtatc
acgttccccc
aaggccaaga
aacgtccgac
gtcatcgaat
gactgcctcg
ctgcactcaa
tggagggtcc
ccaaatggca
ccctgtcggc
cagctcctgg
cgagttcggc
gcgtgaggtc
tgaggacgcg
ggtcagcggc
cgttcgtatc
cccggtggac
cccgctgttc
acttgacatc
ccttcccctc
aacgtattca
gtgcggctca
gaccgcaaga

cgcgcagatc
ccaggactac
tccgatggga
gatcggtgaa
gccgcacaag
gaactacctg
cgccgcgctg
ggtcgacatc
gtcgctgctc
gcccgtgctc
cgagggtctg
cgaccacgtc
gggccaggtc
gatggaagag
ggccgagttc
agcctgactt
ccgcatgaag
caaggccctg
caagaagtcc
ccccactgag
tgagaatcgc
gaacgacgcg
ggacgtgaag
cacgcaggaa
gctggaggtg
cctcacaccg
tacccggaag
cacgagttcg
cggagcggcc
tcgtcacgac
cgaaggcgcg
acaacgaagg
gcgagcacgg
tcttcggtga
tgaagaggta
catctcgcgg
cggcgcaacc
cacctgacca
ccgaacccga
tacgggaagg
gccggctcga
gtattcagtc
aggtcggctc
gcatcggcgg
tgaccgtcta
acgtgctgta
tcagagaaac
agggactgat
cttaacgacg
acggccgcgc
accgccacga
ttcgacggcg
acgaccgaag
ctctcgctgt
aagtccgatc
ggcttccaca
gacttcgcat
aagtgggtca
gcccagagcg
cccccgctcc
ccctcgacag
gcgacggcac
cggtactggc

15241
15301
15361
15421
15481
15541
15601
15661
15721
15781
15841
15901
15961
16021
16081
16141
16201
16261
16321
16381
16441
16501
16561
16621
16681
16741
16801
16861
16921
16981
17041
17101
17161
17221
17281
17341
17401
17461
17521
17581
17641
17701
17761
17821
17881
17941
18001
18061
18121
18181
18241
18301
18361
18421
18481
18541
18601
18661
18721
18781
18841
18901
18961

gagcatcgag
cgaccgcatg
caagctgctc
gctggaggcc
gagcatctcg
gaggccaacc
tccgcgttcg
tacgcactgg
aactcggacc
aacaaggccg
attgcggcca
tcgaagtcgg
taaagaccaa
acatggacgg
agctggacgg
cgaagaagat
cgaagctcaa
tctccaacag
gctgggcggt
gagcgatcac
tcgccgcgct
ccttcgatga
tcgagaagct
gcctggccgc
aggtccgggg
gcgacttcac
ttgccgactg
agaagggccc
tgaaggaact
acccggagaa
cgctggtcga
acggcgaagc
agttcgacaa
cgttcgctga
ggggcatctg
tcgtcagtgg
cgtcggtgtg
ctgccgcccc
tgaacgaggt
cactggctga
tccgtgcggg
cgctgatccc
tcgaaggatt
acaagatcgt
cttccaagct
cgagtgcagc
acaagctctc
tcgaagtcga
cgggcagggc
acctggaaaa
actcggtgat
cggccagcgg
tcctcgagca
acgcggtcgc
aacccgttgg
ggccccggtg
ccgcccgtca
caccgtattc
ggacccaact
gactgcaagc
ggtgagtcgc
gtcatggtcg
gtgacgcaga

gcactcaaga
gtcgacaccg
aaggagctcg
acctcaccgg
tcccagacct
cactcagccc
tggctgcgat
ccgcgatcat
cgaggaaggg
agaagaagta
ggaagagaaa
ccggatttct
gctcgaaggg
gttcgccggg
cgacagcacc
caagctagag
gcccaaggtc
tctgagcaag
catccttgcc
cacagccatc
ggcgctcggc
cctgaaggcg
cggaacgatc
gatggcgcag
tgtcattgac
caccggcttg
gttcaacgac
ggacggcacg
cggcggtggc
gatcaggtcc
cctgtcgaac
gaacggtccg
gatcgactgg
agtgacgatg
ggatggcatt
cgtcatcgcc
ggcgaacatc
gatcatcacc
cagctcgtgg
gatcggctcc
catcggtccc
gaactccccc
cggtgacgcg
ctcgaagatt
gaacctgaac
cacggatacc
cgacgaggct
gcgtcagaag
tgctatccag
ggagcagctc
gggcgacatg
acagctcatg
gggcctcgcc
aggccagcag
acaccctcgt
aaggggaccg
aggtggtata
ttcgccgtga
cctggttgag
tctacatcac
ccgaggtctc
tcatcgcagg
cggatacgac

ccgaagacga
tctcgaagat
acggcgacct
gggaagcgca
caagcactac
ccagtacgtc
ccgtggtggg
caacagcatc
caagccgccg
cgcacccaac
gcagcagaag
atccgggtcg
atcgagaaga
gtggtcgccc
gaccttcaga
ctcgaccccg
gaagtcgatg
attcagatgc
ggtgtcgcgg
gttgcactgc
atggacggcc
acgatgtcgt
ttcccgatgc
tccttcgcgg
gacatcgcga
ctggacctcg
acgggtaagt
tcgaagttcg
ctggtcgaca
ttcaagaccg
cagctcgcgt
atggacttcg
tcgggcatct
ttcgcggcca
tcgaccaacg
aacatcctcc
ccgtcgatga
cagattctca
ccaggcaaga
agagcggcgc
atcggccagg
gccaaggagg
ctgggtgacg
cgggcgatca
ttcaacttcg
agtcgggccc
aagcagcaga
ctgcagaacc
cagcagatcg
gactacgccg
ggcaagaaga
tccgatctcg
ctcggtgagc
accatccaga
ggagcttgag
tggggtgtac
cgaggagccg
catcaccttt
ccgggagtca
gaccccggag
gtggttcacc
cgacccgttc
gttcgacccg
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atcggaagag
tctggagctg
cggtctgctg
gaactcgccg
tacgggattg
ctgatccaca
caggagttcc
cgtgctggca
cttccgagtc
tcgttcgccg
aaggaggctg
tcccagacct
cccttaaggc
agaaggcgaa
aggcagtcga
agttcgacta
tcgacttcaa
cgtcgttcgg
cggtcacgcc
cggggctgat
tcaagaaggc
cggccgtcga
tcaaggaggc
acgcggtcac
atgcgctgaa
tcaaggggtt
cgttcaagga
accgtgcgct
tcggcggcaa
agctcgacgg
cgaacatgtc
ctcccatcca
ggggcaacat
acaccgcgat
ccggaacggc
ggatagctgc
cggctggcgt
cgacgttcat
tcgttggggc
aggcactcgt
cggtcggcgc
gtccgttctc
ctctggcgag
tgcaggccat
gctccctgga
ttggcaatac
aggacctgct
agaagaacgg
accagctcaa
gcaagtacac
tttacgacgc
gcatcagcgg
aattcatctt
acaagaaggc
ggagtcaacg
ctgggtaccg
gggaactacc
ggtgtcgaga
gagtggcgca
tccggtaccc
gatccgcgtg
tggtaccagg
aacccacttc

ggtcgcaccc
gcagcgggta
atgggcgtgc
gcctgatcga
acctccggga
tcaagcatct
gtggatggaa
actacatgtt
cgtggccggt
gaatcgttgc
aatggcaggc
cgacgggttc
gaagatcaag
gaacctcaag
cgcggtaaac
ccggctccga
gcgagggatg
ctcaggcatc
gctgatctcc
cacgtcgatc
agcggaggtc
ggagcagttc
cctgcctggg
atccccgcag
gcaggcagct
caccggcaac
ctgggcgaaa
cgagggcctc
ggcgttggac
agtcgtggcg
gaagattccg
gattcagctc
gaagtccact
caccatcggc
atggaacggt
ccagcttccc
ctggaacacg
caacgtcggc
ccttggcagt
gagtgccctt
tctgatgagc
gggctctggc
cggcattccg
caaggatgtg
gtcggggctc
ggtcagcggc
ggagctcaag
tctcgatccg
cctccagaag
cgatcaggtc
cacaaagaat
caacggtgcg
caacgtcggc
gttgcaattc
gcgaatggtt
acgtgaaggg
ccggcgctcg
ttctcaacga
aggcgtgggc
gctacctcaa
gcaacaagat
acgatgtcgt
cgtggccgtg

tcgatgacat
aggattcccg
tggaaggttg
caggtacggc
gttgttctcg
cccgattgag
cgccgaccgc
cgtcatggcg
tccccaagag
ggcgcaggtc
gcaggaggcg
taccgagagc
gtcgaacccg
gccaaggtca
gcgaagggcc
cagcggctgg
ctcgaccggc
aacccgatgg
ggtctgctgg
cttgtgcccg
ctcaagggac
acgccggtct
gtcactgacg
ggtatggaga
cccggcattg
ctcccgagcg
gacttcaccg
ggctggacgc
ttcttctccg
acggtctcga
ggcttccggg
atcaaggagc
gccgcaggcg
gcgaagttcc
gtcgtcacca
ggccagatcg
gtggtctcga
gtgggcgtga
ttggcctcca
gctgccggta
gcggcgcgtg
tggcgtgcgg
ggccaggagg
ttcggtgacg
aactccgtcg
gcgatgccga
aaggacgagc
aaggacaagg
aagcagatcg
gctgagaccg
gtcgctcaag
ctgtctcagt
tcgatggatg
gataggaggt
caccctcgcg
tctgtatgac
ttacctcaat
cgctgcgata
gttcgaccgc
ggtgcgactc
caaccgcaca
gtactcggct
gccgcaggag

19021
19081
19141
19201
19261
19321
19381
19441
19501
19561
19621
19681
19741
19801
19861
19921
19981
20041
20101
20161
20221
20281
20341
20401
20461
20521
20581
20641
20701
20761
20821
20881
20941
21001
21061
21121
21181
21241
21301
21361
21421
21481
21541
21601
21661
21721
21781
21841
21901
21961
22021
22081
22141
22201
22261
22321
22381
22441
22501
22561
22621
22681
22741

gcgctgccga
aaccccaccg
gcagagccct
tggacggtcc
cccggtctga
cccaagagcg
aacgcgacgg
cgggtggacg
ggtgccctgg
ggcagggttc
atcgacacgg
cggatgaacg
gagctgacgg
tggacaaggc
agcgcgtctg
ccgtcctgac
gtggtggtga
tggatcacca
tcgtcacctt
tccgtgagga
ccaagcacat
tgtggatcat
tcaggctgga
tgccgctgag
gggacaactc
agtcgacgtt
accctcaccc
tgtcgctcat
ggggctcgga
acatcgcgag
ccggcgagta
tcgaggaggg
acaccagctt
gtgtgaacat
tcgacctgcc
tcttcctggc
ccttgctgga
agaacgccac
cgaccagggc
gtgagccagg
tcccgatccc
ctgacggccc
tgaagctctt
aacgaaaacg
ccgaggagca
tgacccatcc
accgcgacta
ccaagcagcg
cggcgcgttg
cgaagatgac
tccaggacta
gacattccgc
ggcagcgatg
actgaccgag
ggctgcgttc
gagcagccag
cctgtacgtc
cttcgccatc
gaggcgcaag
tgttcgccgt
cgttcgccaa
gcaagcgcaa
tttcagccat

ctgagacgct
accagtactc
acgttcccgg
cggactactc
tcggcggtct
gcacattcaa
cagccacgat
gcggtccgac
cgggctcccc
aggtcacccg
acccaaggga
gtgtccggtt
tctccggggc
cctgggggtt
gaataccgcg
gcggttgtgg
cttcgagttc
cctggcgaag
cgacaagcag
gaacggggat
cctttgctgg
cttcggaccg
aacgagtctc
cttcaacatc
caacctgacg
ggaggacgcg
gttcgaggac
cccgattcgg
gacatcgttc
cgacggcatg
ctacacgccg
tccgtacacc
cgtcgctggt
gggcggggac
gccgctgggc
cttccaggaa
ggcatcccag
caaggcgttc
gcacacggcc
ctacggccac
gcacaccgtg
gaagggctgg
cgagctcgtc
aaaggcacgc
cttcgcttgg
ggggttcctg
cttggagcgg
cattcgttgg
ggtgtcgaag
ccagcaggaa
catcccgcag
tatgtccccg
cgggggctga
cttgaacgga
gggctgttcg
aacaacccgc
acgctggcgc
atcccctacg
tcgcatgtcc
catcatgttc
gatcatgccg
cgcatgggtg
cgccgccgac

gtccatcacg
ctgggtgaag
catcccgtgg
gttcgaggac
ccggacggcc
gctcggtcgt
gaagacgcgc
tctgttgagt
gcagcccctg
agcgacggaa
agagcaagtc
ccggcacccg
ggttcccggc
ggaatgagta
atggcccgca
gacggcgaca
atcgaaaacg
tgggtgatga
ggtgcccggt
gtctacctcg
tgtaacccgt
gcgaagtggt
tggacgcttc
tccaactgga
atggtcttct
cagctcacca
ctgcgtgggg
cacggctgcc
ggtggctcct
accgagggtg
tggttcctgg
gggatcaaga
ggagagtcga
ttcctcacct
ggcacgatgg
tggccgactc
aacggtctgg
accctgtcag
cacaccatca
ttctggctcg
ttcgtagaac
gagctcgaca
atgaggttca
cacatgatta
gccctccgca
gtgcagtggt
cttgctgatg
caggccccct
aacaccccgg
caggagttca
cccgacgtgg
cttggggact
tgtacctgct
gtgccccgct
gtgagacgct
gagcgtggcc
tggcctacgg
acctgttgat
actgagattc
atcggctaca
ttcggcacct
gccgaggaca
ctggcggcag
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gtcgacccgg
tggattctgc
ctgggggctc
gagtcactga
gaggttcaga
gacagttcct
ctggaggccg
ccccgccagc
atgctcactg
ggcgctacag
acttcggaga
atcccgccgt
cagatggccg
cgagcaccat
gggcactgcg
tgcgccttcg
acaccggcac
acttccgtgg
ggtccgggtt
acatcgtgtt
tcctgaggcc
gtttgctgct
cggacaaccc
ggaacatcgt
cgcgcttcca
tcgtgtgtcg
agctcaacat
tggtctggga
ggctgaccgg
tcgacgtgtt
ggacctctcc
gctcggagtt
tgcccggtgt
cgatgatcaa
acgcaatcgc
tgcgggcgat
gcgacttcca
cgttcctcgc
aggtgtccga
gatcacgagt
gggtgtcgaa
tcggttaccg
acggagcgat
agccacagga
acatgccgat
cgaaacacct
aggacggcaa
tccggggccc
ctccacagcc
tgttgggcca
cccaagaact
gagagggttg
gatgccccag
gtacgtgtgg
gatgtcaggc
gtcgttcgtc
cgcttcgctc
gatcgcctac
tgcagtacct
tcacgatgca
ggtggcacga
acgaggtcat
tcaatgagaa

ccgatggcaa
ctggctcgac
ccaagtcccc
gcaaccggcg
tcgtcagcct
tgacatcgtc
tctacggggc
cgtggcgggt
agagctctct
cgcccgctga
acggctcgca
ggactaagtc
tgctccgcat
cacgtcgctg
ggagcaggaa
ggggcatgtg
agcctctctc
acgcgagaag
catggatcac
caagcacgat
agaactgcag
gaccctgttc
gctcgatccg
caagccgttc
gtcgttccac
gcgctacctc
cggtccgctc
catcgtggac
cttcatccgt
caccggagac
gcaggctccg
caagtacttc
gaacgagggc
ccaggcactc
gaagccgttg
gggctctccc
ctactacgag
cacgagggcg
cgcggctccg
cggtacaagc
gatcagctac
cgacccgaag
gggccagcta
agaagtcgac
gctcgccggc
gtgggagtgt
catccatgtc
gagaagcaac
ggtgcggctg
gttccgagag
caacgactag
cagctcgctg
atggccctgt
gggctcgtgt
accgagaact
gcccacgccg
tacgacgctg
ctgcactggc
gccacagcag
ggtcatcgag
gaggcagaag
tcaggctctg
ggtccggacg

gggcgggctg
tcaggtcccg
cgccgtcatc
tgtccggatg
gataggcgat
catcgcgtac
gggcaacatc
gtcgttcatc
cggcaacggc
gaacgctctg
gttgtgggcc
cgcgacgttc
cccacgagcg
gaagacgctg
cggctcaagc
gccggggagc
cagctctcgc
cggaacgtca
taccgcgtgg
tacgagcagg
ttcccaaagc
gtcaacatcc
accgagtgga
ccgctcatcg
gacatcgcga
aagggcgagg
gaggacctgt
aactcgggct
gcggtcgtga
ccgacgttcc
tggatcgtgt
gaggcgaccg
atctcggctg
ggcgggttca
tacgagaacg
atcccgatcc
ggttgggtgg
aagatttacg
tactacgtcg
gttctcgggt
tcgtggggcg
gacccgctgc
ggcattctgt
tggaacaagc
gtcggcgcag
ggcttcgccc
agcaagctgc
tacaacaacg
ccggatgtct
ctcggtctga
gacccgcaat
tgcttttcga
cctcggactc
ttgtcgcagc
acatgggttc
cactcatgat
gtgcggcgca
tcttcgcacg
tgggtcggtc
aagtacccga
accaagcgcg
caggctcagg
ttcaccgcgt

22801
22861
22921
22981
23041
23101
23161
23221
23281
23341
23401
23461
23521
23581
23641
23701
23761
23821
23881
23941
24001
24061
24121
24181
24241
24301
24361
24421
24481
24541
24601
24661
24721
24781
24841
24901
24961
25021
25081
25141
25201
25261
25321
25381
25441
25501
25561
25621
25681
25741
25801
25861
25921
25981
26041
26101
26161
26221
26281
26341
26401
26461
26521

ggtcggtcta
cctgcctgct
ccgtcggggc
gaccagggtg
tcaagctggg
ggctctgtgc
gccctgaggt
tacacggcgg
ggtgagttcc
atactcgaga
aaggactggt
gcggctgacc
gccaacctcg
atcctcggat
aacatcgcgg
aactcgggca
tcgatcctca
ctccagtggc
ccgttgatgg
ctcttcggct
tcccgcttct
ggcaccatga
atcaagttcc
cagatcatcg
atgatcggca
atctcggcgc
gcgtaccgag
aactgcatcg
cggctcacct
aactcgatca
tacgccaggc
aaccgcctgt
atcagcttcg
cagacatggg
cggcctggga
gcccacaccc
ccaccggtca
gtgaggaaca
accggatttg
cacgcggtcc
cttgaccttg
ggtctggccg
ggtgcggcga
gacgatcagg
cagctcgtag
ccactcgtag
gccgtcgcag
ggacttcttc
cccgagcata
ggcgtcctgt
ctcgcccttg
ctgggtcttc
gatgggcttg
caggtccttg
gagcacggcc
gacggtcttg
cctgtggctg
tccgaggtag
gtagtccaac
ctgtgcgaag
gatcacgtcc
gtccggacgc
ctgggcttct

cgacgcacgc
gccggatcac
atcgagactg
tccttgagaa
gccaggacta
tcaccgcgtt
acttcaagcc
tcgcgaagat
tggagtggct
ttctgtccgg
ggaacctgat
agttgaccgg
cggacggtct
cgggcttcgg
acgccaacgc
agaagttctt
ccgaggtcgt
tggactcggg
acgactactt
tcgccaaccc
gcttcgctag
cgctgttcgg
gtggcggcac
gcacggtgac
tcggcttcga
tgtcggccaa
cggcgacagg
acacgctcga
acaacggtga
tcccctcggg
tcgaaggcca
ccttcgtcgg
ggttcgagaa
tgaacgccat
ggggggcttt
acgtccacat
cgaagagcag
gcgggttggg
acatgacaca
tggggcacga
gcgtccttca
gtggtctcct
gtgatgagag
cccgcgtcgg
gtgtggtcct
aggaacgcct
ttgaccggtg
cgcgagtgct
gggttcttgg
atctgcttcc
tcatcgagga
aggttcgtga
cccttcgcga
gcgatcccga
ttggtgtctt
tacccgagtg
tcctgggccc
acgaacagct
cgcaggttgt
tcaacacagt
cacttcgagg
acggacgccg
gcccacttgc

tggcaccaca
ctggactact
tgattggagg
gtggctcggc
cacggagaac
cgatgttctc
gctgatcccc
catcgacaac
cggtggcacc
gttgatcgtg
caccggcaag
cacggtgccg
gaccacgctg
cctgcaggac
ggcgctcgcg
cgtcaacttc
caacaccggg
caacgcattc
cgaggtccag
gccgtacaac
ggtgggctac
cacccaggac
atctggtggt
ggataccggc
ggcgcagcct
cgacaacacc
ctcgatcagc
ccacatcagc
gcggccgaag
tggcacctgg
cgaaggcatg
cggcggtact
cacctcgtca
cggtctcgga
tttgcgtttc
ggctgaccag
taggaagaac
cgcgggcttc
caccctggca
cgacctcgat
ggagctgctg
cgacccaccc
acctcatgcg
actcacggcg
cccccggcac
cttccaggag
tccgagagca
gctgggccag
tgtggacccg
aggtgtccca
cgggcttggc
gtgcgtcctt
gcctcgcacg
tcagcgacca
cgtctgtgtc
gcggcagccc
gcgacttgaa
cggccatcat
cctccgcgaa
gcttggtgga
caccctcgtc
agaccccgag
gggcggtctc
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aggtgtcggt
tcgctttcga
taatgcgtga
agcggtgctt
gccgttcggg
gaagagcagc
ggtgccacgg
ctgaccgacc
tacgcggtgc
acaccgatca
acatccaagc
accgacaagg
gtcgacaaca
ctgttcgact
cagcttcagg
ggtgacttcg
cccggttcgg
gcgcagcgga
ttcgtgatgc
tacgccatcg
caacgcgccc
atctcgtacc
gtccgcgtgt
aacgtcagct
cgcggtaacg
ccgcaggcgg
aagggctcgg
agcgacctga
acgttcctcg
cgtcaggtgc
gtggacactt
ccgatggttc
gtcggcatcg
taacaagaga
aggggctacc
aggaacccga
gcggtcggga
cgcttcgacg
taggcgatgt
gttccggggc
gtggtcctcc
ggccgaccgg
ctccaggtag
caggcgggcg
gaacacgcgc
ggtgtcggcc
ccggtagtag
tgtcgctccg
agagcgcggc
gtcgaacgtc
gtgcttcccc
gaccgtgctg
gctacggctg
gccgtcgagc
aagtccaaac
ggacgcccag
ccggttgagt
ggcgtcgatg
catgacgacc
tcggaatgcg
ggtaagccac
gtcctcgaac
tagctgcgct

cacatgggct
gcggctctgg
ccacaccgca
tcgagctcgg
cgttgttcga
tcctcaagct
agaacgactt
tcccgatggc
tgtcgaccga
acgccgccgt
tgggcacaga
tcggcggctt
cggtgaaggc
ccctcaaggg
ccgactgggc
acaacgccaa
tagcgactgt
tgtacctgta
cacggcgctc
gccggtcgaa
gcatcggctg
aagcgcccgc
tccagcttct
acgcaggtgc
ggcagggcac
tcgtcggcac
gtgcgaacgt
cgtggacgcc
tcggcatgag
tctacaagaa
cgaccaacaa
agatgaatcc
tcggctccgg
gcccccttcc
ggtagcggtt
tcatgacgaa
accccgacag
gtacggggta
caaatagcca
ttgttcgagt
gtctcccacg
cgaggcatcg
attcgctcgt
atggtctcgt
cgggtgaccg
tcgtcggcca
cggtagacga
cacttcccgc
gcttgctcgc
ggtggggcga
ttccccgtca
acgttccacg
ccgaggacgc
agcttgccgg
cccttaccgc
cggtcggtct
tctagctgag
cccttggcag
ttctggcgct
cggtccatct
ttgccgaggt
gtgccaacga
tgttgcgaga

ggctctgaga
cgtgacgacc
ccagattccg
tggcggtgat
ggtccccatc
gccgctggaa
cgtggacgtg
cctgttgaag
ggtcaggcag
ccaaggcgtc
cggcaagctg
cggcgggacg
cgcaggcaac
gatgcagtcc
gggcagtgtc
cagcgtcccg
cgatggccag
caacgtcgag
ggaggacgag
cgcctcgggc
catggtcgac
tggcgctcga
ggtcaacaac
gggctaccgg
gccaggcacg
gtccttccgg
gctcccggcg
ggcgactcag
ggtgaagtcg
cggcagcctg
cgacaacgag
gggcgactac
tgacggttcc
caggacccca
cgccatcagc
gatcgaggtg
gatcgagagg
ggggtatggc
ggtcaaccgc
agaggatgaa
cttccccgta
cctccagctt
cctcgtcgga
tgatctgctc
gctggtctgc
cgatgaacac
cggacttgtc
agatgcctat
gcagcgccac
ggacgatctg
tcttgatgcc
gcgcttggtc
ccctgtcgtt
ccatgtcgta
tcggatgcgg
gtcgcagcac
cgaagaacga
cacctggccg
cctctgccca
tcgaccagac
ccggtcgctc
tctcgtgccc
ccttctgcgg

26581
26641
26701
26761
26821
26881
26941
27001
27061
27121
27181
27241
27301
27361
27421
27481
27541
27601
27661
27721
27781
27841
27901
27961
28021
28081
28141
28201
28261
28321
28381
28441
28501
28561
28621
28681
28741
28801
28861
28921
28981
29041
29101
29161
29221
29281
29341
29401
29461
29521
29581
29641
29701
29761
29821
29881
29941
30001
30061
30121
30181
30241
30301

tccttggact
caatgttaca
tcaccagtgc
ggcttggcct
tcgcaggcgt
actctggctc
tcggtggcgg
gccatcccac
actcaagaaa
aacgctgctt
tcagggctgc
gatgaagccg
ctcgttccgc
atcgcaccac
ccactcgaac
tccgcagggg
gagaagcgcg
atcgacgcca
agcaggggct
aaccttgctc
ctcatcccac
aggttcccgt
cggaagacga
agaagatcgg
cgtcgtagtc
ggagcacaag
ggacgcccat
ccggatgctg
gaactcgatc
acggcccttg
tccagggtga
atgaccccct
cgcggtggga
agttgatcgg
gcagccacgc
actcgatgct
gagttcgagc
ttcgtccaga
gatgaagtca
gtcgacggcg
gaccatccag
gaagaagtca
ccacgacgct
ccacgccgag
acgactgatc
cgatggccgg
cggcatgagg
catcgcgtcg
gatcgtcccg
gtccggagct
tccttcatcg
aggcggtcga
agcttgattc
agccccacga
cggccatgag
ccagaatctc
tcagcagtgc
agtaggcacg
tggtgatgta
ccgggtatgc
tctgctcggc
cgtacttccg
tcaggtgaag

acactgactc
ggaactgctg
agatgctatc
tcgcgttgtc
ggatggtccc
tccggacgca
ggaacgtggc
cgttgtggct
gtcgctcagc
gactgcgccc
ccaggggcga
agccgccagg
tcccagcggt
ccgtggtacg
gggtacacca
gctctggtga
ttagcctctg
ggtctggcgt
ccgttgtatc
ctttcacagt
gtcggtctca
tcttgtatcg
caggcgtatt
gatgccgacc
cgagccgccc
tgcggtaacg
gtccgcttgg
acgctgatgt
cgaggctcct
tcgtcctcca
tcgggacacc
tcatgccgct
ctcgaccacc
caggtcaagc
cagggcctca
ggttgcctgt
tccgcgatcc
gccatgtgga
gcgtcttctt
agcacgagga
taggtgtcct
cgatcctcca
ctcgatgagc
cgcgagcttc
cggcagggtg
ggagtctccc
tctgccacga
gggatgaggt
agcttgttca
ggcagtgcga
ccgcgacggc
tgaccgcctc
catccatgtg
gcgaccgccg
ctccccgatc
gtcgtggatc
cctacaagtc
ctgcgggtcg
gccgttccgg
ccggtcgaac
cacggtcttg
ctccgggtca
gtcagcgtcg

gggccccgac
gcagaatcca
cccagtcaga
gttcacggcg
cctcgttgtc
gtggtatgcc
ccacgcgagc
gctggccgca
gtcgatctca
gaccggtgaa
tttgttactc
gctcgtcggg
cctgctcttg
ggtcggtggg
ctcgctcgat
tgtagagagc
catgtactgc
tactcgttcg
cggtagcccg
cagaccgctc
tcgcggcctc
gacgaacacc
cgcggatcgc
gggttcccct
gagtcgcctt
agtttcatcg
gcttcggtgg
cggctctcgc
cgaggacgcc
cgatctggag
gaagccgacg
gtccagtaga
aggccccgct
agtcccgcca
acctcccgct
acggtcatcg
ggcactcccg
gcttgcggac
ctcgctcgaa
aggtgccggg
gtgcccctgt
cgtaggattc
gtccggatcg
tggacggtca
atgtacagct
tctcccccgt
accgcaggaa
agacctcgag
gctcgtagat
ctgcagcctt
ggcgtcgtag
cgctgtggcc
tcctccttgt
acctccgggt
cggttcgctc
ggaagccgaa
acgtcgcgag
accggcagtc
atcgcctcac
cccgcgacga
gcaccgccgc
tccttctgga
tccaggaacg
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cagggctctt
acacattgga
gtggcgacgg
ctcagtgagc
gacggcggca
tggacattgc
ccccacggag
acgcatctga
gagcctcttt
acgacaaaaa
gatggttttg
gagcatcccc
caccacgatc
cccagcacac
gccggcggcg
agctccgcga
gacacaacgt
acgtggacac
aactcgtcgg
ggcagccgcc
cggggcaccc
ccgccagtgc
ggtgtgtcga
gcaccggcat
cacaggcggt
gtttcctctc
gggtgttggt
tcggccgtag
gaactcgcgt
gtagacatcg
atcaaccacg
tgacggtgcg
cacggagccg
gttcgaggtt
tggggaggag
cccgagttcc
cgagtcgcgg
gaggtccgcg
tgaagcgatg
gcccccggcg
ggttttcgac
ccttctcttc
cccagttgcg
gtcggtggtt
cgaccgtcgt
gcatccactt
cgtcagctcc
ggccccctcg
ggccttgccc
cacggaagca
gccaggtcca
gtgcgcttcc
gcgatgtcta
cggtgccgat
cccactccgc
ggtacggagt
acgacgactg
gccggcctcc
gctgcagccg
ccttctgggc
cgtacacccg
tgtgctcacc
cctggatcat

agcggttgtg
agtcgatgag
ccggaacggt
tctcagcgga
tcatcgtcgc
tcatcgtcgg
ccatcgcgat
cggtcctcct
tttccagggc
agcccccagg
ccgacctcat
ggttccatcc
ttcgggagct
acgcagcctt
tcgatcagct
aggtcctctc
gtccctcccg
gtcccgcaac
tccttgacga
cgagcgatcc
agggccccac
cgttggcacg
atcggtgctt
gaagatcacg
caggccgagg
ggttttctga
tcgggctcga
atgccgtagg
ccgttgaagt
cctgcgctca
ccagcaggta
gttggtgggc
gaagacggtc
gcacagcggc
aggcttgatc
tttcgtagtt
tcgtagtcgg
aggcagccgt
aacttacgct
tagtgctcgg
cactgctggt
gagctcggtg
ttcgacctgg
ctccccgaac
tgacggcggt
catgggcgct
ttcggtgcgc
ccgctgagcg
atcagttcct
ccccctctgc
cgaagacctc
cgttctcgac
gtagttggcc
gagcaccggg
ttgctcggcc
gaatcccgcg
gatcaggtag
cagcccgtcg
ttggctgagc
cgtcgccatg
gccgaagttc
gaacgccgcc
ccgctggtcc

gcatagtttc
aaaggacccc
cgcggtcggc
caacggagtg
cacgacggcg
ctcgctcgtg
ggtgatcgcg
ctaccggggg
ttttgcggaa
cagcccagtt
cccggaggtt
ggacggtgta
tgctgcacgg
ccggcttctc
tcgagcagtc
tatcgcagta
agctgtaact
caggacggcc
cgactgcgcc
cgaggaagta
gaggggctcc
ccccccgtag
cgccatcaga
ccgttgggcc
accaaggcca
gacccatcgc
tcaggaccgc
gcacggagtt
gcatgatcgg
cagcagcgcg
cagcagcacg
tcgtacttgg
ggtgtcaccg
ctcccccgct
tggtggtacg
cggcgttttc
cgttgtcggc
ggagaccagc
cgttctcctt
tgtcctcctc
acagcaggtc
atggctgcct
ctcatgttct
tccgggatgg
cgcagcggtg
tccccacata
cagcaggttt
gatgcggcat
cggtcagccc
cttgagtgct
gttcagccac
ggtcagcgtc
ccgtaaagcg
cccatctgtt
ggaaccgacg
tcgtgcagcc
ttgagtgctg
atgaacggtg
ttctggacct
tccagtccgg
accaccttgg
ctggccgtca
ttcgacagcg

30361
30421
30481
30541
30601
30661
30721
30781
30841
30901
30961
31021
31081
31141
31201
31261
31321
31381
31441
31501
31561
31621
31681
31741
31801
31861
31921
31981
32041
32101
32161
32221
32281
32341
32401
32461
32521
32581
32641
32701
32761
32821
32881
32941
33001
33061
33121
33181
33241
33301
33361
33421
33481
33541
33601
33661
33721
33781
33841
33901
33961
34021
34081

ccgcgagcac
cagcgaggaa
ccgttataga
tctgggagtc
tcttggcctc
agagcaccgc
ccatcgactc
tgagcgcgat
tgtactcgac
tgtgctcgtt
gccgcgccgc
ggaccttctt
gcgtcttgac
agtgaccgga
tgtccttgac
ggaggtcata
cgtccccggc
cgaactggac
agtcgagtcc
tctccctgtc
tcatggtgct
acgtcgaagg
aacgcgacct
aacttggctc
gtgttcgagc
tccttctttc
ggtagaagct
cgacgttgac
ccttcatgtc
agcgatctcc
tgcctcgtgg
catcggtgag
cggcaggcca
ccacgcttcg
cacgggcggc
gaacgacagg
gaacgtggcc
gtagtcctcg
gcccgcgaac
ggggctcggc
cagcttgacc
tccgtgtgcg
gcatccaagc
ggccgggagc
ggccaccgcc
agtgctgacc
tcacctgatc
acccggagcc
tcggagctgc
gcgcgtcgaa
cggatgcgaa
gcacgccccg
ctcgaactgc
gatggtcgct
cttgtacctg
ctggtacatc
gatctcctca
gggaatggtg
ttcccggagc
cttggcgaag
aggggccacc
tgctgactgc
aggcgctttc

gcggagctcc
gcagcgccgg
catgcgggcc
cctctgcttg
gatgaccgcc
gtcgtccacc
cagaacgtcg
ctcgttgtag
atcgagcagg
gtccaccagc
gaggatcggg
ccagacgttg
gttgtcggcc
gccaccttcg
cttcggccac
cgctgcgttg
gtagggtcct
tagacggcaa
gaggaacccc
cacgacgttg
cctatcggtg
accgcgctac
cggtcttgtc
gcagctctcg
ttgcgagagc
gcatcagatg
caggtaggca
ctctccctgt
gcctctcagt
cggagctgcg
tagcgagcct
ttggtcatgt
gcgttttcca
gccaggaagt
gtgtgaccgc
tgcctgtggc
gaggcgtgct
ttctcccgag
tccgcgagct
ttgtacccga
ttcaatgtgt
atgtcaagtc
cgaccagggc
cggcggggtg
gccaccaccg
cgcgttctgg
gagggcatcg
gcccttgaag
cttggctgcg
cgccgactcc
tgggtcctgc
gaggcgcact
ttcttggtga
cccttgagca
tcggggtcga
gcctggaacg
gcatcgcgtc
accaccacgg
tcctcgatct
atcgggtgga
gtccgggtct
tcgacctcct
gagtacctgc

tgggcctggt
attgtcgagt
gtccgcgcac
aggaacccgt
gtcgcgaact
ttccgcttgc
gccacctgat
tggctctcct
aagcctgtcc
tcgtcggaga
tccatgcccg
accttcgtcg
accgccgagt
tccttgcccc
atggtctcca
tgcaggacga
ccgcgctcaa
cggaatccgt
tgatgagccc
atgacgacct
gtactgcccc
gtcgcgccgg
caacttcgga
gttctggcga
gtcgatggac
ccttccagcg
cctgagtcgc
gtgcggatga
agctgtaggg
cgagcagttc
tgatgacgta
tcggcagcac
gcacagcgag
gggctgcgtc
ccaacggcgt
gctccagctc
ccagcacgct
tggccgggtt
cgtcagcgtc
gcgactccag
tcctctctca
ggctacagcc
ttgccgttct
cccgcaggcg
ctgttgccac
acgcgctcca
tccaggtcct
gtcaggacga
gccttcttgg
tgcggctcgg
aatgtaacta
cttcatcgac
ttcgctcgta
gacccccgaa
cgttggcggt
cgaggagttg
cgaaccggtc
tgttctgcgc
ggggatcgcc
taccctcact
tgaccggaac
tggcgagctc
ggcctgtcat
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agtcgaccga
ccccagcagg
gcaaagggtt
cgacccatgt
ccccggcctt
cggatggtgt
cagtcgagtt
tgacttggag
gctccatgta
ccttcaccag
agtagagctg
tcttgttcgc
cgatgtagcg
tgggatcaat
tcgggacgcc
acccctggac
ccgggacaac
cgttgtagat
ggatgaagtc
cgtcaccgtc
cggacgatcc
gacacgcccg
cggttcggtc
gcgagctcct
agattcgctt
gtgacaccgc
cggtgatgac
tggtcccgtc
ctcgttgggg
ccctgccagt
ccgccacgcc
cgctcgtgct
gagccgcttg
ccggtactgg
cgggtcgaca
ggtcagcacc
ctcgtggccg
cggccggtcg
ccagtccccg
gacgtaggga
ggggtggaga
agacaggctt
tgccggtacc
gttcctgagc
cggacgcctt
tgagcgcacc
cggcgtggat
ccttgccctc
ccggggcctt
gagcagcctg
cctttcctct
ggagtcggca
aggtgcctgt
ggtcctgagc
gaagctcacc
gttgagcgtc
gacaacctct
gtagaggtca
cttcgagaac
gacgccaggc
cgggattcgc
tcgcagcgtc
ggccaggtag

cgcgatccgg
cagcgtttgg
gatcgctgcg
tttcctccac
ctcgtgctcg
gcggcccttg
gaccttctcg
gtccagcgac
cgagcagatc
cggtgcgagc
gtagtgcggg
cttggccagg
acgtgtcagg
caggtgagcc
cagcgtccgc
catctccagg
ccaggcttcg
gtccagcccg
catgaacccg
cacttcatgc
gggagatggt
ctcggacgag
gattgggacc
cgcgctgttc
cgcgcagagc
gtagtacatg
caacgtgttc
gatcaacagg
atgtcctggt
tcacggattt
cggtggttac
gcctcgcggg
tagtagctct
ttctctggca
taccgttgcg
gagcgactgg
acctcgagga
aacgaccggt
atgccgccag
tcgacctcgg
gggcccccgt
ctcgtcggag
ggacttgtag
gccacgaggg
ggccggtgcc
gagcgtggca
gacgatccac
gcctggcgca
cttgggggct
agcctcgtcg
tgggtgggtt
acggcctgag
ggcatggacg
tgttcaccca
gcgttgtcgg
aaatcctctg
tgcacgaggg
tcctcgacct
cggatgcgcc
atcttcgcga
agctcgtggc
ttccggaagt
gacgccacac

tgcccctcgt
gcaggaatac
tggcaacggt
ttcccggcct
gtcagctcgg
atccggacgc
cacccgtagt
agctcctcgg
gccgcgagct
ttctgaatca
tcctcgaagg
tcggccatca
tcctccagcg
aggatgcggg
tcgaagacct
gccctcttca
ctcggagtac
gtggtctccg
tcgagatcac
cggtgctcga
ggatgggttc
gtccttgatg
cttggtctcc
ccacagcgtc
gcgtttcagt
aggttgggcc
tcgatgggat
acagtgactt
aggtgttggg
cggcgtcggc
cggtcacgac
ccttcttgcg
ccgctgagtc
gctcccacac
agacaacgga
cctcgatgta
tgtgtgcgag
agcagttgcg
cggtctcgta
ttgctgcgat
aggggccccc
ccgcgaggcg
acccagtccg
gcgttggagc
atgcccgcga
ccctggttgg
ggagcgtcga
gcggcaggct
tcaggcggcg
gtggcgggag
atcgaatcgg
cggtcgcagc
attcggggaa
cgacgtgcgg
cccagagcat
cggattcaac
tgtccttggt
cgtagccctg
ggtagaagta
tggtcccggt
tgaactgctg
gcttgtccag
cgaggtgccc

34141
34201
34261
34321
34381
34441
34501
34561
34621
34681
34741
34801
34861
34921
34981
35041
35101
35161
35221
35281
35341
35401
35461
35521
35581
35641
35701
35761
35821
35881
35941
36001
36061
36121
36181
36241
36301
36361
36421
36481
36541
36601
36661
36721
36781
36841
36901
36961
37021
37081
37141
37201
37261
37321
37381
37441
37501
37561
37621
37681
37741
37801
37861

gacgccgatg
gaacgtcgcc
gtcgaccttc
ctcccactcc
gccctggttc
cgtgatccac
catgttcaac
cttgccggtc
catcgacatg
gtcgatctcc
aacctcgcat
gaaggtcttc
gtggctgacc
ttcccgcgag
gacaccggca
gtagagctcc
accgccgccc
ccacccgctc
gtgacggcct
acctggctgc
cgtctcgggc
tacgatctcg
cgcaggtaac
ttgtcgatga
atcgccatcc
gagtcgccgg
gtcgttgttc
tcgatgagtg
gtctcggctt
tgctcggtga
atgaccccgt
agagcagcca
agaacgtcct
agcacctgct
ttggagagct
tcctggacga
gcagcctcca
tcgaccgtga
atggtcagca
tggcgcatgt
ccgtagcccg
gtgtcgaact
tgaccacggt
aggtcgatcc
gccaaggccg
tggacaccga
ttctcggcgt
gacggctgcg
ccgatgaacc
gagacgatca
tccggcgtaa
ggcgatcttc
gtaaccggag
gttgcgctct
ctccttcgtg
gaaactcggt
tttgcctctg
gctgttcggc
cgcgaggacg
gttggcccca
ctcaccttcg
ccacggttga
gatgcagcgg

cgtcggttgc
cggatcagga
ccgttgtcct
tgcagcgtga
gacagggacg
gtcagggcct
gccgtccaga
tcctgcttgc
cgagccgacc
atcgctgcga
acgtcgatca
agcttggcac
tcgtcgcggt
tcctcgatga
tccttcatcg
tgcggcacag
tccatgaggc
acccagcagt
gccggaagca
tggtaccttg
caggtctcgg
ccggtcggtc
cgggcgtgta
gcatcggttt
ggtcgtctcc
tcgactgggt
ctgtcacgtt
cgattgcggc
ggaccgccgc
tggccttgtg
cgtcgtagcg
tagcggtggg
tgacggcctc
cggtgaggat
cctccaactt
ggtcgtccag
tcaccttgac
agcggccgtt
ggccgaaccc
ccatcaggtt
atgtgtgcga
tccgtgccgc
gcccgtgggt
cgaacccgtc
gcgcgtactt
ccgggccgac
cggtgaagac
ggaagtccat
gcagcaccgc
cgatgcgctt
ccggcgatgt
atgaggatca
aacagggccg
ccgtggatga
gacgtagtcg
ctcggtgtac
ctgatgacta
agggtcagtg
tagacggttc
ggcaccccca
gtgatcgcga
tcccccggcg
tagcggatcg

ggtccaggac
accgagccat
tgacgaacgc
tctcaccgca
agtcccagaa
tgtgggcctg
acaggtcgtc
agcggacgaa
ggcgaacacc
tcccgttgag
gcatccgagc
cgaacggccg
agtgggtgtc
cgaaggcacc
cctggtagtc
ggccgtagtc
gcatgaacgt
tgaagaggtg
tcttgaactc
catccaccag
acgagccgtc
cccagttgac
ctcgccgccg
ctcgtcgggg
gttgaacatc
gatccagtca
gccctcctgg
gtcagcagtt
gctgctgaca
ggcgttcttg
gctccggaga
catgatgtcc
cgacgagtag
ttggatggca
ccgttgtgtc
gcccccctcg
catgtgcgat
ggtgatcggg
ggactgccaa
gccgacctcg
caggatgccc
gttgagcgcc
ggtgacccaa
gaagtcgagc
cgagaggtac
gtagatcgtc
cgacccctcg
caggtctccg
acggaccgct
actcaacttc
cggtgaacga
tcaggttggc
cgatgtccga
ggcgctgtgc
tgaatccctt
tcattcggtt
gcgagttgac
ccacacggtt
ggtatccgat
cggccgggag
catcggggac
cggtcatgta
cgacgacgat
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ctcccgtgac
caaccggtgc
cgcgaggttg
ggggttggtg
cccaggctcg
atcgcggacc
cacgacgacc
ctcctcgatc
gccggccacc
agagccaccg
cagcggcagc
cactcgagac
gatcaggtcg
ggcccactcg
gggatgctct
gatgaaccgg
gaactcgaag
ctgggcgttc
ggtgatgagc
cgcgaggttc
aggcttcacc
ttccgttgtc
cagtacagct
aagagctcgg
ccgtcgaaga
tcgaacacgt
tcggttaatt
ggatcactgc
tcaccggctg
agcgcgtcct
gcctctgcgt
ttcaggtacc
aggttgcgac
gctcggcgca
gcaggacgtt
cggccccagg
gtcaagtgtc
atgatctcgg
ttgccagtgc
accccggtga
tgacggtggg
gtgttaccgg
cccggtgcaa
agcgtctcca
gtccgtggcc
cgcagtggag
aactcgcctc
atgtggatca
cggcggtcct
gggttcctct
atcgcggtgg
tacgtcgatg
gaagttctct
ctcttccagg
cccaccaagg
gggtcatgac
atcctcgcca
ggcgaactcg
gaacagctct
gccgcagact
ctcacgcagc
cttgccatgc
ccagccgtgt

ttcggatcac
gaccggatca
atgtggccga
cagacgacct
ccgttggcga
atgatggaca
gagatgttgg
tgagggtcct
acacactgcg
actgtggcga
gggcccgacg
acgtcgtaga
accagggcag
gggtcgtact
tcgtcgcaca
ttcgagtagt
tgatccgagg
ttcacgccgc
ctgatcagct
ccgtcgacca
cgtgagtagg
acttgccgcc
cgcgatcctc
ggaagacctg
tgtcgagtcg
tcgccagctc
cgagttcctc
gtcccccaga
tgatgacgat
gggacggacc
agacggcgtg
ggttgttcga
cgttgaactt
ccgtggcgat
ccagatacca
tgacgagagc
agacctccca
gcttgacgtg
cgcctttgag
cgatcttctt
tgtggcccat
cgatccgcga
ccttgtagaa
ggtggaaagc
gctcatcgtg
cgaggaacct
gagtgtcctt
cctgatccgg
catacggaat
tcgtagatgc
tagccggtgc
tcgctgatcg
cgggggtgcc
atcgactcac
ggcgtcggga
atcctttcca
ggtggcatcg
gctccgggct
cgcatgtagg
tgcgctgtga
agcgcgagag
cctcggtggt
tcccgcgacc

cgaccgggct
ggtcgatggt
ggttgcacgg
cgttgggctc
ccatgccgtc
cctggttcgg
tcgtccagtg
gccagtgcat
cgatggcgtg
tctcgctgag
cccgcccgcc
cgcgctggaa
ccgcccaacc
ccgtcgacag
cgatgtggac
tcgcaccgac
gcttctcggt
tggcccacag
cttcccgttc
cacgctcgac
tccggttgta
tttcaccagt
tgcaggccag
agcgcggtac
tacttcggac
cgtccggtat
atcccccttc
ggatttgcgc
gatgttgacg
gtcctgggga
ctgcttctcc
ccggtccttg
gttcccggcc
tgcctcgggc
cacccagagg
cgacttagcg
agtgtgtccg
gcgaccctcg
gtagtcggcc
ggagatgccg
gatcaccgac
caggctgatc
ctcgggcagc
cttgctctcg
gttgccttcg
cagcttggcc
gttccagcgc
ctgatagtcc
ctgggtgtcg
gttcgacgca
ctttgaccct
ggcgttcgag
cgtagttctt
tcatcgtctt
tcgaggccga
gcagagcgga
ggatcaccct
cgtcgccgtc
gcttccacat
tggcgtcgat
tgttgtacag
cgtggtcctg
agcgcaggta

37921
37981
38041
38101
38161
38221
38281
38341
38401
38461
38521
38581
38641
38701
38761
38821
38881
38941
39001
39061
39121
39181
39241
39301
39361
39421
39481
39541
39601
39661
39721
39781
39841
39901
39961
40021
40081
40141
40201
40261
40321
40381
40441
40501
40561
40621
40681
40741
40801
40861
40921
40981
41041
41101
41161
41221
41281
41341
41401
41461
41521
41581
41641

cgggatcgcc
gagcatgaac
atactcttcg
aaagctcttc
gcccgagcac
agacggcagc
tgccggtgtc
gcggctcatc
ttgatcagct
gcctcgactc
cgttccccga
gcctcgacgc
ccccggacga
gcgcggcggc
gcggtgatgc
ctcttggccc
acgatcccct
cggactgtcg
cgccccgaag
gtcttgatca
accgtgaaca
atctggtcac
agcagcggga
gacaccgact
atggcccggt
cgcgtcggca
gccgcgtcga
gccatagccc
aaggcgcggg
ctgtcgccgt
tcgaagagct
acgccggccg
gtctggtgct
cctcagccaa
agacatcggc
aggtgtccca
cccaggccca
tcccgtccgg
gccagtcccg
gtcgacgttg
cttcgtcttg
ggagaccggc
cggggtgggc
aaagacgagc
ggtgcgctcg
gaacgagccg
ccagacccgg
gccgatgcga
gaggtagttc
cgtaccgacc
ccgatccggc
ctccggacgc
agcgagggtc
tggtgtctcc
cgcggttctt
gcaatgtcaa
tcggcttgtc
cggtgttgcg
cgtcgtcctc
ggtagtcccc
gtgatgcgtt
ggtcggagtt
ccatccggtt

atgaagcccc
cggtcgactt
gctggactgc
tgcgattcgc
gtcgcccttc
cgagggaacc
cttcggtggc
cgttgatggc
catcgaactt
ggtatctcat
tggcttggac
tgtccctgag
tgcccgttgc
agatgtagca
cgtagacatc
ggtggtgcgt
cggccgtgca
gcttacgcct
ccccagacgg
ggtcggccgc
acttgccccc
actcggcgtg
ccgtgtcggc
cctgcagaga
aaccgtcccc
ggttccggcc
tcaggatcgc
cgcccatcga
caatgatgtt
ggttggcggc
cctcgtaggc
agtgacccgc
tcaaattcac
ttccatgcag
tcccagcgcg
gtcggccggg
gcggtccgcg
gctcttgtcg
gcttccggtg
aactccgaca
acgacggact
ttggtcgcga
ttcggcatag
gaggatcacg
tcgtcggccg
acgaacttgg
ccgaacgtgc
ccctcggcct
ttgtcgagca
aaggtgtcgt
ttgtggacga
ggagcgaccg
attggcgggc
gatgaactca
gacggtcgat
gacgagctca
cgcgtcgttg
ggccatcgtg
accaccgccc
gtagccctgg
gtagttgaac
gcggaccgcc
gagctgggtg

ggaacatctc
cgtccctgac
cgttcagact
tcagcctctg
accccgcagg
tcctcggcgt
tcccagtccg
atagacgacg
ctcagcgaac
gctcctcctt
agccggtggg
atgccccagg
gtggtcgtgg
gcagccgccc
catccaccgc
gacgcaccgt
gtcgatgcac
tgtcgtcgtc
ccaccagtag
gaactccggg
ggcgagcgcc
cagtacagcg
cttcgtcagc
ggaaagcagg
gaggatgtcc
aggtgcgatg
ggcgtggacc
atgcccggcg
cgccatgtct
gtccggtgcg
gatggcgctg
cgtcgtgacg
tccttgatgt
ccgaaggtcc
accatctctg
tgatcctcgg
atgtcgtcgg
agctcgtcct
acgaggactc
cgttctgtgc
ccttgccgtt
tcagcgcgga
tcgattcctt
gctgcgagta
ggacgaagtc
tctcgaactt
ggccggtggc
tcatcgacgt
gacgcgccag
agtcgacgtt
cgcggaggta
cctggtactg
cttgcctttc
agctcaacga
acgcgcagag
ggaacgcggg
taggagccgg
tgcaggtagt
gagcggacgt
cagtacgcct
cggattggga
ctggccgaac
aatgcgtcgg
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atgaccaggg
gctgtcgaac
tcgccggtac
cataactcac
ccaggcagtt
ggaacgggca
ggtggtaccg
gtgtcctcga
ttcgcctcgt
tctgtgcgat
tcgtccaggt
acgttccggt
tcgacgctga
tggtgctcgt
tgttcctgtg
gggcccggat
ggcttgcgct
atcgagaccc
agcgatcacg
tcgaccagca
gctgcgctca
gtcggcaccg
gcgtaggccg
ctcagacgct
acgagcccgc
gcgataccct
cggtccggga
atgaccgcct
tcgaccgtgt
atgacgtaga
acgctgagcc
gccacgcggt
atccgtggtt
cgatggactc
cgttgcgtcg
gctcgacctt
caccgcgtgc
gcagggtgcg
gcctcacggc
cagcgggaag
ctcgtccttg
gagcgcctgc
tcgtttgtgc
gtactcggag
gtggtcgtac
ccagtcctgg
gaccaggtca
gtgcgatccg
cgtcgtggcc
ggagaggtac
ggtctcgtcg
gacggtgtcc
gttactggtt
agtcgagtcc
cttcgggccc
tgatctggcc
tgacatggtg
ccatcatcga
tggtgatgtt
tcatcgagtc
tgtcctcgaa
gctccatgct
agtccgcgct

agtgggtcgt
atcagtcccc
cgttcggttg
ctcctcttgc
gaacgcctgg
cagacacttg
gtggatcgcc
cgccggtctt
cctcgtccga
gtcaaggatc
agtcgatgat
tgcacgcggt
gccgcttgcg
agatcgccca
tcagcgttcg
gcggggcctt
tgtgggcccg
tccatgcaga
cgatcacgtc
gccacgagtg
ccccggccgc
agttggcccg
cacgaacgaa
ctctgcgcgt
ccacggcgaa
cgtggtgctc
acatcgcgga
tgtcgacctt
ggccccacgg
acccgaggta
cgtgcatgaa
acccgtcgtc
gacgaccggg
ctcgagcggg
atggcctgct
gtagcccatc
cgcaccgtgg
ccagacctcc
acccagcgcc
cggagaccct
acgagcgact
tggtggatga
gatgtcaagc
ttgttcatca
cagccgccat
gtgatcagat
tccacgaaga
tcgttgggct
gcgatggtcc
tggttggcga
gtcagatcga
cacggggcga
ggaggggtct
ggacgggtcc
gaactcttcg
tttgaccccg
cagcccgacg
ctccaaccct
gtcgaccacc
ctcgatctgg
ctcctctgcg
ccacgcggtc
gaagtacagc

ccacgtaccc
ttgtcgccaa
cctcccggag
ttcttgatca
cgcacgaacg
atccagtcct
tggactatca
gtacgtgtcg
ccggataatc
gggtacgact
ccgttgtgct
gcatagaaga
cttgccgttg
gtactcgtcg
gcgctgcagc
gcgcttggtg
gtcctgactg
ggtagaccca
ccacatcgcc
gaagcccttg
atacggcacg
catcttctcc
ccggagaccg
ccgggagcgc
gcgagccgcc
cttcccggct
gaactcgacc
gagcgatgtc
cagcgagccg
ggacagctcc
cacgagcggg
taggacgagc
atgcctgctg
aaggcatggc
gacttgccgt
tggtgcatcc
actacgacga
ggtcggtccc
tggcggcgag
cgcgggtgac
tacggtccca
tgttcatctt
cagagggcaa
gccagcgttc
cggagtagag
ggaccgcgtc
cccaccgctt
tccgcacgac
ccgacaagcc
gctccagcag
gcaccttctt
agattgcatc
ctgatctgca
atccggccgg
gacactctgt
gacaacggga
acgcaggccc
gagaacgggt
accaggtccg
tcaagactcg
acctcggtga
tggatcgaaa
gtcggaactc

41701
41761
41821
41881
41941
42001
42061
42121
42181
42241
42301
42361
42421
42481
42541
42601
42661
42721
42781
42841
42901
42961
43021
43081
43141
43201
43261
43321
43381
43441
43501
43561
43621
43681
43741
43801
43861
43921
43981
44041
44101
44161
44221
44281
44341
44401
44461
44521
44581
44641
44701
44761
44821
44881
44941
45001
45061
45121
45181
45241
45301
45361
45421

gagccttgag
ccagcgcgag
ggggcagtgg
gcctcctaca
ccgaagacga
cgcttgcggg
cgatgtagcc
gcttcgcgac
acggccgtcc
tgcggccgcg
gtactcggac
tcagccagca
cgggttcgga
gatggcttcc
catccagtag
gtacaccgcg
caacccttcg
atcaatgtcg
ctcggtgtgt
ccggcgtgcg
cggcgtgatt
agcggcctcc
cgcgctcccc
cttgtagctg
ctcttcggtc
tctgtcgggt
ggatcgagtg
ccctctccga
ttggctctgt
gaactccgat
catcccggcc
gcgagtggca
ccgtctgggt
atcattgctc
tcctccggac
gggatgttcg
ctcttgagct
cggagcctcc
tgctgaagca
acgtactgcc
ttcaggtctt
ttcatttgtg
attcagtcaa
ccctgtctcg
ggtacctcgg
gcccggacat
tcccactcga
tcactcggtg
tggcgcggga
gacgcgaggc
gatgtcgacc
tgggcccgtg
gacgatggct
acctcgatcc
ggcgcgtggc
acgcggatgg
tcgacggacg
gcctcgagct
gccattttct
attcgctcgg
caacgcttcc
cggcaatgcc
ttgggcaggc

ggcataggtc
ctggccgcgt
gtcgcccgcc
gcttggtgaa
tcacttcggc
ccttggcagg
ctggtgcgac
gttcatctcc
gggtaccgga
actgacggga
tcggtcgaga
gaaaactcac
tcgaacttgc
ttcgtccagt
tcgcccagct
agctggaagt
tcggtctcga
aagccaagtt
gaagtcgccc
atgtcaagtc
gcacacgccg
agagacatcg
tgcgccgtcc
taggggcact
atgacgcaac
ggacggggta
gctccgtggg
acatgatccc
cgagcagagc
aggtcaggag
tggcgacacg
cggtttcgta
cttcaggtcg
cttcttcggt
ggcgcggccg
ggtcgaactc
tgagatcgtc
ggtacgggga
cgatctctcg
tcgtgactcc
cgaccacagc
tttctccctg
tccttcatgg
ggggatacta
tgcgtctgat
cctccaggtc
ttgcctcgtc
gccggtggtc
ctcccaggga
ggggtctgcg
cagccccagc
ccgtggttgg
accccgatcc
ggtgccagtt
cctgacgggg
cggcgaaggt
gttcctccgg
cctcgatccg
ctccttctct
cgggtgacca
cggtaggcga
gagacttctt
cgtccttggc

agcacgaacg
aggaaccggg
gatcccttga
gcagagccag
aatcacagcc
ccagcttcac
ggcggtgcct
atctggacgt
tgacgggggc
acgggtactc
gcgtcagcga
aggcgaagct
cggcccggac
ccgtgaggtt
cgggcggctc
cgtcaccggg
tcacagcgtc
caataccagg
agtcgatgta
gcccaccgta
cgttgatgta
tgcgcccgct
aggccgcagg
tctcgtactg
ctccaacgtg
cttgcccttc
atcgagggcc
ttggtccgga
cttgacatcc
cagggtgaca
gattacggga
gctttctgcg
gatgtctcgg
caggtcggtg
gtacgcccag
gagcacatgg
catgccgacg
gacaccctgc
cggcgtcagc
gtacatccgg
gagtgttagc
tctgcgggtc
ctttcgccgt
caggccgtaa
ctggtgtttt
catgatgtct
caagtccatg
tcgtggacgc
caatcgcggc
actgaccgga
cgccgcgacc
cgcacatgcc
cagccatcgc
gcgctcaccg
cgagcgggtg
gtagctgagg
gatgtgtgct
tgcgttcaag
ctcagcggaa
tgcctatctc
tgtctgactt
gtctcggtcc
gtcctgctcg
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ctgacttgcc
tgcctttcat
cgcggagact
ccgcccagcg
cgaactcctc
agtccttgtc
ccgcacagag
tcctcacacc
ccggtgggta
gctgtccccg
ttttcgatag
cacgtcgcag
gttggcgtcg
gtaggggtac
gatgccgtac
ctgcttgccc
gataaagcca
cgtgccatcg
cttgccgacc
acgaccgctg
cttctgatag
gcgctcccaa
gcgctgccac
cttgagctgg
tgcagatgct
gtgatgaagt
ccgtcgtaga
agtgattgga
gcgaacatcg
ccgagcaggt
gcggcgagtg
tcttcatgtt
gatcacggtt
tagtcgttga
ccgcctgcct
tcgcggagct
ccaccggtcg
tgcatcggca
cggcctccgt
gcgatctccg
tctggctggt
ttagccgcag
ttatgccgac
ttgacgtgcg
ggtccctacc
tgtggatcgt
tcttcgacgt
ggaccgcgat
accgtgcctt
cggagacttg
gctggcgcag
gggggcggcc
gagggcgaag
atccaggcca
ccgtcctggg
ttgtacttga
tcccggacgg
ccttgcacgg
tctcgctgtt
ggcgggaagg
ggtgagcttc
tccttgggct
gtgcagggcg

cgtaccgggc
ctccagcgcc
ctgcatcggt
caccgagcgc
gtggtacatc
gaacagtcgg
ctgggtgagc
cattcctttc
tgtccttgtg
ctgcccagct
ctctgtgtca
aaccggcagt
agctccttga
gttgccttgc
tcctcggcca
gtcttgtggt
cgaacaagca
ggggcaatcc
tgctccaggc
gcgaaccaat
gactcccgga
gcctctatgg
gccttgtcga
gacacactgc
tgcggatttg
cgaccaccgc
cgagtgagga
ggcagatacg
ggtcggtgtc
tgatggattc
cgagttggtg
cagtgtcatt
cccgaggtgg
cccggatcag
tgctcacgcc
tgttgtagaa
ccatgtactc
ctggcacctg
agtagtgctt
attgggtgta
ttttataggg
agtgtcacat
cggcgacggt
tttacgggcc
cttctagttc
cgctccctga
acattgtcaa
ccccagagcc
gacggtcagc
tactcctgct
gcgtgcttgt
tccgcgtagg
gccagcttcc
ggagctcgtc
tgatgtacca
cgaaccggat
cccgagccag
tgtcgtccac
ttgcggggtc
gggtcagttg
atcagcagta
tgccgctgtc
agggctcgcc

cccgcgcaga
tggaagaccg
gtgtacatgt
gatgatgaag
gggatgaact
atcaggtgct
ttccgtcgct
cattccagcg
cgaaccgcgt
ccacgaacca
tgtcaagtac
tgtcctcgga
acttctcggt
ccgactggcc
gggccacggc
cgcggacgat
caccgtcaag
agatcacctc
cgatgtcgta
actcgaagtt
acaccgcctg
cctcgtggac
ggcgcgagag
ggtgcttgcg
agccggtacc
ttgagcgcgt
ttcccagtag
tttcacggct
tcggaccgct
agcgaacagc
gcaaacgatt
tcgtcgtccc
gaatctccaa
caagtccttg
ttcctcaggc
gccgcgaagc
gccgtgctcg
gaacgggaag
gatccacgag
gcctttgccc
cttgtccgtc
gtaaagcatc
gccgcctcga
gtaggtttta
ctcgatcctg
gagctcggcc
gccctcacct
cgcgccgtgg
ccttgtccct
gggtctcgga
agatcaagcc
gcggggtcgc
tcacgacagc
ccatgccttc
gcggcccagc
cacggttccg
cgccagctcg
gagggttact
tcttgagccg
tgctgagccc
ccagtgcttc
gctcgatgcc
acgctccagg

45481
45541
45601
45661
45721
45781
45841
45901
45961
46021
46081
46141
46201
46261
46321
46381
46441
46501
46561
46621
46681
46741
46801
46861
46921
46981
47041
47101
47161
47221
47281
47341
47401
47461
47521
47581
47641
47701
47761
47821
47881
47941
48001
48061
48121
48181
48241
48301
48361
48421
48481
48541
48601
48661
48721
48781
48841
48901
48961
49021
49081
49141
49201

tggaacctgc
cactcggccg
atggccccgc
ggaactttcg
tcttcggacg
ggtggatgtt
cggcccttgg
ggcttgtact
ctgagcgatg
aaacctccca
tctcgtatcg
acgcacggtg
accaccccgt
cgtcgaccag
tcgctgaagg
acctcacgcc
gacgtgccgt
cccccaccct
tccatgcctc
gggaacagct
ggcgtgcggt
aacaatgaag
ccacttcgcg
ttgaaggccg
cacgactcgt
ggtgccctgg
gccgcacagg
gttgggtacg
ccagatggtc
gaacagcgag
cctcccttgg
tcctgtccga
agcgtggcgt
gacggcagcg
ttccgtggct
accgctgtcc
gactcccgcc
ccgaccgaag
ggcccgcacg
ccatcaggct
acatcgcggt
catctctcgc
tgcctctagc
gcggcgtaca
tcatcggcgt
acgtcgaggt
ttgcgtccct
cggaggatga
ttgacgctcc
tcccttcgct
ctcggtagca
cgtccacgag
gtgtcgtcca
tcatcgagcc
gggagcatgt
agcgcagcga
atcgctggtg
caggtggtcg
ggcgtgacgc
ggcctccacg
ggtgtcgcgc
cagcggtgtt
gtgggtcgtt

ggtcagcagc
tgacatcggc
agaggccggc
gtccttgtag
ggactccccg
gctcatgcct
cgttcacgga
tcgacccgta
taaagtgtgt
gcggctgtgt
gtcccggttc
tgcgatgtca
tgccgatgat
aggtctcgat
ctgcgttcag
cgacgatccc
acaggtgggt
gcgagtcggt
cctcacgctt
tccacatcgc
tggccgtcga
actcgttctc
tcatacccga
gatgcgtctg
ggtcgaagga
ccgatgcctg
atgtcgacgg
ccgaacctct
tgaccgccga
ccgatgcggg
tgatccactc
cagccagacc
cgggtgccat
gcagcgccaa
gcaggttccg
gttgccaccg
gacgagcgcg
cctcatcagg
gcgtttggcg
ccgagcctgg
cattgctcgt
ttgcgattgc
tgctcgggtg
cgcgcttgtg
agacgaacgt
cgacagcttc
cacgcaggac
cgtagtggct
acatgtgctt
catgatctcg
gcggtcagcg
tcgcatccat
cgacgagcac
acatgcccac
cgatgtcgat
tgatcacttc
tcgccgtgcc
atgatggaga
ttcttgccgt
aggagcccgt
ttcatgcctg
gtctttcttc
ccgacgctcg

gggcgtcgtg
ccgagcctcc
gagtatgtac
tactcgggac
acgttgaact
ctcctacgtg
cagcaccgct
ggggcggcga
gactaaggct
ccgctgctgc
ctgacggttc
agcaagaagg
cttcatcgca
gaggtcggtg
tcgagggttg
ttcccatcgc
cgccgtggtc
ggtcagcggt
gttcgggttc
gtcggtcagg
gttgcgggtg
gcttgtgtgg
ggtcggaaag
ttgccttggc
tgtcgatggc
ccttgagtcc
ccggaacctc
tcgcgagcag
agacttcctc
gtccgtggct
atcgagagcg
gtggcggtcg
gcctaacctc
ccctcgagcc
atccacggcg
agctcgcgat
tgagcgatct
tgcagcgaga
ttgtcgaacc
aaccgtgcct
ctcgcttcca
ggtgcggctg
tggctcgggt
cgtcatgacg
cgagtacttg
gccctggacc
acgctggcgt
gcgggtgatg
gtgcaggttg
gacacgacct
atgtctcggg
tgcttgaagg
cgagctctcg
ctggcccggt
gtcggacagg
gatcccttcg
ttacgcatgg
ccagcgcggc
cgtgaccggt
gcgggctccc
tcctctcgtg
cactcgtggc
tcggactcgt

201

tggctctgct
gcgatgatcg
cgtgccttca
cgttgaccgc
cgtcgtcaac
cagcagccgc
ccggaattga
cggtagttgc
gtagccgtcg
cttcgggact
cttatctccg
tcacgaatag
gcggtgcggc
acccatccct
ccgttcttgt
cggatcgccg
cggaggtcca
gtcgggagca
gggcccttgc
gtgtcgccag
cctttggcgt
ggctccgatg
gtcccggaga
actgagtagt
ttctgcgaag
agcggggctc
gtgccagttc
cgtggccgct
gaccgcgagg
catgctgccc
gtcatcagct
tagtcggaca
tcttcttcca
tcttgggctg
cggtcgggtc
gcttcgcagc
cgtgggtgat
ggctgatggt
tcaggtgcca
gcggcggggt
tgccttgcgg
tgccgcgttc
gctcatggct
gccaggtcag
cgggggttgt
agctctccga
cccgcctccg
actcgaccct
aagtagacga
cgaacggacg
tggtcacacc
cggcgtcgga
ccgaggctca
tgatccgagc
tcgactgtgg
gtttggtctg
cgagcatgat
cgaaacctca
gaccgtgaag
ggtcgaagac
tgcgatgtca
ccttggcccg
cgccgtcgat

tgtccgacag
ccggggcgtt
tcgagtcctc
gttggtcagc
gccgaggtgc
agcagggagc
gaacgatggt
gtgccatgcc
cacgtccatc
cggcctgcca
tgtcgtacct
cggctgcggc
tgatcttgcc
cttcccagcc
tcggctcggt
gctcgaactt
tgcctccgtc
gagccactgc
cgtcgcgagc
cgtgcgctgg
cagtcgcgac
gctccagcgg
actcttccca
cctctcacgt
tgagcccaga
acgtcttggc
accttgctca
gccttctcga
tccagacctc
gccaatccgc
cgaccatgcg
tcaggagccg
gacgacgggg
gcggtagcgg
gatgtcttcc
ccacacagcg
cgtctgcatg
gcgggtgcgg
atcgtccaga
catcgtggtc
tggcccttgc
gactgcctga
tgctccttgt
ccccggcgaa
aggtcacaag
caaggccggc
ataccttgcc
tgtccgggcc
agactctcac
cagtccgtcg
catgcgcttg
catgtcatcc
ggtaccagtt
aatcctcttc
gcccgatgcc
acgtgggggg
gtcggcgttc
cccacgggca
cgcaagcctc
ttgcccgtga
agccgtggcc
caggccgacg
gactcggtac

atgggcgtag
gccgagcacg
ttccgtcgct
cagcgcggtg
cagtcctctc
gtcctcgcag
gtgggtcttg
ttgctcctct
ccctgggagc
gggggaacga
tcagttaaac
ctgttggacg
ttcgggggcc
catcatccat
cggtaccggt
gccccactcc
gccgtggtgt
tcctggcagg
cgcaggcgtc
tacctccttc
cggggtgggc
caagagtctt
tcgctcgcat
tctcgatgac
gcccggaccg
aggggaagcc
cgtctccgag
cctcgacctg
cggctccgct
aggcaggaag
gtcgatggct
cagctcttcg
ctgctgctcg
gcgaattgct
atctcgaagc
tcgtgaccat
gtgtcttcgg
tagttgcact
ccgtgctcgt
gggcggtcca
cggggcgctt
gcccgagccg
gcgatgtcaa
cggtgtctcg
cctcgcgttc
gtgtacgttc
ttcgacgttg
ttcgagcgcc
agcgcgtcga
tcgtgcatgt
agcagttggg
ctcctcgacg
gcccgtgtct
gacgcactcg
tagtgcgatg
taccagccgg
acgactcggt
ggatgactgc
cggtcggttc
tctggacgat
cgaatgaagc
accacgcctc
ccgttccatt

49261
49321
49381
49441
49501
49561
49621
49681
49741
49801
49861
49921
49981
50041
50101
50161
50221
50281
50341
50401
50461
50521
50581
50641
50701
50761
50821
50881
50941
51001
51061
51121
51181
51241
51301
51361

cctcgggcag
cgaggatgcc
ggctgtagtc
gcacgccagc
cgctggtcgt
cggcaccgat
cttgagcacg
cgcatccctt
gcacgtcccg
tgggcaggct
atgccttgcg
cgtccgtcga
tggtttctac
ggaatgacgc
ttgccttgtg
gactctgtgc
tgccttcttg
agtggacagc
ctgcctcttc
ccggacagtg
tccaatcaag
cggttacgga
acaaccatgc
gtaagtcatt
cctctgacgg
gggagaactt
gactcgtact
atgtcaagtg
aacccgctgg
acgacgctac
ttgtgctttc
ggtcacaggg
ccccctcctg
gggccctggg
cggggtaccc
ccggtaa

agcctcgcca
ttgcaggtac
cgaagactcg
ctcagccaac
gttcagccgc
gagcaagcct
ctgctgggca
ggatgccatc
aaggcttgct
gttcttcgac
atagccaacg
tccctcgagg
acgggtggtc
ggtaggaccg
cgttctggct
gatgtcaagt
aatcgtgcct
cagcatcgaa
gagctatcgc
cttccggcgg
tctcacgtcc
ccatgactgg
cttgcgcccg
tctgacggcg
gcgacgctga
ggtggtgctg
cggtaccgct
ccgggttgat
catgtgggtt
acgatgcggt
caagctacac
cgtgtcgccc
ccacaggggg
ccaccccccg
ctccggggta

cgcctcgtgg
tcgtcgctcg
gcacgatccc
gcttgcacca
aggttgatcc
gccaagactg
ggcatacctg
gggcacaggt
gccatcatgc
agcttctgct
ctctcgcgaa
ccggcgatca
atgtcttgcc
ctcacccgtc
gatcactcgg
ctgctggtaa
actccgatga
gctggggacc
tccgggttga
gccaacgctt
gatgcgtggc
tcacacgcgg
ccttgcttgg
agctttatcc
ccgaagctat
gtaaaaccaa
tgtgctgttg
ccggctggtt
cccgaaccga
gagcgatgtc
cacggtgctg
ggcgtgtcgc
gtcgggtccc
gtccaggacc
ccccaggggg

202

tgaagggcat
tgtgcgacgg
tcggagacca
tgtgcggtgc
ggccatgcct
gatgcgagag
actgtcccga
tgatcgcacc
ctcgctcggg
gcgatgctcc
gctcagccca
cagcagcccc
tctctgtgcg
tcgatgtctt
tgcttgccgt
aaaaggggca
gcaggtcagt
agtgatgtcg
ggcccaaccc
gcccattagc
ggtccggttt
attcaacacg
ctatcgcttc
ccccgccagc
cggctgactc
cgctagcgga
tgtcttcgac
cgtagtgttc
ttcgcgatgt
aagtgacctg
tgcgatgtca
cccctgctct
ggtcccccct
ccccttcggg
gtataccctc

cgcgacgttg
ttccttggcc
cgcggtgtag
gacgatctcc
acgaagggcc
caggaacgcg
ccgagacagg
ggacaggccg
tgtgagcatg
gctggtcagc
cacctggcgg
gaagtctgcc
atgtcaagtc
cgaccagcac
acacgtccat
tgggtagcgg
cgtcgtttcc
gtcctgcgaa
tgtgattgtg
cttatgtcgt
actgctaccg
ttgtgacatg
gagaagggta
cgagacgggg
ctacccggac
tcgtgtgtgc
tctagctgat
ctgtgcgctg
ccgctgtgct
ctctgcgatc
aaccccaatc
gggtaccccc
tcggggggac
gggtcctggc
cacccccgga

cctccgctgg
gagtacgtca
tcgtacatca
cagcggatgt
gaccgaatct
gtcctcacag
cacgctgcgg
aaggcttccc
agaccgaagc
agtgcggccg
gcccaccgca
ttgctgagga
tcagggcaga
tcgcaggacg
gtccactcct
ccaggacgat
aaccatgcct
cctgcctgtc
tgcgttgttc
ccgcaacact
gcatagacca
gtgtggctca
cgtccctgcc
ggatgatgcc
aagtcgacgg
gatgtcaagt
ggactgtgcg
tgctgtctca
gttgtcgagt
ccctgtgctg
tgtttgccct
cgggggtacc
cgggcccggt
cggcccccct
ccccgaccgg

